Date of event requiring this shell company report.
INTRODUCTION
We are an Israel based global defense electronics company. We specialize in the development, manufacture,
marketing and sales of tactical land radars for defense forces and for critical infrastructure protection applications, and military avionics
for manned and unmanned aircraft. Our shares are traded on the NASDAQ Capital Market and the Tel Aviv Stock Exchange under the symbol
“RADA.”
Statements made in this annual report concerning the contents of any
contract, agreement or other document
are summaries of such
contracts, agreements or documents and are not complete descriptions of all of their terms. If we filed any of these
documents as an exhibit to this annual report or to any previous filing with the Securities and Exchange Commission, or the SEC, you may
read the document itself for a complete recitation of its terms.
Definitions
In this annual report, unless the context otherwise requires:
|
● |
References to “RADA,” the “Company,” the “Registrant,” “our company,” “us,”
“we” and “our” refer to RADA Electronic Industries Ltd. and its consolidated subsidiaries; |
|
● |
References to “our shares,” “Ordinary Shares” and similar expressions refer to RADA’s Ordinary Shares,
NIS 0.03 par value per share; |
|
● |
References to “dollars”, “U.S. dollars”, “U.S. $” and “$” are to United States Dollars;
|
|
● |
References to “shekels” and “NIS” are to New Israeli Shekels, the Israeli currency; |
|
● |
References to the “Securities Act” are to the Securities Act of 1933, as amended; |
|
● |
References to the “Exchange Act” are to the Securities Exchange Act of 1934, as amended; |
|
● |
References to “NASDAQ” are to the NASDAQ Stock Market; |
|
● |
References to the “TASE” are to the Tel Aviv Stock Exchange; and |
|
● |
References to the “SEC” are to the United States Securities and Exchange Commission. |
Market and Industry Data
We operate in an industry in which it is difficult to obtain precise market and industry information. We
have generally obtained the market data in this prospectus supplement from public filings, from industry publications, from studies conducted
by third party sources that we believe to be reliable, and based on our experience and our own investigation of market condition
Cautionary Note Regarding Forward-Looking Statements
Except for the historical information contained in this annual report, the statements contained in this
annual report are
“forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act, and the Private Securities Litigation Reform
Act of 1995, as amended, with respect to our business, financial condition and results of operations. Such forward-looking statements
reflect our current view with respect to future events and financial results. We urge you to consider that statements which use the terms
“anticipate,” “believe,” “do not believe,” “expect,” “plan,” “intend,”
“estimate,” and similar expressions are intended to identify forward-looking statements. We remind readers that forward-looking
statements are merely predictions and therefore inherently subject to uncertainties and other factors and involve known and unknown risks
that could cause the actual results, performance, levels of activity, or our achievements, or industry results, to be materially different
from any future results, performance, levels of activity, or our achievements expressed or implied by such forward-looking statements.
Such forward-looking statements are also included in Item 4 –
“Information on the Company” and Item 5 –
“Operating
and Financial Review and Prospects.” Readers are cautioned not to place undue reliance on these forward-looking statements, which
speak only as of the date hereof. Except as required by applicable law, including the securities laws of the United States, we undertake
no obligation to publicly release any update or revision to any forward-looking statements to reflect new information, future events or
circumstances, or otherwise after the date hereof. We have attempted to identify significant uncertainties and other factors affecting
forward-looking statements in the Risk Factors section that appears in Item 3D.
“Key Information - Risk Factors.”
|
|
|
Page No. |
|
|
1 |
|
|
|
|
|
|
1 |
|
|
1 |
|
|
1 |
|
A. |
|
1 |
|
B. |
Capitalization and Indebtedness |
1 |
|
C. |
Reasons for the Offer and Use of Proceeds |
1 |
|
D. |
Risk Factors |
1 |
|
|
17 |
|
A. |
|
17 |
|
B. |
Business Overview |
17 |
|
C. |
Organizational Structure |
24 |
|
D. |
Property, Plants and Equipment |
24 |
|
|
25 |
|
|
25 |
|
A. |
Operating Results |
25 |
|
B. |
Liquidity and Capital Resources |
28 |
|
C. |
Research and Development, Patents and Licenses |
30 |
|
D. |
Trend Information |
31 |
|
E. |
Critical Accounting Estimates |
32 |
|
|
34 |
|
A. |
Directors and Senior Management |
34 |
|
B. |
Compensation |
38 |
|
C. |
Board Practices |
40 |
|
D. |
Employees |
48 |
|
E. |
Beneficial Ownership of Executive Officers and Directors |
49 |
|
|
50 |
|
A. |
Major Shareholders |
50 |
|
B. |
Related Party Transactions |
51 |
|
C. |
Interests of Experts and Counsel |
51 |
|
|
51 |
|
A. |
Consolidated Statements and Other Financial Information |
51 |
|
B. |
Significant Changes |
52 |
|
|
52 |
|
A. |
Offer and Listing Details |
52 |
|
B. |
Plan of Distribution |
52 |
|
C. |
Markets |
52 |
|
D. |
Selling Shareholders |
52 |
|
E. |
Dilution |
52 |
|
F. |
Expense of the Issue |
52 |
|
|
52 |
|
A. |
Share Capital |
52 |
|
B. |
|
52 |
|
C. |
|
53 |
|
D. |
Exchange Controls |
53 |
|
E. |
Taxation |
53 |
|
F. |
Dividend and Paying Agents |
64 |
|
G. |
Statement by Experts |
64 |
|
H. |
Documents on Display |
64 |
|
I. |
Subsidiary Information |
64 |
|
|
64 |
|
|
65 |
|
|
65 |
|
|
|
|
|
65 |
|
|
65 |
|
|
65 |
|
|
66 |
|
|
66 |
|
|
66 |
|
|
66 |
|
|
67 |
|
|
67 |
|
|
67 |
|
|
67 |
|
|
68 |
|
|
68 |
|
|
|
|
|
68 |
|
|
|
|
|
68 |
|
|
68 |
|
|
69 |
|
IDENTITY OF DIRECTORS, SENIOR MANAGEMENT AND ADVISERS
|
Not applicable.
|
OFFER STATISTICS AND EXPECTED TIMETABLE |
Not applicable.
A. [Reserved]
B. Capitalization and Indebtedness
Not applicable.
C. Reasons for the Offer and Use of Proceeds
Not applicable.
D. Risk Factors
Investing in our Ordinary Shares involves a high degree of risk and uncertainty. You should carefully consider
the risks and uncertainties described below before investing in our Ordinary Shares. Our business, prospects, financial condition and
results of operations could be adversely affected due to any of the following risks. In that case, the value of our Ordinary Shares could
decline, and you could lose all or part of your investment. These risks include, but are not limited
to, the following:
Risks Related to Our Business and Our Industry
|
• |
While we have met with initial success in the introduction of our advanced radars for tactical applications such as defense forces
protection and border protection, there can be no assurance that we will succeed in obtaining general market acceptance. |
|
• |
We have a history of operating losses and may not be able to sustain profitable operations in the future. To the extent that we incur
operating losses in the future, we may not have sufficient working capital to fund our operations. |
|
• |
Reductions in defense budgets worldwide may cause a reduction in our revenues, which would adversely affect our business, operating
results and financial condition. |
|
• |
We may be required to obtain financing for strategic opportunities, which financing may not be available for us in a timely manner
or on favorable terms, and which may dilute the holdings of our shareholders and/or require us to incur additional debt. |
|
• |
Competition in the market for defense electronics is intense. Our products may not achieve market acceptance, which could adversely
affect our business, financial condition and results of operations. |
|
• |
We may not be able to implement our growth strategy which could adversely affect our business, financial condition and results of
operations. |
|
• |
Due to inaccurate forecasts, mistakes or business changes, we may be exposed to inventory-related losses on inventory we purchased
in advance and part of our inventory may be written off, which would increase our cost of revenues. |
|
• |
Epidemics and pandemics, such as the COVID-19 pandemic, could materially disrupt our business and have a negative impact on our financial
results and financial condition. |
|
• |
Other unfavorable national and global economic conditions could have a material adverse effect on our business, operating results
and financial condition. |
|
• |
Sales of our products are subject to governmental procurement procedures and practices; termination, reduction or modification of
contracts with our customers or a substantial decrease in our customers’ budgets may adversely affect our business, operating results
and financial condition. |
|
• |
If we do not receive the governmental approvals necessary for the export of our products, our revenues may decrease. Similarly, if
our suppliers and partners do not receive government approvals necessary to export their products or designs to us, our revenues may decrease,
and we may fail to implement our growth strategy. |
|
• |
We would be adversely affected if we are unable to attract and retain key personnel. |
|
• |
We depend on sales to key customers and the loss of one or more of our key customers would result in a loss of a significant amount
of our revenues, which would adversely affect our business, financial condition and results of operations. |
|
• |
We depend on suppliers of components for our products and if we are unable to obtain these components when needed, we could experience
delays in the manufacturing of our products and our financial results could be adversely affected. |
|
• |
Rapid technological changes may adversely affect the market acceptance of our products and could adversely affect our business, financial
condition and results of operations. |
|
• |
We enter into fixed-price contracts that could expose us to losses in the event we fail to properly estimate our costs. |
|
• |
Breaches of network or information technology security, natural disasters or terrorist attacks could have an adverse effect on our
business. |
|
• |
We are subject to risks associated with international operations; we generate a significant portion of our sales from customers located
in countries that may be adversely affected by political or economic instability and corruption. |
|
• |
Many of our end users are U.S. government customers, which subject us to risks including early termination, audits, investigations,
sanctions, or penalties. |
|
• |
We may acquire or invest in companies which may divert our management’s attention and result in debt or dilution to our shareholders.
We may be unable to integrate acquired businesses and technologies successfully or achieve the expected benefits of such acquisitions
|
|
• |
Currency exchange rate fluctuations in the world markets in which we conduct business could have a material adverse effect on our
business, results of operations and financial condition. |
|
• |
Claims that our products infringe upon the intellectual property of third parties may require us to incur significant costs, enter
into licensing agreements or license substitute technology. |
|
• |
If we are unable to protect our intellectual property rights from unauthorized use or infringement by third parties, our business
could be adversely affected. |
|
• |
Increasing scrutiny and changing expectations from investors, lenders, customers and other market participants with respect to our
Environmental, Social and Governance, or ESG, policies may impose additional costs on us or expose us to additional risks. |
|
• |
Regulations related to conflict minerals may cause us to incur additional expenses and could limit the supply and increase the costs
of certain metals used in the manufacturing of our solutions. |
|
• |
We may fail to maintain effective internal controls in accordance with Section 404 of the Sarbanes-Oxley Act of 2002, which could
have an adverse effect on our financial results and the market price of our Ordinary Shares. |
Risk Related to Our Ordinary Shares
|
• |
Our Ordinary Shares are traded on more than one market and this may result in price variations. |
|
• |
While our Ordinary Shares are listed on the TASE, there is no guarantee as to how long such listing will be maintained. |
|
• |
Our share price has been volatile in the past and may decline in the future. |
|
• |
We do not intend to pay dividends. |
|
• |
We may be classified as a passive foreign investment company, or PFIC, which would subject our U.S. investors to adverse tax rules.
|
Risks Related to Our Location in Israel
|
• |
Political, economic and military instability in Israel may disrupt our operations and negatively affect our business condition, harm
our results of operations and adversely affect our share price. |
|
• |
Our results of operations may be negatively affected by the obligation of our personnel to perform military service. |
|
• |
We may not be able to enforce covenants not-to-compete under current Israeli law. |
|
• |
We may become subject to claims for remuneration or royalties for assigned service invention rights by our employees, which could
result in litigation and adversely affect our business. |
|
• |
Service and enforcement of legal process on us and our directors and officers may be difficult to obtain. |
|
• |
The rights and responsibilities of our shareholders are governed by Israeli law and differ in some respects from those of a typical
U.S. corporation. |
|
• |
Israeli government programs and tax benefits may be terminated or reduced in the future, which could increase our tax expenses.
|
|
• |
As a foreign private issuer whose shares are listed on the NASDAQ Capital Market, we may follow certain home country corporate governance
practices instead of certain NASDAQ requirements. |
Risks Related to Our Business and Our Industry
While we have met with initial success in the introduction of our
advanced ground radars for tactical applications such as defense forces protection and border protection, there can be no assurance that
we will succeed in obtaining general market acceptance.
We have developed a number of radar hardware platforms for use in combat vehicles and tactical protection
applications for defense forces and border protection. In December 2014, we announced the first significant order for this product family
and while we have been successful in marketing our ground radar products since then, we cannot assure you that our ground radars will
achieve broad market acceptance.
We have a history of operating losses and may not be able to sustain
profitable operations in the future. To the extent that we incur operating losses in the future, we may not have sufficient working capital
to fund our operations.
We incurred operating losses in three of the six years ended
December 31, 2021 and may not be able to achieve
or sustain profitable operations in the future or generate positive cash flows from operations. As of
December 31, 2021, our accumulated
deficit was $48 million. To the extent that we incur significant operating losses in the future or are unable to generate free cash flows
from our business, we may not have sufficient working capital to fund our operations and will be required to obtain additional financing.
Such financing may not be available, or if available, may not be on terms satisfactory to us. If adequate funds are not available to us,
our business, and results of operations and financial condition will be adversely affected.
Reductions in defense budgets worldwide may cause a reduction in
our revenues, which would adversely affect our business, operating results and financial condition.
Substantially all of our revenues are derived from the sale of products with military applications.
We expect the U.S. government will continue to place a high priority on national security and will continue
to invest in products such as ours. Further, the U.S. Department of Defense, or DoD, budget remains the largest in the world and this
offers substantial opportunity for growth.
The U.S. government's fiscal year (FY) begins on October 1 and ends on September 30. On
April 9, 2021,
the Biden Administration introduced the initial FY 2022 discretionary budget plan. The proposal requests $753 billion in discretionary
funding for national defense and includes $715 billion for the DoD. The $715 billion DoD request compares to the FY 2021 enacted amount
of $704 billion. On
September 30, 2021, the President signed a continuing resolution (CR) into law that provides continuing FY 2022 appropriations
to federal agencies through the earlier of
December 3, 2021, or the enactment of the applicable appropriations act. The CR funds most
programs and activities at the FY2021 levels with several exceptions.
In December 2021, Biden signed a $770 billion defense policy bill for fiscal year 2022, which reflects
a 5% increase from the previous fiscal year’s defense policy measure and includes a 2.7% pay raise for service members and more
naval ship and aircraft purchases. The FY 2022 National Defense Authorization Act authorizes the formation of a 16-member commission to
look into the Afghanistan war and includes $4 billion for the European Defense Initiative, $300 million for the Ukraine Security Assistance
Initiative and $150 million for Baltic security cooperation.
There are risks associated with the timing and amount of future appropriations. If annual appropriations
bills are not enacted in the future, the U.S. government may operate under a CR, restricting new
contract or program starts and additional
government shutdowns, which might involve all government agencies, including the DoD, could arise. Future CR’s and government shutdowns
may lead to delays in procurement of products due to lack of funding, and those delays may adversely affect our revenue, results of operations
and cash flow. Finally, there remains uncertainty surrounding future discretionary defense funding levels and priorities of the Biden
Administration and Congress, which could adversely impact demand for our products.
In addition, the defense budgets of a number of countries have declined and may be reduced in the future.
Declines in defense budgets may result in reduced demand for our products. This would result in reduction in our core business’
revenues and adversely affect our business, results of operations and financial condition.
We may be required to obtain financing for strategic opportunities,
which financing may not be available for us in a timely manner or on favorable terms, and which may dilute the holdings of our shareholders
and/or require us to incur additional debt.
In order to invest in strategic opportunities in support of our growth plans and/or business development
activities, we may be required to obtain funds from financing sources, including through debt vehicles or re-financing, sale of new securities
or other financing alternatives. There is no assurance that we will be able to obtain sufficient funding, if at all, from the financing
sources detailed above or other sources in a timely manner (or on commercially reasonable terms) in order to allow us to fund our growth
plans and/or business development activities, which may adversely affect our financial position and operations, may dilute the holdings
of our shareholders or require us to incur additional debt.
Competition in the market for defense electronics is intense. Our
products may not achieve market acceptance, which could adversely affect our business, financial condition and results of operations.
The market for our products is highly competitive and we may not be able to compete effectively. Our principal
competitors in the defense electronics market, include Israel Aerospace Industries Ltd., or IAI, Raytheon Company, Northrop Grumman Corporation,
Thales Group, and SRC Inc. We expect to continue to face competition from these and other competitors. Most of our competitors are larger
and have substantially greater resources than us, including financial, technological, marketing and distribution capabilities, and enjoy
greater market recognition than we do. These competitors are able to achieve greater economies of scale and may be less vulnerable to
price competition than us. We may not be able to offer our products as part of integrated systems to the same extent as our competitors
or successfully develop or introduce new products that are more cost effective or offer better performance than those of our competitors.
Failure to do so could adversely affect our business, financial condition and results of operations.
Further, we derive a portion of our revenue from direct and indirect sales to governments and their agencies
and our competitors are increasingly targeting such governmental agencies as potential clients. Such government
contracts are subject
to various procurement, competition and other laws and regulations, as well as contractual provisions, and violations could result in
the imposition of various civil and criminal penalties, termination of
contracts, forfeiture of profits, suspension of payments, or suspension
of future government contracting. In addition, these entities may require license terms that we are unwilling to agree to (e.g., open
data rights). As such, we may lose government clients to our competitors, our government
contracts may be terminated or not be renewed
or we may be suspended from government work or the ability to compete for new
contracts.
We may not be able to implement our growth strategy which could
adversely affect our business, financial condition and results of operations.
In line with our growth strategy, we entered into a number of strategic relationships with Lockheed Martin
Corporation, or Lockheed Martin, Boeing Defense, Space & Security, or Boeing, Rafael Advanced Defense Systems Ltd., or Rafael, Elbit
Systems Ltd., or Elbit, Leonardo DRS, or DRS, Anduril Industries, or Anduril and Ascent Vision Technologies (a CACI subsidiary), or
CACI, to increase our penetration into the defense electronics market. We are currently investing and intend to continue to invest significant
resources to develop these relationships and additional new relationships. Should our relationships fail to materialize into significant
agreements or should we fail to work efficiently with these companies, we may lose sales and marketing opportunities and our business,
results of operations and financial condition could be adversely affected.
Our growth is dependent in part on the development of new products, based on internal research and development,
including the expansion of our radar offerings. We may not accurately identify market needs before we invest in the development of a new
product. We may also face difficulties or delays in the development process that will result in our inability to timely offer products
that satisfy the market and competing products may emerge during the development and certification process.
Due to inaccurate forecasts, mistakes or business changes, we may
be exposed to inventory-related losses on inventory we purchased in advance and part of our inventory may be written off, which would
increase our cost of revenues.
We normally purchase more inventory than is immediately required in order to shorten our delivery time
especially in the event of an increase in demand for our products. We have also increased our inventory level in order to accommodate
possible consequences of COVID-19. If the actual orders from our customers are lower than projected or if we decide to change our product
line or our product support strategy, we will have excess inventory of components or finished products. Our inventory levels may be too
high, and inventory may become obsolete or over-stated on our balance sheet. Our inventory of finished products may accumulate. The rate
of accumulation may increase in a period of economic downturn. This would require us to write off inventory, which could adversely affect
our gross profit and results of operation.
Epidemics and pandemics, such as the COVID-19 pandemic, could materially
disrupt our business and have a negative impact on our financial results and financial condition.
We are vulnerable to the general economic effects of epidemics, pandemics and other public health crises,
such as the COVID-19 pandemic. Due to the recent outbreak of COVID-19, there has been a substantial curtailment of travel and business
activities, which is causing significant disruptions to the global economy. The extent to which COVID-19 impacts our results will depend
primarily on future developments, which are highly uncertain and cannot be predicted with confidence, including the severity and duration
of the crisis, the speed and effectiveness of vaccine and treatment developments and deployment, potential mutations of COVID-19, and
the impact of actions taken and that will be taken to contain COVID-19 or treat its impact, among others. For example, if COVID-19 continues
to spread, we may need to limit operations or implement additional restrictions as a result of widespread government restrictions.
Our increased reliance on personnel working from home may negatively impact productivity or disrupt, delay
or otherwise adversely impact its business. Israel and other countries have enforced quarantines and shutdowns to slow the spread of COVID-19,
and restricted international travel during this pandemic.
We are continuing to closely monitor COVID-related impacts on all aspects of our business and geographies,
including on our workforce, supply chain and customers. On
September 9, 2021, President Biden announced a COVID-19 action plan, including
an executive order, the Safer Workforce Task Force guidance issued on
September 24, 2021 and the Force Health Protection guidance. This
executive order and guidance (as amended) requires U.S. based federal contractors’ employees to have had their final vaccination
dose by
January 4, 2022, with exceptions including where an employee is legally entitled to an accommodation.
State and local governments are also continuing to take actions related to the pandemic, imposing additional
and varying requirements on our industry. We are continuing to evaluate these evolving requirements. We cannot at this stage predict the
various impacts they may have on our workforce, our suppliers, or
our company. These evolving government requirements, including regarding
a vaccine mandate, along with broader impacts of the continuing pandemic, could impact our workforce and performance, as well as those
of our suppliers.
Our future results of operations and liquidity could be adversely impacted by delays in payments of outstanding
receivable amounts beyond normal payment terms, supply chain disruptions and operational challenges faced by our customers. Continued
outbreaks of COVID-19 could result in a widespread health crisis that could adversely affect the economies and financial markets of many
countries, resulting in an economic downturn or a global recession that could cause significant volatility or decline in the trading price
of our securities, affect our ability to execute strategic business activities, affect demand for our products and likely impact our operating
results. These may further limit or restrict our ability to access capital on favorable terms, or at all, lead to consolidation that negatively
impacts our business, weaken demand, increase competition, cause us to reduce our capital spend further, or otherwise disrupt our business.
Other unfavorable national and global economic conditions could
have a material adverse effect on our business, operating results and financial condition.
During periods of slowing economic activity, our customers may reduce their demand for our products, technology
and professional services, which would reduce our sales, and our business, operating results and financial condition may be adversely
affected. Significant portions of our operations are conducted outside the markets in which our products and solutions are manufactured
or generally sold, and accordingly, we often export a substantial number of products into such markets. We may, therefore, be denied access
to potential customers or suppliers or denied the ability to ship products from any of our
subsidiaries into the countries in which we
currently operate or wish to operate, as a result of economic, legislative, political and military conditions, including hostilities and
acts of terrorism, in such countries.
We could also be exposed to credit risk and payment delinquencies on our accounts receivable. In particular,
there is currently significant uncertainty about the future relationship between the U.S. and various other countries, with respect to
trade policies, treaties, government regulations, and tariffs. Although we partially manufacture in the US, major developments in trade
relations, including the imposition of new or increased tariffs by the U.S. and/or other countries, and any emerging nationalist trends
in specific countries could alter the trade environment and consumer purchasing behavior which, in turn, could have a material effect
on our financial condition and results of operations.
Any slowdown or instability in the global economy could impact income, purchasing power and consumption
levels among other things, which could limit growth, increase delinquency rates and ultimately have a material adverse effect on us. In
addition, any global economic slowdown or uncertainty may result in volatile conditions in the global financial markets, which could have
a material adverse effect on us, including on our ability to access capital and liquidity on financial terms acceptable to us, if at all.
Any such adverse effect on capital markets funding availability or costs or in deposit rates could have a material adverse effect on our
interest margins and liquidity.
We may also be required in the future to increase our reserves for doubtful accounts. In addition, the
fair value of some of our assets may decrease as a result of an uncertain economy and as a result, we may be required to record impairment
charges in the future. If global economic and market conditions or economic conditions in key markets remain uncertain or weaken further,
our financial condition and operating results may be materially adversely affected.
Sales of our products are subject to governmental procurement procedures
and practices; termination, reduction or modification of
contracts with our customers or a substantial decrease in our customers’
budgets may adversely affect our business, operating results and financial condition.
Our products are primarily sold to governmental agencies, governmental authorities and government-owned
companies, many of which have complex and time-consuming procurement procedures. A substantial period of time often elapses from the time
we begin marketing a product until we actually sell that product to a particular customer. In addition, our sales to governmental agencies,
authorities and companies are directly affected by these customers’ budgetary constraints and the priority given in their budgets
to the procurement of our products. A decrease in governmental funding for our customers’ budgets would adversely affect our results
of operations. This risk is heightened during periods of global economic slowdown. Accordingly, governmental purchases of our systems,
products and services may decline in the future as the governmental purchasing agencies may terminate, reduce or modify
contracts or subcontracts
if:
|
● |
their requirements or budgetary constraints change; |
|
● |
they cancel multi-year contracts and related orders if funds become unavailable; |
|
● |
they shift spending priorities into other areas or for other products; or |
|
● |
they adjust contract costs and fees on the basis of audits. |
Any such event may have a material adverse effect on us.
Further, our business with the State of Israel and other governmental entities is, in general, subject
to delays in funding and performance of
contracts and the termination for convenience (among other reasons) of
contracts or subcontracts
with governmental entities. The termination, reduction or modification of our
contracts or subcontracts with the Government of Israel
in the event of change in requirements, policies or budgetary constraints would have an adverse effect on our business, operating results
and financial condition.
If we do not receive the governmental approvals necessary
for the export of our products, our revenues may decrease. Similarly, if our suppliers and partners
do not receive government approvals necessary to export their products or designs to us, our revenues may decrease, and we may fail to
implement our growth strategy.
Israel’s defense export policy regulates the sale of our systems and products. Current Israeli policy
encourages export to approved customers of defense systems and products, such as ours, as long as the export is consistent with Israeli
government policy. A license is required to initiate marketing activities. We are also required to obtain a specific export license for
any hardware exported from Israel. We may not be able to receive all the required permits and licenses for which we may apply in the future.
If we do not receive the required permits for which we apply, our revenues may decrease.
We are subject to laws regulating export of
“dual use” items (items that are typically sold
in the commercial market, but that also may be used in the defense market) and defense export control legislation. Additionally, our participation
in governmental procurement processes in Israel and other countries is subject to specific regulations governing the conduct of the process
of procuring defense
contracts. Furthermore, solicitations for procurements by governmental purchasing agencies in Israel and other countries
are governed by laws, regulations and procedures relating to procurement integrity, including avoiding conflicts of interest and corruption
in the procurement process. We may not be able to respond quickly and effectively to changing laws and regulations and any failure to
comply with such laws and regulations may subject us to significant liability and penalties.
We would be adversely affected if we are unable
to attract and retain key personnel
Our success depends in part on key management, sales, marketing and development personnel and our continuing
ability to attract and retain highly qualified personnel, including with respect to our recently formed
subsidiaries. There is competition
for the services of such personnel. The loss of the services of senior management and key personnel, or the failure to attract highly
qualified personnel in the future, may have a negative impact on our business. Moreover, our competitors may hire and gain access to the
expertise of our former employees or our former employees may compete with us. There is no assurance that we will be successful in attracting,
integrating, motivating and retaining key personnel or that former employees will not compete with in the future. If we are unable to
retain our key personnel and attract additional qualified personnel as and when needed, our business may be adversely affected.
We depend on sales to key customers and the loss of one or more
of our key customers would result in a loss of a significant amount of our revenues, which would adversely affect our business, financial
condition and results of operations.
A significant portion of our revenues is derived from a small number of customers. During the years ended
December 31, 2021 and
2020, 49% and 51% of our revenues, were attributable to five customers. We anticipate that a significant portion
of our future revenues will continue to be derived from sales to a small number of customers. No assurances can be given that our customers
will continue to purchase our products, that we will be successful in any bid for new
contracts to provide such products, or that if we
were granted subsequent orders, such orders would be of a scope comparable to the sales that we have experienced to date. If our principal
customers do not continue to purchase products from us at current levels or if we do not retain such customers and we are not able to
derive sufficient revenues from sales to new customers to compensate for their loss, our revenues would be reduced and adversely affect
our business, cash flows, financial condition and results of operations.
We depend on suppliers of components for our products and if we
are unable to obtain these components when needed, we could experience delays in the manufacturing of our products and our financial results
could be adversely affected.
We acquire most of the components for the manufacturing of our products from suppliers and subcontractors,
most of whom are located in Israel and the U.S. A number of these suppliers are currently the sole source of one or more components upon
which we are dependent. Suppliers of some of the components for manufacturing require us to place orders with significant lead-time to
assure supply in accordance with our manufacturing requirements. Delays in supply may significantly hurt our ability to fulfill our contractual
obligations and may significantly hurt our business and result of operations. In addition, we may not be able to continue to obtain such
components from these suppliers on satisfactory commercial terms. Temporary disruptions of our manufacturing operations would ensue if
we were required to obtain components from alternative sources, which may have an adverse effect on our financial results.
Rapid technological changes may adversely affect the market acceptance
of our products and could adversely affect our business, financial condition and results of operations.
The defense electronics market in which we compete is subject to technological changes, introduction of
new products, change in customer demands and evolving industry standards. Our future success will depend upon our ability to keep pace
with technological developments and to timely address the increasingly sophisticated needs of our customers by supporting existing and
new technologies and by developing and introducing enhancements to our current products and new products. We may not be successful in
developing and marketing enhancements to our products that will respond to technological change, evolving industry standards or customer
requirements. In addition, we may experience difficulties that could delay or prevent the successful development, introduction and sale
of such enhancements and such enhancements may not adequately meet the requirements of the market and may not achieve any significant
degrees of market acceptance. If release dates of our new products or enhancements are delayed or, if when released, they fail to achieve
market acceptance, our business, operating results and financial condition may be adversely affected.
We enter into fixed-price
contracts that could expose us to losses
in the event we fail to properly estimate our costs.
We enter into firm fixed-price
contracts. If our initial cost estimates are incorrect, we can lose money
on these
contracts. To the extent we underestimate the costs to be incurred in any fixed-price
contract, we could experience a loss on
the
contract, which could have a negative effect on our results of operations, financial position and cash flow.
Breaches of network or information technology security,
natural disasters or terrorist attacks could have an adverse effect on our business.
Cyber-attacks or other breaches
of network or IT security, natural disasters, terrorist acts or acts of war may cause equipment failures or disrupt our systems and operations.
We may be subject to attempts to breach the security of our networks and IT infrastructure through cyber-attack, malware, computer viruses
and other means of unauthorized access, which could also impact the operation of our products and services. The potential liabilities
associated with these events could exceed the insurance coverage we maintain. Our inability to operate our facilities as a result of such
events, even for a limited period of time, may result in significant expenses or loss of market share to other competitors in the defense
electronics market. In addition, a failure to protect the privacy of customer and employee confidential data against breaches of network
or IT security could result in damage to our reputation. We have experienced and defended against certain threats to our systems and security
(such as phishing and ransomware attempts), and none have had a material adverse effect on our business or operations to date. However,
we could incur significant costs in order to investigate and respond to future attacks, to respond to evolving regulatory oversight requirements,
to upgrade our cybersecurity systems and controls, and to remediate security compromise or damage. In response to past threats and attacks,
we have implemented further controls and planned for other preventative actions to further strengthen our systems against future attacks.
However, we cannot assure you that such measures will provide absolute security, that we will be able to react in a timely manner, or
that our remediation efforts following past or future attacks will be successful. Consequently, our financial performance and results
of operations would be materially adversely affected.
We are subject to risks associated with international operations;
we generate a significant portion of our sales from customers located in countries that may be adversely affected by political or economic
instability and corruption.
We are a defense company with worldwide operations. Although 87% of our sales are in Israel and North America,
we expect to derive an increasing portion of our sales and future growth from other regions such as Latin America, India, the Middle East
and Central and Eastern Europe, which may be more susceptible to political or economic instability and the economic impact of the spread
of COVID-19. In addition, in many less-developed markets, we rely heavily on third-party representatives, consultants and other agents
for business development, marketing and distribution of our products. Many of these third parties do not have internal compliance resources
comparable to ours. Business activities in many of these markets have historically been more susceptible to corruption. If our efforts
to screen third party agents and detect cases of potential misconduct fail, we could be held responsible for the noncompliance of these
third parties under applicable laws and regulations, which may adversely affect our reputation and our business, financial condition or
results of operations.
Exports (whether direct sales or revenues of our U.S. subsidiary - RTL) accounted for 85% of our revenues
in 2021, 80% of our revenues in 2020 and 72% of our revenues in 2019. Our reliance on export sales subjects us to many risks inherent
in engaging in international business, including:
|
● |
Limitations and disruptions resulting from the imposition of government controls; |
|
● |
Changes in regulatory requirements; |
|
● |
The global impact of the COVID-19 pandemic; |
|
● |
Export license requirements; |
|
● |
Economic or political instability; |
|
● |
Longer receivable collection periods and greater difficulty in accounts receivable collection; |
|
● |
Greater difficulty in safeguarding intellectual property; |
|
● |
Difficulties in managing overseas subsidiaries and international operations; and |
|
● |
Potential adverse tax consequences. |
We may not be able to sustain or increase revenues from international operations and may encounter significant
difficulties, in connection with the sale of our products in international markets. Any of those events may adversely affect our business,
operating results and financial condition.
In response to the to the invasion of the Ukraine by Russia in February 2022, the U.S. and other countries
have imposed various sanctions against Russia, including restrictions on selling or importing goods, services or technology in or from
affected regions and travel bans and asset freezes impacting connected individuals and political, military, business and financial organizations
in Russia. The U.S. and other countries could impose wider sanctions and take other actions. It is not possible to predict the broader
consequences of this conflict, which could include further sanctions, embargoes, regional instability, geopolitical shifts in the Middle
East and worldwide and adverse effects on macroeconomic conditions, currency exchange rates and financial markets, all of which could
impact our business, financial condition and results of operations.
As a company registered with the SEC, we are subject to the regulations imposed by the Foreign Corrupt
Practices Act, or FCPA, which generally prohibits registrants and their intermediaries from making improper payments to foreign officials,
for the purpose of obtaining or keeping business or obtaining an improper business benefit. We have adopted proactive procedures to promote
compliance with the FCPA, but we may be held liable for actions taken by our strategic or local partners or agents even though these partners
may not themselves be subject to the FCPA. Any determination that we have violated the FCPA could materially and adversely affect our
business, results of operations, and cash flows.
Finally, our business also must be conducted in compliance with applicable economic and trade sanctions
and export control laws and regulations, including those administered and enforced by the U.S. Department of the Treasury’s Office
of Foreign Assets Control, the U.S. State Department of State, the U.S. Department of Commerce, the United Nations Security Council, and
other relevant authorities. Our global operations expose us to the risk of violating, or being accused of violating, such laws and regulations.
Our failure to comply with these trade-related laws and regulations may expose us to reputational harm as well as significant penalties,
including criminal fines, imprisonment, civil fines, disgorgement of profits, injunctions and debarment from government
contracts, as
well as other remedial measures. Investigations of alleged violations can be expensive and disruptive. Despite our compliance
efforts and activities, we cannot assure compliance by our employees or representatives for which we may be held responsible, and any
such violation could materially adversely affect our reputation, business, financial condition and results of operations.
Many of our end users are U.S. government customers,
which subject us to risks including early termination, audits, investigations, sanctions, or penalties.
We derive a substantial portion of our revenue from
contracts with U.S. defense contractors and systems
integrators that ultimately provide our products to the U.S. government, including the DoD. We also occasionally enter into
contracts
directly with the U.S. government.
We may enter into further
contracts with U.S. defense contractors and systems integrators as well as directly
with the U.S. government. These
contracts subject us to statutes and regulations applicable to companies doing business with the
U.S. government. These types of
contracts customarily contain provisions that give the government substantial rights and remedies,
many of which are not typically found in commercial
contracts and which are unfavorable to contractors, including provisions that allow
the government to unilaterally terminate or modify
contracts, in whole or in part, at the government’s convenience or in the government’s
best interest, including if funds become unavailable to the applicable government agency.
In addition, government
contracts and subcontracts normally contain additional requirements that may increase
our costs of doing business, reduce our profits, and expose us to liability for failure to comply with these terms and conditions.
These requirements include, for example:
|
• |
compliance with complex regulations for procurement, formation, administration, and performance of government contracts and subcontracts
under the Federal Acquisition Regulations, or FAR, and agency-specific regulations supplemental to the FAR; |
|
• |
specialized disclosure and accounting requirements unique to government contracts and subcontracts; |
|
• |
mandatory financial and compliance audits that may result in potential liability for price or cost adjustments, recoupment of government
funds after such funds have been spent, civil and criminal penalties, or administrative sanctions such as suspension or debarment from
doing business with the U.S. government; |
|
• |
public disclosures of certain contract and company information; and |
|
• |
mandatory socioeconomic compliance requirements, including labor requirements, non-discrimination and affirmative action programs
and environmental compliance requirements. |
Government
contracts and subcontracts are also generally subject to greater scrutiny by the government,
which can unilaterally initiate reviews, audits and investigations regarding our compliance with government
contract requirements.
In addition, if we fail to comply with government
contract laws, regulations and
contract requirements, our
contracts and subcontracts
may be subject to termination or suspension, and we may be subject to financial or other liability under our
contracts or under the Federal
Civil False Claims Act. The False Claims Act’s
“whistleblower” provisions allow private individuals, including
present and former employees, to sue on behalf of the U.S. government. The False Claims Act statute provides for treble damages and other
penalties and, if our operations are found to be in violation of the False Claims Act, we could face other adverse action, including suspension
or prohibition from doing business with the United States government. Any penalties, damages, fines, suspension, or damages could adversely
affect our ability to operate our business and our financial results. Further, the negative publicity that could arise from any
such penalties, sanctions or findings could have an adverse effect on our reputation and reduce our ability to compete for new
contracts
with both government and commercial clients. Moreover, government entities typically finance projects through appropriated funds. While
these projects are often planned and executed as multi-year projects, government entities usually reserve the right to change the scope
of or terminate these projects for lack of approved funding or at their convenience. Changes in government or political developments,
including legislative or regulatory changes, budget deficits, shortfalls or uncertainties, government spending reductions or other debt
or funding constraints, could result in lower governmental sales and our projects being reduced in price or scope or terminated altogether,
which also could limit our recovery of incurred costs, reimbursable expenses and profits on work completed prior to the termination.
We may acquire or invest in companies which may divert our management’s
attention and result in debt or dilution to our shareholders. We may be unable to integrate acquired businesses and technologies successfully
or achieve the expected benefits of such acquisitions.
We intend to evaluate and consider potential strategic transactions, including acquisitions of, or investments in,
businesses, technologies, services, products and other assets in the future. For example, in March 2021, we signed a Shares Purchase Agreement
to invest $3 million in consideration for a 12% interest in RadSee Technologies Ltd., an early-stage advanced radar technology company.
We also may enter into relationships with other businesses to expand our products which could involve investments in or acquisitions
of other companies.
Any acquisition, investment or business relationship may result in unforeseen operating difficulties and
expenditures. In particular, we may encounter difficulties or delays in assimilating or integrating the businesses,
technologies, products, employees or operations of the acquired companies, particularly if the key employees of the acquired company choose
not to work for us, their products or services are not easily adapted to work with our products, or we have difficulty retaining the customers
of any acquired business due to changes in ownership, management or otherwise. In addition, we may discover liabilities or deficiencies
associated with the assets or companies we acquire or ineffective or inadequate controls, procedures or policies at an acquired business
that were not identified in advance, any of which could result in significant unanticipated costs. Acquisitions also may disrupt our business,
divert our resources or require significant management attention that would otherwise be available for development of our existing business.
Moreover, the anticipated benefits of any acquisition, investment or business relationship may not be realized or we may be exposed to
unknown risks or liabilities.
Negotiating these transactions can be time consuming, difficult and expensive, and our ability to complete
these transactions may often be subject to approvals that are beyond our control. Consequently, these transactions, even if announced,
may not be completed. For one or more of those transactions, we may:
|
• |
issue additional equity securities that would dilute our existing shareholders; |
|
• |
use cash that we may need in the future to operate our business; |
|
• |
incur large charges or substantial liabilities; |
|
• |
incur debt on terms unfavorable to us or that we are unable to repay; |
|
• |
encounter difficulties retaining key employees of the acquired company or integrating business cultures; |
|
• |
encounter difficulties retaining the acquired company’s customers; or |
|
• |
become subject to adverse tax consequences, substantial depreciation, or deferred compensation charges. |
The occurrence of any of these foregoing could adversely affect our business, results of operations and
financial condition.
Currency exchange rate fluctuations in the world markets in which
we conduct business could have a material adverse effect on our business, results of operations and financial condition.
Most of our revenues are in dollars or are linked to the dollar, while a portion of our expenses, principally
salaries and related personnel expenses, are incurred in other currencies, particularly in NIS. Therefore, our costs in such other currencies,
as expressed in dollars, are influenced by the exchange rate between the dollar and the relevant currency. We are also exposed to the
risk that the rate of inflation in Israel will exceed the rate of depreciation of the NIS in relation to the dollar or that the timing
of this depreciation lags behind inflation in Israel. This would have the effect of increasing the dollar cost of our operations. In the
past, the NIS exchange rate with the dollar and other foreign currencies has fluctuated, generally reflecting inflation rate differentials.
We cannot predict any future trends in the rate of inflation in Israel or the rate of depreciation or appreciation of the NIS against
the dollar. If the dollar cost of our operations in Israel increases, our dollar-measured results of operations will be adversely affected.
We engage in currency hedging transactions intended to partly reduce the effect of fluctuations in foreign currency exchange rates on
our results of operations. However, such transactions may not materially reduce the effect of fluctuations in foreign currency exchange
rates on our results of operations.
Claims that our products infringe upon the intellectual property
of third parties may require us to incur significant costs, enter into licensing agreements or license substitute technology.
Third parties may assert that we have infringed, misappropriated or otherwise violated a patent, copyright,
trademark or other proprietary or intellectual property right belonging to them. Any infringement claim, even one without merit, could
result in the expenditure of significant financial and managerial resources to defend against the claim. Moreover, a successful claim
of product infringement against us or a settlement could require us to pay substantial amounts or obtain a license to continue to use
the technology that is the subject of the claim, or otherwise restrict or prohibit our use of the technology. We might not be able to
obtain a license from the third party asserting the claim on commercially reasonable terms, if at all. We also may not be able to obtain
a license from another provider of suitable alternative technology to permit us to continue offering the product. Infringement claims
asserted against us could have a material adverse effect on our business, operating results and financial condition.
If we are unable to protect our intellectual property rights from
unauthorized use or infringement by third parties, our business could be adversely affected.
Our success depends, in part, upon our ability to protect our intellectual property. Although we take steps
to protect our intellectual property such as requiring employees and consultants to execute confidentiality agreements, such individuals
may breach the terms of such agreements. Further, competitors may develop products and services similar to or superior to ours. Further,
we might not be able to detect unauthorized use of, or take appropriate and timely steps to enforce, our intellectual property rights.
Enforcing our rights might require considerable time, money and oversight, and we may not be successful in enforcing our rights.
Increasing scrutiny and changing expectations from investors, lenders,
customers and other market participants with respect to our Environmental, Social and Governance, or ESG, policies may impose additional
costs on us or expose us to additional risks.
Companies across all industries are facing increasing scrutiny relating to their ESG policies. Investors,
lenders and other market participants are increasingly focused on ESG practices and in recent years have placed increasing importance
on the implications and social cost of their investments. The increased focus and activism related to ESG may hinder our access
to capital, as investors and lenders may reconsider their capital investment allocation as a result of their assessment of our ESG practices.
If we do not adapt to or comply with investor, lender or other industry shareholder expectations and standards, which are evolving, or
if we are perceived to have not responded appropriately to the growing concern for ESG issues, regardless of whether there is a legal
requirement to do so, we may suffer from reputational damage and the business, financial condition and the price of
our company’s
shares could be materially and adversely affected.
Regulations related to conflict minerals may cause us to incur additional
expenses and could limit the supply and increase the costs of certain metals used in the manufacturing of our solutions.
The Dodd-Frank Wall Street Reform and Consumer Protection Act imposes disclosure requirements regarding
the use in components of our products of “conflict minerals” mined from the Democratic Republic of Congo and adjoining countries,
whether the components of our products are manufactured by us or third parties. These requirements could affect the pricing, sourcing
and availability of minerals used in the manufacture of components we use in our products. Although the U.S. Securities and Exchange Commission,
or the SEC, has provided guidance with respect to a portion of the conflict mineral filing requirements that may somewhat reduce
our reporting practices, there are costs associated with complying with the disclosure requirements and customer requests, such as costs
related to our due diligence to determine the source of any conflict minerals used in our products. Because of the complexity
of our supply chain, we may face reputational challenges if we are unable to sufficiently verify the origins of the subject minerals.
Moreover, we are likely to encounter challenges to satisfy those customers who require that all of the components of our products are
certified as “conflict free.” If we cannot satisfy these customers, they may choose a competitor’s products.
We may fail to maintain effective internal controls in accordance
with Section 404 of the Sarbanes-Oxley Act of 2002, which could have an adverse effect on our financial results and the market price of
our Ordinary Shares.
The Sarbanes-Oxley Act of 2002 imposes certain duties on us and our executives and directors. Our efforts
to comply with the requirements of Section 404(a) of the Sarbanes-Oxley Act of 2002 governing internal controls and procedures for financial
reporting, which started, in connection with our 2007 Annual Report on form 20-F, have resulted in increased general and administrative
expense and a diversion of management time and attention, and we expect these efforts to require the continued commitment of significant
resources. We may identify material weaknesses or significant deficiencies in our assessments of our internal controls over financial
reporting. Failure to maintain effective internal controls over financial reporting could result in investigation or sanctions by regulatory
authorities and could have a material adverse effect on our operating results, investor confidence in our reported financial information
and the market price of our Ordinary Shares.
Risks Related to Our Ordinary Shares
Our Ordinary Shares are traded on more than one market and this
may result in price variations.
In 2021, our Ordinary Shares were admitted for trading on the Tel Aviv Stock Exchange (“TASE”)
in addition to the NASDAQ Capital Market under the Israeli regulatory “dual listing” regime that provides companies whose
securities are listed both on NASDAQ and the TASE certain reporting leniencies. Trading in our Ordinary Shares on these markets is made
in different currencies (U.S. dollars on the NASDAQ Capital Market, and NIS on the TASE), and at different times (resulting from different
time zones, different trading days and different public holidays in the U.S. and Israel). Consequently, the trading prices of our Ordinary
Shares on these two markets often differ. Any decrease in the trading price of our Ordinary Shares on one of these markets could cause
a decrease in the trading price of our Ordinary Shares on the other market.
While our Ordinary Shares are currently listed on the TASE, there
is no guarantee as to how long such listing will be maintained.
Our Ordinary Shares are listed on each of NASDAQ and the TASE under the symbol “RADA.” We plan
to continuously examine the various considerations in respect of our dual listing and, in particular, the advisability of maintaining
or terminating such dual listing. We may in the future voluntarily delist our securities from the TASE, provided we furnish notice thereof
at least 90 days in advance of such delisting. If our Ordinary Shares are delisted, some holders of our Ordinary Shares that are traded
on the TASE may be required or will choose to sell their shares, which could result in a decline in the market price of our Ordinary Shares.
Our share price has been volatile in the past and may decline in
the future.
Our Ordinary Shares have experienced significant market price and volume fluctuations in the past and may
experience significant market price and volume fluctuations in the future in response to factors such as the following, some of which
are beyond our control:
|
● |
Quarterly variations in our operating results; |
|
● |
Operating results that vary from the expectations of securities analysts and investors; |
|
● |
Changes in expectations as to our future financial performance, including financial estimates by securities analysts and investors;
|
|
● |
Announcements of technological innovations or new products by us or our competitors; |
|
● |
Announcements by us or our competitors of significant contracts, acquisitions, strategic partnerships, joint ventures or capital
commitments; |
|
● |
Changes in the status of our intellectual property rights; |
|
● |
Announcements by third parties of significant claims or proceedings against us; |
|
● |
Additions or departures of key personnel; |
|
● |
Future sales of our Ordinary Shares; |
|
● |
Delisting of our shares from the NASDAQ Capital Market or the TASE; and |
|
● |
Stock market price and volume fluctuations. |
Domestic and international stock markets often experience extreme price and volume fluctuations. Market
fluctuations, as well as general political and economic conditions, such as a recessions, pandemics, interest and currency rate fluctuations,
and political events or hostilities in or surrounding Israel, could adversely affect the market price of our Ordinary Shares.
In the past, securities class action litigation has often been brought against companies following periods
of volatility in the market price of its securities. We may in the future be the target of similar litigation. Securities litigation could
result in substantial costs and divert management’s attention and resources both of which could have a material adverse effect on
our business and results of operations.
We do not intend to pay dividends.
We have never declared or paid cash dividends on our Ordinary Shares and do not expect to do so in the
foreseeable future. The declaration of dividends is subject to the discretion of our board of directors and will depend on various factors,
including our operating results, financial condition, future prospects and any other factors deemed relevant by our board of directors.
You should not rely on an investment in
our company if you require dividend income from your investment in
our company. The success of
your investment will likely depend entirely upon any future appreciation of the market price of our Ordinary Shares, which is uncertain
and unpredictable. There is no guarantee that our Ordinary Shares will appreciate in value or even maintain the price at which you purchased
your Ordinary Shares.
We may be classified as a passive foreign investment company, or
PFIC, which would subject our U.S. investors to adverse tax rules.
U.S. holders of our Ordinary Shares may face income tax risks. Based on the composition of our income,
assets (including the value of our goodwill, going-concern value or any other unbooked intangibles, which may be determined based on the
price of the ordinary shares), and operations, we believe we will not be classified as a “passive foreign investment company”,
or PFIC, for the 2021 taxable year. However, because PFIC status is based on our income, assets and activities for the entire taxable
year, it is not possible to determine whether we will be characterized as a PFIC for our current taxable year or future taxable years
until after the close of the applicable taxable year. Moreover, we must determine our PFIC status annually based on tests that are factual
in nature, and our status in the current year and future years will depend on our income, assets and activities in each of those years
and, as a result, cannot be predicted with certainty as of the date hereof. Furthermore, fluctuations in the market price of our ordinary
shares may cause our classification as a PFIC for the current or future taxable years to change because the aggregate value of our assets
for purposes of the asset test, including the value of our goodwill and unbooked intangibles, generally will be determined by reference
to the market price of our shares from time to time (which may be volatile). The IRS or a court may disagree with our determinations,
including the manner in which we determine the value of our assets and the percentage of our assets that are passive assets under the
PFIC rules. Therefore, there can be no assurance that we will not be a PFIC for the current taxable year or for any future taxable year.
Our treatment as a PFIC could result in a reduction in the after-tax return to U.S. Holders (as defined below under Item 10E. “Additional
Information – Taxation”) of our Ordinary Shares and would likely cause a reduction in the value of such shares. A foreign
corporation will be treated as a PFIC for U.S. federal income tax purposes if either (1) at least 75% of its gross income for any taxable
year consists of certain types of “passive income,” or (2) at least 50% of the average value of the corporation’s gross
assets produce, or are held for the production of, such “passive income.” For purposes of these tests, “passive income”
includes dividends, interest, gains from the sale or exchange of investment property and rents and royalties other than rents and royalties
that are received from unrelated parties in connection with the active conduct of a trade or business. If we are treated as a PFIC, U.S.
Holders of Ordinary Shares would be subject to a special adverse U.S. federal income tax regime with respect to the income derived by
us, the distributions they receive from us, and the gain, if any, they derive from the sale or other disposition of their Ordinary Shares.
U.S. Holders should carefully read Item 10E. “Additional Information – Taxation” for a more complete discussion of the
U.S. federal income tax risks related to owning and disposing of our Ordinary Shares.
Risks Related to Our Location in Israel
Political, economic and military instability in Israel may disrupt
our operations and negatively affect our business condition, harm our results of operations and adversely affect our share price.
We are incorporated under the laws of, and our principal executive offices and manufacturing and research
and development facilities are located in the State of Israel. As a result, political, economic and military conditions affecting Israel
directly influence us. Any major hostilities involving Israel, a full or partial mobilization of the reserve forces of the Israeli army,
the interruption or curtailment of trade between Israel and its present trading partners, or a significant downturn in the economic or
financial condition of Israel could adversely affect our business, financial condition and results of operations.
Conflicts in North Africa and the Middle East, including in Egypt and Syria which border Israel, have resulted
in continued political uncertainty and violence in the region. Efforts to improve Israel’s relationship with the Palestinian Authority
have failed to result in a permanent solution, and there have been numerous periods of hostility in recent years. In addition, relations
between Israel and Iran continue to be seriously strained, especially with regard to Iran’s nuclear program. Such instability may
affect the local and global economy, could negatively affect business conditions and, therefore, could adversely affect our operations.
To date, these matters have not had any material effect on our business and results of operations; however, the regional security situation
and worldwide perceptions of it are outside our control and there can be no assurance that these matters will not negatively affect our
business, financial condition and results of operations in the future.
Furthermore, we could be adversely affected by the interruption or reduction of trade between Israel and
its trading partners. Some countries, companies and organizations continue to participate in a boycott of Israeli companies and others
doing business with Israel or with Israeli companies. As a result, we are precluded from marketing our products to these countries, companies
and organizations. Foreign government defense export policies towards Israel could also make it more difficult for us to obtain the export
authorizations necessary for our activities. Also, over the past several years there have been calls in Europe and elsewhere to reduce
trade with Israel. Restrictive laws, policies or practices directed towards Israel or Israeli businesses may have an adverse impact on
our operations, our financial results or the expansion of our business. Israel has also been aggressive in mandating quarantines and restricting
local and international travel during the COVID-19 pandemic.
Our results of operations may be negatively affected by the obligation
of our personnel to perform military service.
Some of our employees in Israel are obligated to perform annual military reserve duty and are subject to
being called for active duty under emergency circumstances. If a military conflict or war arises, these individuals could be required
to serve in the military for extended periods of time. Our operations could be disrupted by the absence for a significant period of one
or more of our executive officers or key employees or a significant number of other employees due to military service. Any disruption
in our operations could adversely affect our business.
We may not be able to enforce covenants not-to-compete under current
Israeli law.
We have non-competition agreements with most of our employees, many of which are governed by Israeli law.
These agreements generally prohibit our employees from competing with us or working for our competitors for a specified period following
termination of their employment. However, Israeli courts are reluctant to enforce non-compete undertakings of former employees and tend,
if at all, to enforce those provisions for relatively brief periods of time in restricted geographical areas and only when the employee
has unique value specific to that employer’s business and not just regarding the professional development of the employee. Any such
inability to enforce non-compete covenants may cause us to lose any competitive advantage resulting from advantages provided to us by
such confidential information.
We may become subject to claims for remuneration or royalties for
assigned service invention rights by our employees, which could result in litigation and adversely affect our business.
A significant portion of our intellectual property has been developed by our Israeli employees in the course
of their employment for us. Under the Israeli Patent Law, 5727-1967, or Israeli Patent Law, inventions conceived by an employee during
the term and as part of the scope of his or her employment with a company are regarded as “service inventions,” which belong
to the employer, absent a specific agreement between the employee and employer giving the employee service invention rights. The Israeli
Patent Law also provides that if there is no such agreement between an employer and an employee, the Israeli Compensation and Royalties
Committee, or C&R Committee, a body constituted under the Israeli Patent Law, shall determine whether the employee is entitled to
remuneration for his inventions. The C&R Committee (decisions of which have been upheld by the Israeli Supreme Court) has held that
employees may be entitled to remuneration for their service inventions despite having specifically waived any such rights. Further, the
C&R Committee has not yet set specific guidelines regarding the method for calculating this remuneration or the criteria or circumstances
under which an employee’s waiver of his right to remuneration will be disregarded. We generally enter into intellectual property
assignment agreements with our employees pursuant to which such employees assign to us all rights to any inventions created in the scope
of their employment or engagement with us. Although our employees have agreed to assign to us service invention rights and have specifically
waived their right to receive any special remuneration for such assignment beyond their regular salary and benefits, we may face claims
demanding remuneration in consideration for assigned inventions. As a consequence of such claims, we could be required to pay additional
remuneration or royalties to our current or former employees, or be forced to litigate such claims, which could negatively affect our
business.
Service and enforcement of legal process on us and our directors
and officers may be difficult to obtain.
Service of process upon our directors and officers and the Israeli experts named in this annual report,
most of who reside outside the U.S., may be difficult to obtain within the U.S. Furthermore, since substantially most of our assets, our
directors and officers and the Israeli experts named in this annual report are located outside the U.S., any judgment obtained in the
U.S. against us or these individuals or entities may not be collectible within the U.S.
There is doubt as to the enforceability of civil liabilities under the Securities Act and the Securities
Exchange Act in original actions instituted in Israel. However, subject to certain time limitations and other conditions, Israeli courts
may enforce final judgments of U.S. courts for liquidated amounts in civil matters, including judgments based upon the civil liability
provisions of those Acts.
The rights and responsibilities of our shareholders are governed
by Israeli law and differ in some respects from those of a typical U.S. corporation.
We are incorporated under Israeli law and the rights and responsibilities of holders of our Ordinary Shares
are governed by our
articles of association and by Israeli law. These rights and responsibilities differ in some respects from the rights
and responsibilities of shareholders in typical U.S. corporations. In particular, a shareholder of an Israeli company has a duty to act
in good faith in exercising his or her rights and fulfilling his or her obligations toward
the company and other shareholders and to refrain
from abusing his power in
the company, including, among other things, in voting at the general meeting of shareholders on certain matters.
Israeli law provides that these duties are applicable to shareholder votes at the general meeting with respect to, among other things,
amendments to a company’s
articles of association, increases in a company’s authorized share capital, mergers and actions
and transactions involving interests of officers, directors or other interested parties which require the shareholders’ approval.
In addition, a controlling shareholder of an Israeli company or a shareholder who knows that he or she possesses the power to determine
the outcome of a vote at a meeting of our shareholders, or who has, by virtue of
the company’s
articles of association, the power
to appoint or prevent the appointment of an office holder in
the company, or any other power with respect to
the company, has a duty of
fairness toward
the company. However, Israeli law does not define the substance of this duty of fairness. There is little case law available
to assist in understanding the implications of these provisions that govern shareholder behavior.
Israeli government programs and tax benefits may be terminated or
reduced in the future, which could increase our tax expenses.
We participate from time to time in programs of the Israeli Innovation Authority (formerly the Office of
the Chief Scientist) of the Israeli Ministry of Economy, or Innovation Authority, for which we receive funding for the development of
technologies and products. We may benefit from certain Israeli government programs and tax benefits, particularly from tax exemptions
and cash incentives, including “Approved Enterprise” status due to our manufacturing facilities in Israel. To be eligible
for these programs and tax benefits or similar programs in the future, we must meet certain conditions, including making specified investments
in fixed assets and equipment. For more information about these programs, see Item 5. “Operating
and financial review and prospects – Research & Developments – Israeli Innovation Authority.”
If we fail to comply with these conditions, we may be required to pay additional penalties, make refunds and may be denied future benefits.
From time to time, the Government of Israel has discussed reducing or eliminating the benefits available under these programs, and therefore
these benefits may not be available to us in the future at their current levels or at all.
As a foreign private issuer whose shares are listed on the NASDAQ
Capital Market, we may follow certain home country corporate governance practices instead of certain NASDAQ requirements.
As a foreign private issuer whose shares are listed on the NASDAQ Capital Market, we are permitted to follow
certain home country corporate governance practices instead of certain requirements of The NASDAQ Stock Market Rules. Among other things,
as a foreign private issuer we may follow home country practice with regard to the composition of the board of directors, director nomination
procedure, and quorum at shareholders’ meetings. In addition, we may follow our home country law, instead of the NASDAQ Stock Market
Rules, which require that we obtain shareholder approval for certain dilutive events such as for the establishment or amendment of certain
equity based compensation plans, an issuance that will result in a change of control of
the company, certain transactions other than a
public offering involving issuances of a 20% or more interest in
the company, and certain acquisitions of the stock or assets of another
company. A foreign private issuer that elects to follow a home country practice instead of NASDAQ requirements must submit to NASDAQ in
advance a written statement from an independent counsel in such issuer’s home country certifying that the issuer’s practices
are not prohibited by the home country’s laws. In addition, a foreign private issuer must disclose in its annual reports filed with
the SEC each such requirement that it does not follow and describe the home country practice followed by the issuer instead of any such
requirement. Accordingly, our shareholders may not be afforded the same protection as provided under NASDAQ’s corporate governance
rules.
We were incorporated under the laws of the State of Israel on December 8, 1970. We are a public limited
company under the Israeli Companies Law 1999-5759, or the Israeli Companies Law, and operate under this law and associated legislation.
Our registered offices and principal place of business are located at 7 Giborei Israel Street, Netanya 4250407, Israel, and our telephone
number is: +972-76-538-6200. Our
website address is
www.rada.com. The information on our
website is not
incorporated by reference into this annual report.
We develop, manufacture and sell defense electronics, including tactical land-based radars for defense
forces and for critical infrastructure protection solutions, avionics solutions for unmanned aerial vehicles and airborne data/video recording
and management systems. In 2019 we completed the sale of our legacy commercial products subsidiary, Beijing
Hua Rui Aircraft Maintenance and Service, Co., Ltd., known as CACS. The financial results presented in this annual report were adjusted
to present CACS’ results in a separate line as “Discontinued Operations.”
In March 2018, we announced the formation of a joint venture company with SAZE Technologies LLC. The new
company, RADA Technologies LLC, or RTL is based in Germantown, Maryland. In July 2019, we acquired full ownership of RTL. RTL is focused
on the adaptation of our tactical radar technology for the U.S. market, certifying the radars to U.S. standards, producing our radars
for the U.S. market needs, and providing infrastructure for maintenance and support. In 2020, we formed a new company, RADA Innovations
LLC, or RIL, to perform certain classified work on our radars for the U.S. market. RIL began its operations in 2021.
B. Business Overview
Industry Overview
We are a product-oriented company focused on the defense electronics market. This is a growing market and
is currently a large part of the defense industry. The defense electronics market reflects two contradictory trends, the proliferation
of defense electronics, which has been offset by the significant reduction in the price of electronic systems which is reducing the dollar
value of the market. Today, new military vehicles of all kinds are equipped with significantly more electronic systems than they used
to carry in the past. The increasing usage of advanced electronics in modern vehicles, including upgrades of existing technology and the
growing use of unmanned vehicles of all kinds, have provided significant growth to the market.
Today’s advanced defense electronics systems typically incorporate components that are derived from
the industrial or the consumer electronics markets, especially from the telecom and automotive markets. Most of the defense electronics
systems are built with commercial components and even with sub-systems, which reduce the overall price, and at the same time may generate
complex obsolescence issues.
Purchasers of defense electronics products are either governments or major integrators. Engagement in business
relationships with these customers is complex, have a long sales cycle and requires long-term commitments for future support of delivered
hardware. Production batches of such products are relatively small.
Suppliers of defense electronic systems are either providers of products and sub-systems to major integrators
and platform manufacturers or are providers of integrated systems to the industry or to the armed forces. These companies are typically
very large and have diversified product offerings.
New products in the defense electronic market are usually developed utilizing customer sponsored research
and development funds and are typically tailored to specific customer needs. In many cases, the customer who pays for the design and adaptation,
limits the use of intellectual property that was funded by it for other applications, due to either commercial or security reasons. We
are developing our products utilizing our internal resources, and as a result we own the proprietary rights and are able to address a
wide range of customers and integrators.
Products and Services
We primarily sell state-of-the-art defense electronics products. We may also provide end-to-end solutions
for one or more systems or sub-systems. Our current product lines are:
|
● |
Tactical radars, land-based, for defense forces and critical infrastructure protection solutions; and |
|
● |
Military Avionics (data/video recorders, and core avionics for aircraft and UAVs). |
Land-Based Tactical Radars for Defense Forces and Critical Infrastructure Protection
Solutions.
We develop advanced land-based radars for tactical applications such as defense forces protection and critical
infrastructure protection. Our pulse Doppler, software-defined radars are solid-state, fully digital, incorporate active electronically
scanned array, or AESA antenna, are compact, mobile and highly reliable, provide hemispheric spatial coverage and multi-mission capabilities
and can operate on-the-move, or OTM.
The conflicts in which modern armies have been engaged in recent years dictate the needs for instantaneous
and real-time intelligence, minimal cycle time for target acquisition, highly accurate weapons with minimal collateral damage and discrimination
between hostiles and civilians. Our tactical radars, which move with the maneuvering combat units in the field and operate OTM, provide
the real-time knowledge of whether and from where they are threatened, detect all relevant threats, whether unfriendly fire or Drones/UAVs/fighters/helicopters
from any angle (including very high angles), discriminate among threats and provide the needed intelligence for any course of action,
whether counter-fire or avoidance. We believe that the performance-over-price ratio of our radars makes them ideal solutions for the current
needs and requirements of the maneuver forces, and for the protection of critical infrastructure against a variety of threats that can
be applied on it.
We have developed various radar hardware platforms: the compact hemispheric radar, or CHR, and its advanced
variants, eCHR, aCHR and iCHR, which are tailored for use on combat vehicles and short-range protection applications; and a family of
multi-mission hemispheric radars, or MHRs, and its advanced variants, ieMHR, nMHR and exMHR, which are tailored for use in force and critical
infrastructure protection applications. All of our radar platforms share basic characteristics, but differ in range, size, frequency band
in some cases, weight, and price. We implement several operational missions for our platforms by soft-changing the radar operational parameters.
The current operational missions of the CHR family of radar platforms are:
|
● |
Radar sensors for active protection systems, or APS, detecting all relevant threats that may be fired at combat vehicles, including
RPGs, anti-tank guided missiles (ATGMs) and projectiles and provide 360° hemispheric coverage. The system delivers threat data to
the APS, enabling it to neutralize threats. |
|
● |
Very-short-range hemispheric air surveillance radar system which can detect, classify and track aerial vehicles, with emphasis on
small UAVs. Mobile or stationary, the system can be integrated with any C4I system and other radars and sensors, and can operate either
as a stand-alone, or as part of a large-scale surveillance system. |
|
● |
Perimeter and border protection, detecting, identifying, and tracking aerial and surface intruders including slow and small aircraft,
vehicles, vessels, and pedestrians at tactical ranges. Our radars can operate either on a stand-alone basis, or as part of a large-scale
surveillance system. |
The current operational missions of the MHR family of radar platforms are the following:
|
● |
Hostile fire detection radar systems which detect, track, classify and locate direct and elevated threats fired at stationary or
mobile forces. They compute the Point-of-Origin (POO) and Point-of-Impact (POI) of the threats, which may be rockets, artillery, mortars,
ATGMs, RPGs, and more other threats. The systems can be integrated with any protection and Command, Control, Communications, Computers
and Intelligence (C4I) system and be installed at stationary bases and posts, or onboard fighting vehicles. |
|
● |
Tactical hemispheric air surveillance radar systems which detect, classify and track all types of aerial vehicles, including fighters,
helicopters, UAVs, transport aircraft, etc. at tactical ranges. Mobile or stationary, the systems can be integrated with any C4I system
and other radars and sensors, and can operate either as a stand-alone, or as part of a large-scale surveillance system. |
|
● |
Three-dimensional perimeter surveillance radar systems for critical infrastructure protection can detect, identify, and track aerial
and surface intruders including slow and small aircraft, air breathing targets, vehicles, vessels, and pedestrians at tactical ranges.
The systems can operate either as a stand-alone, or as part of a large-scale surveillance system. |
Among our customers and users of our radar systems are leading defense forces and defense contractors worldwide,
including the Israeli MOD, IMI (an Elbit Systems subsidiary), Elbit, Rafael, MER Group, Lockheed Martin, Boeing, Leonardo DRS, Anduril,
CACI, General Atomics, Elettronica, the U.S. Marine Corps and Navy, the U.S. Air Force, Indian Security Forces, Rheinmetall, Leonardo,
MBDA, Thales and many additional integrators and end-users. Some of our customers have purchased a small number of radars for evaluation
and integration in their air defense and/or other systems. These initial purchases may turn into larger production orders upon evaluation.
Military Avionics
We are active in the field of mission data and video recording, management, and post-mission analysis and
debriefing for fighter and trainer aircrafts. Over the past 25 years we have developed, fielded and supported a wide range of solid-state
digital recorders, cameras and debriefing systems for aerospace and military applications, including:
|
● |
Digital video/audio/data recorders, or DVDR (with data transfer functions); |
|
● |
HD-DVDR, high definition digital video/audio/data recording for fighter and trainer aircraft; |
|
● |
A wide range of head-up-displays color video cameras, or HCVC, for fighter aircraft; and |
|
● |
A variety of ground debriefing solutions, or GDS. |
These digital recorders feature state-of-the-art technologies and are designed for military applications.
Our high-performance recorders provide simultaneous, high-capacity video (both analog and digital/HD), audio and data recording, high
throughput and mass storage handling capabilities, supporting rapid dissemination and real-time playback. Our video recorders implement
MPEG-2 and/or MPEG-4 (H.264) compression formats and facilitate continuous recording over extended mission durations. Recent upgrades
to our recorders provide the ability to record high-definition video formats such as HD-SDI.
Our GDS synchronized video, audio, data, and air combat maneuvering debriefing. GDS vary from personal,
laptop-size debriefing units, through robust desktop multi-channel systems supporting the mission debriefing of four-aircraft formations
up to large-scale simultaneous debriefing systems. These network-based systems support large numbers of participants operating from different
locations and provide advanced data management features.
We have been a developer and manufacturer of core avionics systems for over 35 years. We currently offer
a wide spectrum of military avionics systems designed for integration in new and upgraded military aircraft and UAVs worldwide. Our core
avionics products are easily adapted to western, eastern, and indigenous-origin platforms of all kinds. In particular, our avionics for
UAVs are extremely compact through modern board connectivity solutions, use of innovative passive/conductive cooling techniques, withstand
extreme environmental conditions and are very reliable and affordable.
We offer the following avionics solutions:
|
● |
Mission data recorders and debriefing solutions and HUD video cameras (as described above); and |
|
● |
Avionics for UAVs (Interface control processors, engine control computers, Payload management computers and others). |
Our airborne products and system solutions are fully qualified and operated by leading air forces and prime
integrators worldwide, such as the Israeli Air Force, Lockheed Martin, Boeing Company, HAL, Embraer, IAI, Rafael, the Chilean Air Force,
and many others. Our units are installed onboard F-16, F-15, T-6, A-4, Jaguar, MiG-27, Su-30MKI, Dhruv Helicopter, MiG-29, Super-Tucano
and other aircraft, and onboard a large number of UAVs.
Business Development, Sales and Marketing
Strategy
Our business development strategy is based on the following principles:
|
● |
Becoming a reliable and trusted supplier of sensors and avionics sub-systems to defense system integrators and major platforms manufacturers
with global sales, such as Lockheed Martin, Boeing, Elbit, IAI, Anduril, Rafael, Leonardo DRS, Embraer, HAL, Elettronica, CACI and others;
|
|
● |
Establishing operations in our primary target markets (i.e. U.S.), either through subsidiaries or through joint ventures, for local
presence, direct market development, localization of the technology, production and customer support; |
|
● |
Expanding our global business development efforts and potential customer base, by engaging business development consultants and service
providers in the countries and territories in which our products may be used, and actively managing this global network; and |
|
● |
Establishing strategic relationships with leading integrators in the prime target markets for tactical radars, i.e. U.S., Europe,
India; such relationships may involve indigenization and localization of our technologies to enable sales in significant quantities in
these markets. |
Strategic Relationships and Customers
As part of our strategy, we have established a number of strategic relationships with leading global defense
contractors and several air forces. We have focused our marketing and sales efforts to support these relationships.
Lockheed Martin. Lockheed Martin is the manufacturer of the F-16
aircraft, one of the most popular fighter aircraft in the western world today. We are supplying the DVDR, HD-DVDR and GDS for new F-16
aircraft production and for F-16 upgrade programs led by Lockheed Martin. In 2015, Lockheed Martin ordered a single radar system for integration
in their internally funded high energy laser research and development program and recently acquired a second radar for the same purpose.
IMI Systems. IMI (a subsidiary of Elbit Systems) is a world leader
in the field of APS for land platforms and is the developer and manufacturer of the “Iron Fist” APS. We teamed with IMI on
the integration and production of our CHR family of radars as part of their “Iron Fist” APS solution for local and global
customers. During 2016, there was a global increase in the interest of major forces in APS. As a result, since then, we are engaged in
extensive efforts with IMI to integrate, test and provide its “Iron Fist” APS to customers in Europe and North America, along
with our on-going support. We have sold dozens of radars to IMI to support these activities. We anticipate that these testing efforts
will mature into acquisition programs. The first acquisition program was purchased by the IMOD in the end of 2019 to equip the Eitan fighting
vehicle with the Iron Fist APS.
Boeing Defense, Space and Security. Boeing, a provider of air defense
and high-energy laser systems, acquired our MHR in 2013 for evaluation of its use as part its directed energy tactical systems and in
2017 acquired our MHR for integration into critical infrastructure surveillance solutions. We also provide Boeing with recorders and debriefing
stations for the T-45 VMTS and have received follow-on orders from Boeing.
Leonardo DRS. DRS is a major player in the defense electronics
market in North America, with a focus on tactical systems and radars. In 2017, we signed a cooperation agreement with DRS to market and
sell our tactical radars in the North American market for counter-UAV, short-range air defense, and other solutions. DRS has acquired
a few MHR radars and is actively promoting our radars as part of their system solutions. In 2018, DRS was selected by the US Army as the
mission equipment package provider for the Army’s IM-SHORAD program, which includes our MHR radars as onboard search sensors. This
program has the potential for sale of 144 vehicles, each with 4 MHR radars on board. To date, we have delivered radars for nine prototype
units and spares, and a production purchase order for 87 vehicles incorporating 348 radar units.
Anduril Industries Inc. Anduril is a fast-growing player in the
defense electronics market in North America. Anduril provides base defense and force protection applications, critical infrastructure
protection solutions, border security and counter drone systems. Our radars are integrated within such solutions. In 2020 & 2021,
we delivered more than 220 radars of the MHR family to be integrated with Anduril’s systems.
European Air Defense Integrators. Two major European air defense
integrators have purchased radars for integration and testing. We have signed a value-added representation agreement with one of the integrators
for certain countries where it has a dominant position in sales of air defense and other solutions.
Rafael Advanced Defense Systems Ltd. Rafael is a world leader in
the development and supply of missiles, smart weapons and pods of various types. Rafael has become a strategic customer of ours as a result
of our development and production of a few advanced built-to-specification products in recent years. Recently, Rafael selected the MHR
as the radar for the “Drone Dome” system that is designed to counter UAVs and drones and is purchasing radars from us for
their customers.
Military Forces. We are a provider of digital recorders and debriefing
solutions to the Chilean Air Force and to the Indian Air Force, through HAL. Two other Asian military forces have purchased radars for
air surveillance and counter-mortar applications. Our tactical radars are used by all the U.S. defense forces for ground-based air
defense, point defense, counter rocket, artillery and mortar solutions, and counter unmanned aerial systems. We believe that these strategic
relationships with military forces provide us with the potential for prolonged cooperation.
Israel Aerospace Industries. We actively supply avionics and test
equipment to four different divisions of IAI, and in particular to the MALAT division, who is a major UAS global provider and utilizes
our products and services for repeated follow-on orders.
Hindustan Aeronautics Ltd. HAL is the major aerospace integrator
in India. We are currently cooperating with four divisions of HAL and supply DVDRs, HCVCs, GDS, support equipment and other services.
Embraer S.A. The Military Aircraft Division of the Brazilian aircraft
manufacturer is a strategic customer. In addition to supplying avionics such as DVDR, INS and HCVC to Embraer, we are participating in
Embraer’s programs through the development and supply of avionic units per their specifications and their training and support activities.
Business Development and Marketing
Our Chief Executive Officer, Mr.
Dov Sella, together with Mr. Gil Schwartz, our VP Business Development
& Marketing and Mr. Rann Maron, our VP Business Development for India, lead our business development and marketing efforts from Israel.
Mr. Bill Watson, Ms. Charlene Caputo and Mr. Max Cohen are responsible for our business development and marketing efforts in North America.
We currently employ fifteen additional professionals (some of whom are part-time consultants) in business development and the sales of
our products. Our program managers, Chief Technology Officer, Chief Operating Officer, VP Product Development and our product managers
and engineering departments support our marketing and sales efforts with respect to proposal preparations and product demonstrations.
In addition, we have engaged business development consultants in Europe, South America and Asia who receive success fees for sales generated
by them. Our RTL subsidiary is responsible for business development in the North American market and works directly with and in
cooperation with our U.S. partners on the exploitation of large opportunities in the U.S. Four of our seven part-time consultants are
supporting this activity.
The Israeli Ministry of Defense has historically supported and continues to support our marketing efforts
through its defense export assistance branch and through various projects for the IDF and its related divisions. There is no guarantee
that this type of assistance will be available to us in the future.
We take part and present our tactical radars at the major land systems exhibitions on a regular basis,
such as the AUSA Annual Meetings, Eurosatory in Paris, DSEI in London, and in regional or focused exhibitions such as DefExpo in India
and SOFIC, MDM and many others in the USA.
Some of our
contracts are fixed-price
contracts, under which the price is not subject to adjustment due
to the costs incurred in the performance of the
contracts, as long as the costs incurred, and work performed, fall within governmental
guidelines. Under our fixed-price
contracts, we assume the risk of increased or unexpected costs that may reduce our profits or even generate
losses. This risk can be particularly significant under fixed-price
contracts for research and development involving new technologies.
Our books and records may be subject to audits by the Israeli Ministry of Defense and other governmental
agencies, including the U.S. Department of Defense. These audits may result in adjustments to
contract costs and profits.
Principal Customers
We generally complete a few major transactions each year, each accounting for 10% or more of our revenues
for such year. As a result, each year a significant portion of our revenues is derived from a small number of customers. The following
table sets forth our principal customers in 2019, 2020 and 2021:
|
|
Percentage of Revenues |
|
|
|
2019 |
|
|
2020 |
|
|
2021 |
|
Customer A |
|
|
7 |
% |
|
|
2 |
% |
|
|
26 |
% |
Customer B |
|
|
- |
% |
|
|
21 |
% |
|
|
16 |
% |
Customer C |
|
|
7 |
% |
|
|
14 |
% |
|
|
4 |
% |
Customer D |
|
|
- |
% |
|
|
10 |
% |
|
|
2 |
% |
Customer E |
|
|
12 |
% |
|
|
4 |
% |
|
|
1 |
% |
Although we continually strive to increase the number of our customers, we anticipate that a significant
portion of our future revenues will continue to be derived from a small number of customers. Because of our dependency on a small number
of customers and on government
contracts, we are subject to business risks, including changes in governmental appropriations and changes
in national defense policies and priorities. Although many of the programs in which we participate as a contractor or subcontractor may
extend for several years, our business is dependent upon annual appropriations and funding of new and existing
contracts. Most of the
contracts are subject to termination for the convenience of the customer, pursuant to which the customer pays only for reimbursement of
costs incurred and the applicable profit on work performed. The Israeli Government or any other government may discontinue funding purchases
of our products.
Geographical Markets
We sell our products to various air forces and companies worldwide. The following table presents our revenues
by geographical markets for the periods indicated:
|
|
2019 |
|
|
2020 |
|
|
2021 |
|
North America |
|
|
50 |
% |
|
|
60 |
% |
|
|
72 |
% |
Israel |
|
|
28 |
% |
|
|
20 |
% |
|
|
15 |
% |
Asia |
|
|
6 |
% |
|
|
2 |
% |
|
|
8 |
% |
Europe |
|
|
14 |
% |
|
|
16 |
% |
|
|
4 |
% |
South and Latin America |
|
|
2 |
% |
|
|
1 |
% |
|
|
- |
% |
Other |
|
|
- |
% |
|
|
1 |
% |
|
|
1 |
% |
Joint Venture in India
In August 2021, we signed a Memorandum of Understanding with Alpha Design Technologies Pvt. Ltd. (“Alpha
Design”), to establish a joint venture to market, manufacture, sell and support our radars in India. Alpha Design is 1,200+ person-strong,
professional R&D and production organization, focused on the defense and aerospace domains.
Competition
The markets for our products are highly competitive. Our principal competitors in the avionics and recorder
markets include Elbit Systems Ltd., Honeywell International Inc., IAI, Northrop Grumman Corporation, Sagem Avionics LLC., Thales Group
and Zodiac Aerospace Group. Our principal competitors on tactical radars are IAI (through its subsidiary, Elta), SRC Inc., Raytheon, Northrop
Grumman, Dynetics (Leidos), SAAB, Thales, Hensoldt and Leonardo Selex. We expect to continue to face competition from these and other
competitors. All of our competitors are larger and have substantially greater resources than us, including financial, technological, marketing
and distribution capabilities, and enjoy greater market recognition than we do. These competitors may be able to achieve greater economies
of scale and may be less vulnerable to price competition than us. We may not be able to offer our products as part of integrated systems
to the same extent as our competitors or successfully develop or introduce new products that are more cost effective or offer better performance
than those of our competitors. Failure to do so could adversely affect our business, financial condition and results of operations.
Government Regulations
Israel’s defense export policy regulates the sales of our systems and products. Current Israeli policy
encourages export to approved customers of defense systems and products, such as ours, as long as the export is consistent with Israeli
government policy.
A license is required to initiate marketing activities. We are also required to obtain a specific export
license for any hardware exported from Israel. We are regulated by an Israeli law regulating export of
“dual use” items (items
that are typically sold in the commercial market, but that also may be used in the defense market) and the Defense Export Control Law
and its supplemental regulations. Those laws and regulations govern the enforcement of export control and defined certain new areas of
licensing, particularly with respect to transfer of technology. It is not certain that we will receive all the required permits and licenses
for which we may apply in the future. Our participation in governmental procurement processes in Israel and other countries is subject
to specific regulations governing the process of procuring defense
contracts. Furthermore, solicitations for procurements by governmental
purchasing agencies in Israel and other countries are governed by laws, regulations and procedures relating to procurement integrity,
including avoiding conflicts of interest and corruption in the procurement process.
In addition, antitrust laws and regulations in Israel and other countries often require governmental approvals
for transactions that are considered to limit competition. Such transactions may include cooperative agreements for specific programs
or areas, as well as mergers and acquisitions.
Intellectual Property
We generally do not rely on patent protection to protect our products and instead choose to rely upon a
combination of trade secret laws’ logical and physical security measures and contractual restrictions to protect such rights. These
measures may not be adequate to protect our technology from third-party infringement, and our competitors might independently develop
technologies that are substantially equivalent or superior to ours. Additionally, our products may be sold in foreign countries that provide
less protection for intellectual property rights than that provided under U.S. or Israeli laws.
We also rely on our trademarks and trade names to distinguish our products from the products of our competitors
and other third parties. Third parties may oppose our trademark applications, or otherwise challenge our use of our trademarks. In the
event that our trademarks are successfully challenged, we could be forced to rebrand our products, which could result in loss of brand
recognition, and could require us to devote significant resources to rebranding.
The Israeli government usually retains certain rights in technologies and inventions resulting from our
performance as a prime contractor or subcontractor under Israeli government
contracts and may generally disclose such information to third
parties, including other defense contractors. When the Israeli government funds research and development, it may acquire rights to proprietary
data and title to inventions; we may retain a non-exclusive, royalty-free license for such inventions. However, if the Israeli government
purchases only the end product, we may retain the principal rights and the government may use the data and take an irrevocable, non-exclusive,
royalty-free license.
Manufacturing and Quality Management
Our Israeli production plant is located in Beit She’an, Israel. The plant is equipped to handle most
of our manufacturing processes and testing requirements. For some processes we utilize outsourced resources. This structure allows us
flexibility and versatility. To support the growth in radar production, we have established a supply chain of board assembly providers
and chassis/casting providers, while final assembly, calibration and testing is accomplished internally. We duplicated our Israeli assembly
facilities in our facility in Maryland. that is now supplying our radars to the U.S. market.
We place great emphasis on quality management and control in all of our operations processes. Commencing
with customer requirements and expectations, via raw material inspection through completion, specifications are repeatedly checked. We
maintain a quality assurance team that participates in every stage of the design and manufacturing of the products. Our quality management
system is certified by the Standards Institute of Israel, or SII, pursuant to ISO 9001:2015 for hardware design and production and ISO
90003:2018 for software design. SII performs quality system audits twice a year and various customers perform audits four to six times
a year. Our environmental management system is certified by SII to ISO 14001:2015 (both in Israel and in the U.S.) and our quality management
system is also certified according to AS-9100D (2016), a quality management system for aerospace requirements (both in Israel and in the
U.S.). In February 2022,
our company successfully achieved ISO 45000 Certification for occupational, health and safety management systems.
According to the standard warranty incorporated in most of our sales
contracts, we warrant that our products
will be free from defects in design, materials or workmanship, and guarantee repair or replacement of defective parts typically for periods
between one to two years following delivery of a product to a customer. We also provide maintenance services to customers who sign maintenance
contracts.
Source and Availability of Raw Materials
We acquire most of the components for the manufacturing of our products from suppliers and subcontractors,
most of whom are located in Israel and the U.S. Some of these suppliers are currently the sole source of one or more components upon which
we are dependent. Since many of our purchases require long lead-times, a delay in supply of an item can significantly delay the delivery
of a product. To date, we have not experienced any specific difficulties in obtaining timely deliveries of necessary components. We depend
on a limited number of suppliers of components for our products and if we are unable to obtain these components when needed, we would
experience delays in manufacturing our products and our financial results could be adversely affected.
C. Organizational Structure
RADA Technologies LLC and RADA Innovations LLC, are our Germantown, Maryland based
subsidiaries in the
U.S.
D. Property, Plants and Equipment
We own a 30,000 square feet industrial building in Beit She’an, Israel. The building, which includes
manufacturing facilities and warehouse space, is situated on land leased from the Israel Land Authority for a period of 49 years ending
in 2034. The plant has sufficient capacity to meet our current requirements.
Our executive offices, sales and marketing and research and development facilities are located in a 30,500
square feet office facility in Netanya, Israel and a 1,450 square feet R&D facility in Beer Sheva, Israel. The Netanya lease expires
in March 2026 and the Beer Sheva lease expires in March 2022 and a new lease agreement planned to be sign afterwards. We also signed a
lease for two warehouses in Beit She’an, Israel, consisting of 14,500 square feet in total, that expire in August 2032. The aggregate
annual rent for our offices in Israel was approximately $850,000 in 2021.
As of
December 31, 2021, RTL is occupying approximately 27,500 square feet of office and production facilities
in Germantown, Maryland (also for RIL). The lease for this facility, whose current monthly rental cost is approximately $65,000, expires
in July 2030.
|
UNRESOLVED STAFF COMMENTS |
Not applicable.
|
OPERATING AND FINANCIAL REVIEW AND PROSPECTS |
A. Operating Results
The following discussion of our results of operations should be read together with
our consolidated financial statements and the related notes, which appear elsewhere in this annual report. The following discussion contains
forward-looking statements that reflect our current plans, estimates and beliefs and involve risks and uncertainties. Our actual results
may differ materially from those discussed in the forward-looking statements. Factors that could cause or contribute to such differences
include those discussed below and elsewhere in this annual report.
Overview
We develop, manufacture and sell defense electronics including tactical land radars for force and critical
infrastructure protection applications, and military avionics systems for manned and unmanned aircraft. Our U.S. wholly owned subsidiary,
RTL, is focused on adapting our tactical radar technology for the U.S. market by altering our technology to meet U.S. customer requirements,
certifying the radars to U.S. standards, manufacturing radars and providing local maintenance and support services.
General
Our consolidated financial statements appearing in this annual report are prepared in dollars and in accordance
with U.S. GAAP. Transactions and balances originally denominated in dollars are presented at their original amounts. Transactions and
balances in other currencies are re-measured into dollars in accordance with the principles set forth in the Financial Accounting Standards
Board, or FASB, Accounting Standards Codification, or ASC 830. The majority of our sales are made outside of Israel and a substantial
part of them are in dollars. In addition, a substantial portion of our costs are incurred in dollars. Since the dollar is the primary
currency of the economic environment in which we operate, the dollar is our functional and reporting currency and, accordingly, monetary
accounts maintained in currencies other than the dollar are re-measured using the foreign exchange rate at the balance sheet date. Operational
accounts and non-monetary balance sheet accounts are measured and recorded at the exchange rate in effect at the date of the transaction.
All monetary balance sheet accounts have been re-measured using the exchange rates in effect at the balance sheet date. Statement of operations
amounts have been re-measured using the average exchange rate for the period.
Impact of the COVID-19 Pandemic on Our Operations
The impact of the COVID-19 pandemic has resulted in and will likely
continue to result in significant disruptions to the global economy, as well as businesses and capital markets around the world. In an
effort to halt the outbreak of COVID-19, a number of countries, including the United States and Israel where we have key operations, placed
significant restrictions on travel, and many businesses announced extended closures. It is unclear how long total or partial shutdowns
may last and whether additional shutdowns will be necessary to the extent future outbreaks occur.
Sales. We have taken various
steps to safeguard employees that have had the effect of curtailing direct sales activities. It may take an extended period after current
restrictions end for us to engage potential new customers. We continue to monitor our sales pipeline on a day-to-day basis in order to
assess the effect of these limitations on our current sales and our future pipeline development.
Production and Supply Chain.
We encountered several delays in receiving parts shipments and our freight costs increased during 2020 and 2021. These delays have not
affected our product availability as we have increased our inventory levels, but our manufacturing may be impacted in the future due to
supply chain delays or adverse impacts on our production capacity due to government directives or health protocols that might impact our
production facilities. In addition, given the current limitations on our sales activities, it has become difficult for us to effectively
forecast future requirements for our products. Accordingly, there is a greater risk that we may overproduce or underproduce compared to
actual sales.
Negative impacts on our suppliers
and employees. COVID-19 may impact the health of our employees, management, or customers, reduce the availability of our workforce
or those of companies with which we do business, or create disruptions in our supply networks. The adverse effects of such events on us
may include disruption to our operations, or demand for our products in the short and/or long term.
Results of Operations
The following table presents certain financial data expressed as a percentage of total revenues for the
periods indicated:
|
|
|
|
|
|
|
|
|
2020 |
|
|
2021 |
|
Revenues |
|
|
100 |
% |
|
|
100 |
% |
|
|
100 |
% |
Cost of revenues |
|
|
64.0 |
% |
|
|
62.8 |
% |
|
|
59.4 |
% |
Gross profit |
|
|
36.0 |
% |
|
|
37.2 |
% |
|
|
40.6 |
% |
Research and development |
|
|
15.6 |
% |
|
|
11.6 |
% |
|
|
8.5 |
% |
Marketing and selling |
|
|
9.1 |
% |
|
|
6.6 |
% |
|
|
5.3 |
% |
General and administrative |
|
|
16.0 |
% |
|
|
11.8 |
% |
|
|
9.3 |
% |
Net loss from sale of fixed assets |
|
|
0.0 |
% |
|
|
0.0 |
% |
|
|
0.0 |
% |
Operating income (loss) |
|
|
(4.7 |
)% |
|
|
7.2 |
% |
|
|
17.4 |
% |
Financial (expenses) income, net |
|
|
(0.3 |
)% |
|
|
0.2 |
% |
|
|
(0.1 |
)% |
Net income (loss) from continuing operations |
|
|
(5.0 |
)% |
|
|
7.4 |
% |
|
|
17.2 |
% |
Net income (loss) from discontinued operations |
|
|
(0.3 |
)% |
|
|
0.0 |
% |
|
|
0.0 |
% |
Tax benefit |
|
|
0.0 |
% |
|
|
0.0 |
% |
|
|
4.2 |
% |
Net income (loss) |
|
|
(5.3 |
)% |
|
|
7.4 |
% |
|
|
21.4 |
% |
Net income (loss) attributable to non-controlling interest |
|
|
(0.7 |
)% |
|
|
0.0 |
% |
|
|
0.0 |
% |
Net income (loss) attributable to RADA Electronic Industries’ shareholders |
|
|
(4.6 |
)% |
|
|
7.4 |
% |
|
|
21.4 |
% |
Revenues. Our revenues increased by 54% to $$117.2 million in 2021
from $76.2 million in 2020, mainly due to the increase in sales of our radars in the U.S.
Cost of Revenues. Cost of revenues were $69.6 million in 2021 and
$47.9 million in 2020, reflecting the increase in revenues.
Gross Profit. Our gross profit increased by 68% to $47.5 million
in 2021 from $28.3 million in 2020. Our gross profit margin was approximately 40.6% in 2021 and 37.2% in 2020. The increase in our gross
profit in 2021 was mainly attributable to the increase in revenues generated from the sale of radars and improved production efficiencies.
Research and Development Expenses. Our research and development
expenses increased by 13% to $10.0 million in 2021 from $8.8 million in 2020. The increase is a result of our strategy to achieve and
maintain a technological edge for our products, including the development of our next generation of radars.
Marketing and Selling Expenses. Marketing and selling expenses
increased by 24% to approximately $6.2 million in 2021 from $5.0 million in 2020. We increased our level of marketing and selling expenses
primarily due to our efforts to sell our radar products, mainly reflected in the costs incurred as part of our participation in field
demonstrations requested by our potential customers as well as a result of our increased revenues.
General and Administrative Expenses. General and administrative
expenses increased by 22% to approximately $10.9 million in 2021 from $9.0 million in 2020. The increase is primarily attributable to
the expansion of our infrastructure to support our continued revenue growth as well as to the increase in the non-cash expense associated
with employee stock-based compensation.
Financial Income, Net. We had net financial expenses of $0.2 million
in 2021 compared to $0.2 million of net financial income in 2020, reflecting the influence of the changes in the exchange rate between
the US dollar and the NIS.
Tax Benefit. A deferred tax asset was recorded in the second quarter
of 2021 in view of our continued profitability.
Our Location in Israel
We are incorporated under the laws of the State of Israel, and our principal executive offices and principal
manufacture, research and development facilities are located in Israel. See Item 3D “Key Information
– Risk Factors – Risks Relating to Our Location in Israel” for a description of governmental, economic, fiscal,
monetary or political polices or factors that have materially affected or could materially affect our operations.
Corporate Tax Rate
Israeli companies were generally subject to corporate tax at a rate of 23% in 2021 and are subject to the
same corporate tax rate in 2022. Nevertheless, our effective tax rate, considering the Israeli tax benefits related to our activities,
is expected to be 10.2%.
As of
December 31, 2021, our net operating loss carry forward for Israeli tax purposes was approximately
$55.6 million and capital loss carry forwards of approximately $8.8 million. As of
December 31, 2021, our U.S.
subsidiaries have
no U.S. federal carry forward tax losses.
Trade Relations
Israel is a member of the United Nations, the International Monetary Fund, the International Bank for Reconstruction
and Development, and the International Finance Corporation. Israel is a member of the World Trade Organization and is a signatory to the
General Agreement on Tariffs and Trade. Israel is a member of the Organization for Economic Co-operation and Development, or the OECD,
an international organization whose members are governments of mostly developed economies. The OECD’s main goal is to promote policies
that will improve the economic and social well-being of people around the world. In addition, Israel has been granted preferences under
the Generalized System of Preferences from the U.S., Australia, Canada and Japan. These preferences allow Israel to export the products
covered by such programs either duty-free or at reduced duties.
Israel and the E.U. concluded a Free Trade Agreement in July 1975 that confers some advantages with respect
to Israeli exports to most European countries and obligates Israel to lower its tariffs with respect to imports from these countries over
a number of years. In 1985, Israel and the U.S. entered into an agreement to establish a Free Trade Area. The Free Trade Area has eliminated
all tariff and some non-tariff barriers on most trade between the two countries. On
January 1, 1993, an agreement between Israel and the
European Free Trade Association, known as the
“EFTA,” established a free-trade zone between Israel and the EFTA nations. In
November 1995, Israel entered into a new agreement with the E.U., which includes a redefinition of rules of origin and other improvements,
such as allowing Israel to become a member of the Research and Technology programs of the E.U.
Impact of Currency Fluctuation and of Inflation
A significant portion of the cost of our Israeli operations, primarily personnel and facility-related,
is incurred in NIS. Therefore, our NIS related costs, as expressed in dollars, are influenced by the exchange rate between the dollar
and the NIS. In addition, if the rate of inflation in Israel will exceed the rate of devaluation of the NIS in relation to the dollar,
or if the timing of such devaluations were to lag considerably behind inflation, our cost as expressed in dollars may increase. NIS linked
balance sheet items, may also create foreign exchange gains or losses, depending upon the relative dollar values of the NIS at the beginning
and end of the reporting period, affecting our net income and earnings per share. Although we may use hedging techniques, we may not be
able to eliminate the effects of currency fluctuations. Therefore, exchange rate fluctuations could have a material adverse impact on
our operating results. The caption “Financial expenses, net” in our consolidated financial statements includes the impact
of these factors as well as traditional interest income or expense.
The following table sets forth, for the periods indicated, (i) depreciation or appreciation of the NIS
against the most important currency for our business, the dollar, until December 31 of each year and the year before, and (ii) inflation
as reflected in changes in the Israeli consumer price index.
|
|
|
|
|
|
|
|
|
2018 |
|
|
2019 |
|
|
2020 |
|
|
2021 |
|
NIS vs. U.S. Dollar |
|
|
(9.8 |
)% |
|
|
3.2 |
% |
|
|
(7.8 |
)% |
|
|
(7.0 |
)% |
|
|
(3.0 |
)% |
Israeli Consumer Price Index |
|
|
(1.5 |
)% |
|
|
0.8 |
% |
|
|
0.6 |
% |
|
|
(0.7 |
)% |
|
|
2.5 |
% |
Since exchange rates between the NIS and the dollar fluctuate continuously, exchange rate fluctuations,
particularly larger periodic devaluations, may have an impact on our profitability and period-to-period comparisons of our results. We
cannot assure you that in the future our results of operations may not be materially adversely affected by currency fluctuations.
Recently Issued Accounting Standards
New accounting pronouncements not yet effective
Not applicable.
Recently Adopted Accounting Pronouncements
Not applicable.
B. Liquidity and Capital Resources
We have historically met our financial requirements primarily through cash generated by operations, funds
generated by our public offerings, private placements of our Ordinary Shares and debt securities, loans from our principal shareholders,
short-term loans and credit facilities from banks, research and development grants from the Government of Israel and the Israel-U.S. Binational
Industrial Research and Development Foundation, investment grants for approved enterprise programs and marketing grants from the Government
of Israel.
In January 2020, we raised $25,300,023 in an underwritten public offering of 4,819,052 Ordinary Shares
at a price of $5.25 per share.
In March 2021, we raised $59,512,500 in an underwritten public offering of 5,175,000 Ordinary Shares at
a price of $11.50 per share.
We had working capital of $125.9 million as of
December 31, 2021 compared with working capital of $56.8
million at
December 31, 2020. Cash and cash equivalents were $78.7 million as of
December 31, 2021 compared to $36.3 million as of
December
31, 2020. The increase in working capital and cash and cash equivalents is due to the proceeds from our March 2021 public offering.
As of
December 31, 2021, our banks provided $0.49 million of guarantees on our behalf, mainly to our customers
and suppliers in the ordinary course of business. The guarantees are secured by a first priority charge on our restricted cash total $0.49
million as of
December 31, 2021.
We made capital expenditures of $6.1 million in the year ended
December 31, 2021, primarily for machinery
and equipment for use by RTL and our manufacturing facility in Israel
. In 2021, we also increased
our inventories by $21.68 million to support our increased level of sales. We currently do not have any significant capital spending or
purchase commitments.
Cash Flows
The following table summarizes our cash flows for the periods presented:
|
|
|
|
|
|
|
|
|
2020 |
|
|
2021 |
|
|
|
(U.S. dollars in thousands) |
|
Net cash provided by (used in) operating activities |
|
|
(3,461 |
) |
|
|
3,614 |
|
|
|
(4,361 |
) |
Net cash used in investing activities |
|
|
(5,133 |
) |
|
|
(4,930 |
) |
|
|
(9,194 |
) |
Net cash provided by financing activities |
|
|
966 |
|
|
|
24,038 |
|
|
|
55,937 |
|
Increase (decrease) in cash and cash equivalents and restricted cash |
|
|
(7,628 |
) |
|
|
22,722 |
|
|
|
42,382 |
|
Cash and cash equivalents and restricted cash at beginning of the year |
|
|
21,762 |
|
|
|
14,134 |
|
|
|
36,856 |
|
Cash and cash equivalents and restricted cash at end of the year |
|
|
14,134 |
|
|
|
36,856 |
|
|
|
79,238 |
|
Net cash used by our operating activities was $4,361,000 in 2021. This was primarily due an increase
in inventories of $21,688,000, an increase in trade receivables, net of $18,652,000 and deferred tax assets of $5,681,000, offset by the
net income for the year, an increase in trade payables of $7,458,000, an increase in other accounts payable of $3,031,000, depreciation
and amortization expenses of $3,660,000 and share based non-cash compensation to employees of $3,022,000. Net cash provided by operating
activities was $3,614,000 in 2020. This was primarily due the net income for the year, an increase in trade payables of $1,872,000
and an increase in other accounts payable of $5,042,000, offset by an increase in inventories of $12,820,000, depreciation and amortization
expenses of $2,289,000, share based non-cash compensation to employees of $1,436,000. Further details concerning comparative
financial data for 2020, are available in our Form 20-F for the fiscal year ended
December 31, 2020.
Net cash used in investing activities was $9,194,000 in 2021, primarily due to the investment of $6,170,000in
property, plant and equipment and an investment in privately-held company of $3,000,000. Net cash used in investing activities was $4,930,000
in 2020, primarily due to the investment of $4,853,000 in property, plant and equipment. Further details concerning comparative financial
data for 2020, are available in our Form 20-F for the fiscal year ended
December 31, 2020.
Net cash provided by financing activities was $55,937,000 in 2021, reflecting the proceeds from our March
2021 public offering. Net cash provided by financing activities was $24,038,000 in 2020 reflecting mainly the issuance of Ordinary Shares
in a registered direct offering. Further details concerning comparative financial data for 2020, are available in our Form 20-F for the
fiscal year ended
December 31, 2020.
As a result of the foregoing, at
December 31, 2021, we had working capital of $125,909,000 and cash and
cash equivalents of $78,746,000 as compared to working capital of $56,775,000 and cash and cash equivalents of $36,289,000, at
December
31, 2020.
We expect to fund our short-term liquidity needs in 2022, including our obligations under, contractual
agreements and any other working capital requirements, from our cash and cash equivalents, and operating cash flow. We project that our
current cash and cash equivalents and our expected cash flow from operations, will be sufficient to meet our cash requirements in 2022.
We are not a party to any material off-balance sheet arrangements. In addition, we have no unconsolidated
special purpose financing or partnership entities that are likely to create material contingent obligations.
The following table summarizes our minimum contractual obligations and commercial commitments, as of
December
31, 2021 and the effect we expect them to have on our liquidity and cash flow in future periods:
Contractual Obligations |
|
Payments due by Period |
|
|
|
(U.S. dollars in thousands) |
|
|
|
Total |
|
|
1st year |
|
|
2nd-3rd
year |
|
|
4th-5th
year |
|
|
After 5th
year |
|
Long-term debt obligations |
|
|
50 |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
50 |
|
Operating lease obligations |
|
|
13,521 |
|
|
|
2,363 |
|
|
|
4,043 |
|
|
|
2,953 |
|
|
|
4,162 |
|
Total |
|
|
13,571 |
|
|
|
2,363 |
|
|
|
4,043 |
|
|
|
2,953 |
|
|
|
4,212 |
|
We have long-term liabilities for severance pay for certain employees that are calculated pursuant to Israeli
law generally based on the most recent salary of the employees multiplied by the number of years of employment, as of the balance sheet
date. Under Israeli law, employees are entitled to one month’s salary for each year of employment or a portion thereof upon termination
of employment in certain circumstances, including the retirement or death of an employee or the termination of employment of an employee
without due cause. As of
December 31, 2021, our severance pay liability was $0.8 million.
We also received in 2020 a $50,000 incentive loan from Germantown County, Maryland based on the recent
capital investments by RTL.
Other than liabilities, commitments and obligations that are described in our financial reports, we do
not have any material commitments or obligations, including contingent obligations, arising from arrangements with unconsolidated entities
or persons that have, or are reasonably likely to have, a material current or future effect on our financial condition, changes in financial
condition, revenues or expenses, results of operations, liquidity, cash requirements or capital resources.
C. Research and Development, Patents and Licenses
Research and Development
Our research and development activities focus on improvements to our existing products, the development
of complementary products that provide continued support for our current customers and improve our capability to market our products to
new customers and to keep a competitive edge over our competitors. In 2021, 2020 and 2019, we incurred $10.0 million, $8.8
million
and $6.9 million, respectively, of research and development expenses, net. The vast majority of these expenses are attributable to the
development of our radars. In 2022, we intend to continue our investment in the research and development of new products. As of
December
31, 2021, we employed 96 engineers (including 2 sub-contractors) who principally concentrate on research and development activities.
The Israel Innovation Authority, or the IIA, encourages research and development by providing grants to
Israeli companies, pursuant to the Law for the Encouragement of Industrial Research and Development, 1984, as amended. The terms of such
grants prohibit the manufacture of the developed products outside of Israel and the transfer of technologies developed using the grants
to any person without the prior written consent of the IIA. During recent years, we developed a new radar sensor for APS, partly financed
by the IIA. We received royalty bearing grants of $1.138 million from the IIA. Pursuant to applicable Israeli law, we are required to
pay royalties at the rate of 3% of sales of products developed with certain grants received from the IIA, up to 100% of the amount of
such grants, adjusted by the exchange rate with the dollar. As of
December 31, 2021, our remaining obligation for royalty payments to
the IIA were fully paid.
D. Trend Information
In 2021, our revenues increased by approximately 54% compared to our revenues in 2020. Our future revenues
will, in great measure, be dependent upon the success of our sales and marketing strategy. We are currently focusing our sales efforts
on tactical radar systems for force and critical infrastructure protection solutions and military avionics.
We cannot provide any assurances that we will be successful in meeting our targets in the future. As a
result of the unpredictable business environment in which we operate and the potential effects of the spread of COVID-19, we are unable
to provide any specific guidance as to sales and profitability trends. However, on
January 11, 2022 we provided revenues guidance for
2022 of $140
million, which guidance is subject to change. If we are unsuccessful in our sales
efforts, it is unlikely that we will be able to achieve profitability in the future and we will require additional capital.
Our operations in the last five years were characterized by significant revenue growth, improved gross
profits and operating income, substantial investments in research & development capabilities together with geographic expansion into
the U.S. that impacted our marketing & selling expenses as well as our general & administrative expenses. During this period,
we constantly increased our cash and cash equivalent balances as well as our shareholders' equity.
Statement of Operations Highlights:
|
|
|
|
|
|
|
|
|
2018 |
|
|
2019 |
|
|
2020 |
|
|
2021 |
|
|
|
(U.S. dollars in thousands) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Revenues |
|
$ |
26,182 |
|
|
$ |
28,032 |
|
|
$ |
44,331 |
|
|
$ |
76,217 |
|
|
$ |
117,236 |
|
Gross profit |
|
|
8,341 |
|
|
|
10,215 |
|
|
|
15,937 |
|
|
|
28,335 |
|
|
|
47,545 |
|
Operating income (loss) |
|
|
1,983 |
|
|
|
62 |
|
|
|
(2,103 |
) |
|
|
22,862 |
|
|
|
27,187 |
|
Income (loss) from before tax continuing operations |
|
|
1,827 |
|
|
|
181 |
|
|
|
(2,224 |
) |
|
|
5,640 |
|
|
|
20,199 |
|
Income (loss) before tax from discontinued operations |
|
|
515 |
|
|
|
(404 |
)
|
|
|
(115 |
) |
|
|
- |
|
|
|
- |
|
Net income (loss) |
|
|
2,342 |
|
|
|
(223 |
) |
|
|
(2,339 |
) |
|
|
5,640 |
|
|
|
25,074 |
|
Net income (loss) attributable to non-controlling interest from discontinued operations |
|
|
103 |
|
|
|
(386 |
) |
|
|
(309 |
) |
|
|
- |
|
|
|
- |
|
Net income (loss) attributable to RADA Electronic Industries’ shareholders |
|
$ |
2,239 |
|
|
$ |
163 |
|
|
$ |
(2,030 |
) |
|
$ |
5,640 |
|
|
$ |
25,074 |
|
Balance Sheet Highlights:
|
|
|
|
|
|
|
|
|
2018 |
|
|
2019 |
|
|
2020 |
|
|
2021 |
|
|
|
(U.S. dollars in thousands) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Working capital |
|
$ |
25,641 |
|
|
$ |
37,840 |
|
|
$ |
31,805 |
|
|
$ |
56,775 |
|
|
$ |
125,909 |
|
Total assets |
|
|
36,030 |
|
|
|
53,502 |
|
|
|
64,915 |
|
|
|
106,906 |
|
|
|
203,843 |
|
Short-term credits and current maturities of long-term loans |
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
454 |
|
|
|
- |
|
Shareholders’ equity (Excluding Non-controlling interest) |
|
$ |
28,526 |
|
|
$ |
42,213 |
|
|
$ |
41,420 |
|
|
$ |
72,033 |
|
|
$ |
156,066 |
|
E. Critical Accounting Estimates
The preparation of our financial statements is in conformity with U.S. Generally Accepted Accounting Principles
(U.S. GAAP), which requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses,
and related disclosure of contingent assets and liabilities. On an ongoing basis, we evaluate our estimates, mainly related to trade receivables,
inventories, deferred charges, long-lived assets, intangibles and goodwill, revenues, stock-based compensation relating to options and
contingencies. We base our estimates on historical experience and on various assumptions that are believed to be reasonable under the
circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not
readily apparent from other sources. Actual results may differ from these estimates.
Our critical accounting policies, including the assumptions and judgments underlying them, are disclosed
in the notes to our consolidated financial statements. These policies have been consistently applied in all material respects. While the
estimates and judgments associated with the application of these policies may be affected by different assumptions or conditions, we believe
the estimates and judgments associated with the reported amounts are appropriate under the circumstances. We believe the following accounting
policies are the most critical in fully understanding and evaluating our financial condition and results of our operations under U.S.
GAAP.
Revenue Recognition. We account for revenue recognition when (or
as) it satisfies performance obligations by transferring promised goods or services to its customers in an amount that reflects the consideration
the Company expects to receive. In order to achieve that core principle, we apply the following five-step approach: (1) identify the
contract
with a customer, (2) identify the performance obligations in the
contract, (3) determine the transaction price, (4) allocate the transaction
price to the performance obligations in the
contract, and (5) recognize revenue when a performance obligation is satisfied.
The Company generally satisfies performance obligations at a point in time, once the customer has obtained
the legal title to the items purchased or service provided. Revenues from long-term and short-term fixed price
contracts are usually recognized
over time based on the cost-to-cost input method that best depicts the transfer of control over the performance obligation to the customer.
Provisions for estimated losses on uncompleted
contracts are made in the period in which such losses are determined.
Bill and hold arrangements, whereby
the Company produces and sells to customers, and the product is subsequently
remains at the customer’s request and warehoused at a Company's location for an extended period of time in accordance with directions
received from
the Company’s customers. Even though the product remains in
the Company’s possession, a sale is recognized at
the point in time when the customer obtains control of the product. Control is transferred to the customer in bill and hold transactions
when: customer acceptance specifications have been met, legal title has transferred, the customer has a present obligation to pay for
the product and the risk and rewards of ownership have transferred to the customer. Additionally, all the following bill and hold criteria
have been met in order for control to be transferred to the customer: the customer has requested the product be warehoused, the product
has been identified as separately belonging to the customer, the product is currently ready for physical transfer to the customer, and
the Company does not have the ability to use the product or direct it to another customer.
Impairment of Long-Lived Assets. We are required to assess the
impairment of long-lived assets whenever events or changes in circumstances indicate that the carrying value may not be recoverable. We
assess the impairment of our assets based on a number of factors, including any significant changes in the manner of our use of the respective
assets or the strategy of our overall business and significant negative industry or economic trends. Upon determination that the carrying
value of a long-lived asset may not be recoverable, based upon a comparison of expected undiscounted future cash flows to the carrying
amount of the asset, an impairment charge is recorded in the amount of the carrying value of the asset exceeds its fair value. Assets
to be disposed of are reported at the lower of the carrying amount or fair value less costs to sell. As of
December 31, 2021,
2020 and
2019, no impairment losses were identified.
Accounting for income taxes. On
January 1, 2007, we adopted FASB
ASC 740-10 “
Income Taxes,” which contains a two-step approach to recognizing and measuring
uncertain tax positions accounted for in accordance with ASC 740-10. The first step is to evaluate the tax position taken or expected
to be taken in a tax return by determining if the weight of available evidence indicates that it is more likely than not that, on an evaluation
of the technical merits, the tax position will be sustained on audit, including resolution of any related appeals or litigation processes.
The second step is to measure the tax benefit as the largest amount that is more than 50% likely to be realized upon ultimate settlement
ASC 740-10. We provided a valuation allowance in respect to the deferred tax assets resulting from operating loss carry forwards and other
temporary differences.
Inventory valuation. The majority of our inventory consists of
work in progress, raw materials and components. Inventories are valued at the lower of cost or market. Cost of finished goods is determined
on the basis of direct manufacturing costs plus allocable indirect costs representing allocable operating overhead expenses and manufacturing
costs. Raw material is valued using the
“FIFO” method. We assess the valuation of our inventory on a quarterly basis and periodically
write down the value for different finished goods and raw material items based on their potential utilization. If we consider specific
inventory to be damaged, we write such inventory down to zero. Inventory write-offs are provided to cover risks arising from slow-moving
items, discontinued products, and excess inventories. The process for evaluating these write-offs often requires us to make subjective
judgments and estimates concerning the future utilization of the inventory items. Write-offs of inventories for the years ended
December
31, 2021,
2020 and
2019 amounted to $108,000, $132,000 and $230,000, respectively. The write-offs were due to slow-moving items and excess
inventories and were recorded in cost of revenues.
Deferred Tax Assets. The Company assesses its ability to recover
its deferred tax assets on an ongoing basis. Significant management judgment is required in determining any valuation allowance recorded
against deferred tax assets. In evaluating the ability to recover deferred tax assets,
the Company considers available positive and negative
evidence including its recent retained earnings, its ability to carry-back losses against prior taxable income and its projected financial
results.
The Company also considers, commensurate with its objective verifiability, the forecast of future taxable income including the
reversal of temporary differences and the implementation of feasible and prudent tax planning strategies. A valuation allowance may be
recorded in the event it is deemed to be more-likely-than-not that the deferred tax asset cannot be realized. Previously established valuation
allowances may also be released in the event it is deemed to be more-likely-than-not that the deferred tax asset can be realized. Any
release of valuation allowance will be recorded as a tax benefit which will positively impact
the Company’s operating results. Management
determined on the basis of the quarterly assessment performed at
June 30, 2021, that these deferred tax assets are more-likely-than-not
to be realized. During the six months ended
June 30, 2021,
the Company released $6,038 of valuation allowance
and recorded deferred tax assets primarily related to net operating loss carry forwards. As of
December 31, 2021, the balance of deferred
income tax assets totaled $5,681.
Equity investments in privately-held company. Investments in privately-held
company equity securities without readily determinable fair values where
the Company does not have control or the ability to exercise
significant influence over the operation and financial policies of the issuer of the securities.
The Company has elected to measure these
investments at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for
the identical or similar investment in the same issuer. This election is reassessed at each reporting period as to whether the investment
continues to qualify for this election. Additionally, at each reporting period,
the Company makes a qualitative assessment considering
impairment indicators to evaluate whether the investment is impaired.
Explanation of Key Income Statement Items
Revenues. Our revenues are mainly derived from sales of defense
electronics and their supporting ground systems.
Cost of Revenues. Cost of revenues consists primarily of salaries,
raw materials, subcontractor expenses, related depreciation costs, inventories write-downs and overhead allocated to cost of revenues
activities.
Research and Development Expenses, net. Research and development
expenses consist primarily of salaries for research and development personnel, use of subcontractors and other costs incurred in the process
of developing product prototypes.
Marketing and Selling Expenses. Marketing and selling expenses
consist primarily of salaries for marketing and business development personnel, marketing activities, public relations, promotional materials,
travel expenses, trade show exhibit expenses, and success fees to business development consultants.
General and Administrative Expenses. General and administrative
expenses consist primarily of salaries and related expenses for executive, accounting, legal, administrative personnel, professional fees,
provisions for doubtful accounts and other general corporate expenses.
Financial Expenses, Net. Financial expenses consist of interest
and bank expenses, interest on convertible note and loans, amortization expenses of discount on convertible note, deferred charges and
currency re-measurement losses. Financial income consists of interest on cash and cash equivalent balances and currency re-measurement
gains.
|
DIRECTORS, SENIOR MANAGEMENT AND EMPLOYEES |
A. Directors and Senior Management
Set forth below are the name, age, principal position and a biographical description of each of our directors
and executive officers:
Name |
|
Age |
|
Position |
Yossi Ben Shalom (2)
|
|
65 |
|
Executive Chairman of the Board of Directors |
Prof. Alon Dumanis (1)(2)
|
|
71 |
|
Independent Director |
Joseph Weiss |
|
70 |
|
Director |
Elan Sigal (1) |
|
54 |
|
External Director |
Guy Zur (2) |
|
60 |
|
Director |
Ofra Brown (1) |
|
67 |
|
Independent Director |
|
|
66 |
|
Chief Executive Officer |
Avi Israel |
|
57 |
|
Chief Financial Officer |
Oleg Kiperman |
|
68 |
|
Chief Technology Officer |
Yaniv Dorani |
|
46 |
|
Chief Operating Officer |
Max Cohen |
|
48 |
|
Chief Executive Officer of RADA Sensors Inc. (3)
|
William Watson |
|
58 |
|
Chief Executive Officer of RADA Technologies LLC |
Scott Wood |
|
50 |
|
Chief Executive Officer of RADA Innovations LLC |
(1) |
Member of the Audit Committee |
(2) |
Member of the Business Development Committee |
(3) |
RADA Sensors Inc. is the sole shareholder of RADA Technologies LLC and of RADA Innovations LLC |
Messrs. Yossi Ben Shalom, Joseph Weiss, Guy Zur and Alon Dumanis and Ms. Ofra Brown will serve as directors
until our 2022 annual general meeting of shareholders. Mr. Sigal serves as an external director and currently holds office for a three-year
term until
August 30, 2022.
In August 2021, Mr. Haim Regev resigned from the Board due to his nomination to serve as the Israeli Ambassador
to the EU and the NATO forces.
In October 2021, we announced the appointment of Ms. Ofra Brown as a director, to fill the vacancy resulting
from the conclusion of the term of office of Ms. Tal Misch as an external director, on
October 21, 2021.
Yossi Ben Shalom was appointed as a director
of RADA effective as of
May 18, 2016 and has served as the Chairman of our Board of Directors since
June 14, 2016. Mr. Ben-Shalom was
Executive Vice President and Chief Financial Officer of Koor Industries Ltd. from 1998 through to 2000. Before that, Mr. Ben-Shalom served
as Chief Financial Officer of Tadiran Ltd. Mr. Ben-Shalom was an active director on numerous boards of directors, including: NICE Systems
Ltd. (NASDAQ: NICE) (computer telephony); Machteshim Agan (chemistry); and Investec Bank. He also participated in the creation of TDA
VC fund (a joint venture between Templeton and Tadiran) and was an active Chairman of Scopus – a technology company with sales of
over $30 million. Yossi is a co-founder of DBSI Investments Ltd. As such, he currently serves as the Chairman of Shagrir Group Car Services
Ltd. (TASE: SHGR), a director of Tadir-Gan (Accurate Products) 1993 Ltd. (TASE: TDFN), a director of ETGA Group Ltd. (TASE: ETGA) and
several other privately held companies. Mr. Ben-Shalom holds a B.A. degree in Economics and an M.A. degree in Business Management from
Tel Aviv University.
Prof. Alon Dumanis has served as a director
of RADA since
September 16, 2015. He is the Chief Executive Officer of Dumanis Investments Ltd and its affiliates. He is currently chairman
of Aposense, Managing Partner of Augmentum Ltd., Co-Chairman and Founder of AIS Applied Industrial Scan Ltd. and a director of Lapidoth
Capital (TASE:LAPD) and a director of SirVir Ltd. Between 2001 and 2015, Prof. Dumanis served as the Chief Executive Officer of Docor
International Management Ltd. and the General Manager of Crecor B.V. and Docor International B.V., Dutch investment companies,
subsidiaries
of The Van-Leer Group Foundation. Prof. Dumanis is a former director of El Al Israel Airlines (TASE:LY), Tadiran Communications (TASE:TDCM),
Nova Measuring Instruments (NASDAQ:NVMI), Protalix Biotherapeutics (NYSE:PLX), Spectronix (TASE:SPCT), Collplant (TASE:CLPT) and
Inventech Investments Co. Ltd. (TASE:IVTC). Previously, Prof. Dumanis served as the Head of Material Command for the Israeli Air Force,
where he held the rank of Brigadier General. Prof. Dumanis holds a Doctorate of Philosophy degree in Aerospace Engineering from Purdue
University and he is currently a faculty member of the Azrieli College of Engineering Jerusalem.
Joseph Weiss has served as director of RADA
since
December 25, 2019. Mr. Weiss served as the President and Chief Executive Officer of Israel Aerospace Industries Ltd (
“IAI”),
Israel's largest aerospace corporation and the country's largest high-tech company from 2012 until
August 31, 2018. Mr. Weiss joined IAI
in 1998, after serving in Israel's navy for 25 years in various field and headquarter positions and retired as a Captain (N). While at
IAI Mr. Weiss held a number of managerial positions and was also appointed as Chairman of the Board of ELTA, IAI's subsidiary which provides
design, development, manufacture and support of radars and electronic intelligence & defense systems for military, paramilitary and
law-enforcement markets. Mr. Weiss also serves as a member of the Board of Governors of the Technion – Israel Institute of Technology
in Haifa, as a Director of Bet Shemesh Engines Ltd., a jet engine parts manufacturer, as a director of UVision Air Ltd., UVision designs,
manufactures and delivers innovative, cost-effective, unmanned aerial loitering munition systems for customers worldwide, since August
2021, serves as Chairman of the Board of Maris-Tech Ltd. (NASDAQ:MTEK), a provider of remote video, audio, telemetry acquisition, distribution
and sharing solutions and products, using high-end digital video, audio and wireless communication technologies. Since January, 2021 Mr.
Weiss has served as a director of Spacecom Ltd. (TASE:SCC) and as a director of Blade Ranger Ltd. (TASE:BLRN). Mr. Weiss holds a BSc.
degree (with honors) in Mechanical Engineering from the Technion and an MBA degree from Tel Aviv University. He also completed MSc studies
at the Technion.
Elan Sigal has served as an external director
of RADA since August 2013. From October 2019 until May 2020, Mr. Sigal served as the Chief Financial Officer of Scodix, a capital equipment
manufacturer in the printing industry. From January 2013 to August 2017, Mr. Sigal served as the Chief Financial Officer of Landa Corporation
(Israel), an Israeli company that develops printing systems with proprietary nanography technology for the commercial market. Between
January 2008 and December 2012, Mr. Sigal was the Chief Financial Officer of Objet Geometries Ltd., an Israeli company that is engaged
in the design, development and manufacture of 3D printers. Between 2004 and December 2007, Mr. Sigal served as the Chief Financial Officer
of
our company. From May 2000 to December 2003, Mr. Sigal worked as a management consultant in the London office of McKinsey & Co.,
a leading global management consulting firm. For ten years Mr. Sigal served as a fighter pilot in the Israeli Air Force. Mr. Sigal holds
a B.A. degree in Economics from Tel Aviv University.
Guy Zur has served as a director of RADA since
March 27, 2017. Mr. Zur joined the IDF in 1980 and served in the military until 2016 in a variety of positions retiring with the rank
of Major General. Mr. Zur served as the commander of the Ground Forces from 2013 until 2016. Between 2010 and 2013, Mr. Zur served as
the Head of the IDF Planning Division. Between 2007 and 2010, Mr. Zur served as the commander of the National Training Center for Ground
Trainings (NTC). Mr. Zur is currently the CEO of some Taavura Group
subsidiaries, one of the largest logistics and transportation conglomerates
in Israel, as well as a technology entrepreneur. Mr. Zur holds an M.B.A. degree from Be’er Sheva University, a Bc.S. degree in Mechanical
Engineering from Tel Aviv University and is an alumnus of the Royal College of Defense Studies, London.
Ofra Brown has served as an independent director,
since
October 22, 2021. Ms. Brown has since 2013 served as Secretary and Corporate Affairs Officer of VIZRT Ltd, a technological leader
in the areas of real-time 3D graphics, studio automation, sports analysis and management tools for the media and entertainment industries.
She served as chief financial officer of VIZRT from 2001 to 2013, during which time it was a public company traded on the Frankfurt Stock
Exchange and on the Oslo Stock Exchange. Ms. Brown has since May 2018 served as an advisory director of Daroma Tzafona, a non-profit
organization in Israel, whose mission is to transform the landscape of economic opportunity and bring sustainable socio-economic change
in the Negev and Galilee. From 2010 to 2019, she served as an external director of Taldor Computer Systems (1986) Ltd. From 1999 until
2001, Ms. Brown served as the chief financial officer of BVR Technologies Ltd, a company that was traded on NASDAQ. From 1978 through
1998 Ms. Brown served as the Credit Manager for Electronic and Hi-Tech Industries – Industrial Development Bank of Israel Ltd. Ms.
Brown previously served as a director of Cimatron Ltd., Investec Underwriting and Consulting (Israel) Ltd. and Pointer Telocation Systems
Ltd. Ms. Brown holds a bachelor’s degree in economics from Tel Aviv University and a master’s degree in business administration
from City University of Seattle.
Dov Sella has served as our Chief Executive
Officer since November 2016 and previously, since July 2007, served as our chief business development officer. Prior to that and from
January 2003, Mr. Sella served as our chief operating officer. Mr. Sella has over 30 years of senior management and product development
experience. From 1982 until 1997, Mr. Sella worked for Elbit Systems Ltd., a leading Israeli defense contractor. Among his positions at
Elbit, he served as director of programs, director of avionics engineering and director of business development. Between 1997 and 2000,
Mr. Sella served as executive vice president and vice president of business development and vice president of research and development
of UltraGuide Ltd., a medical devices start-up. During the three years prior to joining
our company, Mr. Sella was the president of NeuroVision
Inc., a medical technology start-up. Since 2021 he has served as a director of RadSee Technologies Ltd. Mr. Sella holds a B.Sc. degree
(cum laude) in Computer Engineering from the Technion - Israeli Institute of Technology. Mr. Sella served as a fighter aircraft navigator
in the IAF.
Avi Israel has served as our Chief Financial
Officer since November 2017. Prior to that and since 2014, Mr. Israel has served as the CEO of Logisticare Ltd., a leading Israeli private
company providing third-party logistics and supply chain services. Between 2010 and 2013, Mr. Israel served as the CEO of Brimag Communication
Ltd., the Israeli importer and distributor of mobile phones and other cellular products manufactured by LG Electronics. Prior to that
and since 2004, Mr. Israel served in several positions (including Deputy CEO and Finance Director) of Telit Communications PLC., an IoT
(Internet of Things) company listed on AIM in London. Between 1996 and 2004, Mr. Israel served in several positions in the Formula Systems
Group, as the VP M&A in charge of the international operations of Matrix Ltd. (TASE: MTRX), one of Israel’s largest software
solutions companies, as well as the CFO of New Applicom Ltd., an Israeli software company that merged with Matrix. Prior to that and since
1992, Mr. Israel acted as the CFO of Burford International Application Ltd in the United Kingdom. Between 1989 and 1992, Mr. Israel was
a certified public accountant with Almagor & Co, (today Deloitte Israel). Mr. Israel also served between the years 2011-2017 as an
external director of Analyst Portfolio Management Ltd. and between 2004 and 2010 as an external director of Semicom Industries Ltd. Currently,
Mr. Israel is also an external director of Or Shay Ltd., whose bonds are traded on the TASE. Mr. Israel holds a B.A. degree in Economics
and Accounting and an M.B.A. degree, both from Bar-Ilan University in Israel. Mr. Israel is a CPA and a member of the Israeli Accountants
Council.
Oleg Kiperman has served as our Chief Technology
Officer since July 2007. Mr. Kiperman joined us in 1984 as project manager of several embedded avionics development programs and in 2000
was named as our director of engineering. From 1982 until 1984, Mr. Kiperman served as a hardware development team leader at Tadiran Ltd.
developing digital communication systems. From 1977 until 1982, Mr. Kiperman served as a senior engineer in the IAF Weapons Control Branch.
Mr. Kiperman holds a B.Sc. degree in Electrical Engineering from the Technion - Israeli Institute of Technology.
Yaniv Dorani has served as our Chief Operating
Officer since March 2020. Mr. Dorani served as the Chief Financial Officer of Pointer Telocation Ltd. (NASDAQ: PNTR) from April 2017 until
Pointer’s acquisition by PowerFleet Inc. (NASDAQ: PWFL) in October 2019. Mr. Dorani was employed in various capacities with Pointer
starting in 2008. Prior to joining Pointer, Mr. Dorani served as Corporate Controller at Medis Technologies and assistant controller at
Delta Galil Industries. Before joining Delta Galil, Mr. Dorani was a senior auditor for the accounting firm KPMG in Israel. Mr. Dorani
holds a B.A. degree in Economics and Accounting and a M.B.A. degree from Bar Ilan University in Tel Aviv. Mr. Dorani is a Certified
Public Accountant in Israel.
Max Cohen has served as the Chief Executive
Officer of RADA Sensors Inc. since December 2019. Mr. Cohen joined RADA in May 2018 and served as our Executive Vice President for the
U.S. market. Mr. Cohen retired from the Israeli Defence Forces (IDF) in March 2018 after 26 years of service. Between 2013 to 2017, Mr.
Cohen served as the head of the Sky Picture Department in the Israeli Air Force, during which time he led the development of the air picture
command and control systems (C2) and the air picture radars. Between 2016 to 2017 Mr. Cohen initiated and managed a comprehensive
national program to deal with the emerging use of commercial and military drones in the battlefield. Mr. Cohen retired with the rank of
Lieutenant Colonel (LTC). After his retirement, Mr. Cohen founded FLYON Aerosystems Ltd., a start-up company engaged in the development
of a new commercial flying platform. Mr. Cohen holds a BSc. degree in Electrical and Computer Engineering from Ben-Gurion University.
William Watson has served as the Chief Executive
Officer of RADA Technologies LLC (RTL) since March 2018. Mr. Watson has over 30 years of product and business development experience in
the defense market. Prior to joining RADA, Mr. Watson was responsible for worldwide sales and business development for L3 Technologies,
GCS between July 2017 and January 2018. Mr. Watson also developed a worldwide sales team for
Safran Vectronix in March 2015 and December 2016. He previously spent 27 years with DRS Technologies, a major US defense contractor, in
a variety of roles including P&L responsibilities as VP, Radar & Communication Systems; and also VP Naval C4 Systems. During his
tenure with DRS, Mr. Watson also held leadership positions in Program Management, Engineering and Business Operations. Mr. Watson holds
an M.B.A. degree in Business Administration and Management from Long Island University (C.W. Post) and o a Bachelor of Engineering degree
(BEng) in Mechanical Engineering from the State University of New York (Stony Brook).
Scott Wood has served as the Chief Executive
Officer of RADA Innovations LLC (RIL) since October 2020. Mr. Wood joined RTL in April of 2019, serving as Vice President and Chief Engineer
for RTL. Prior to joining RTL and from 2014, Mr. Wood worked for Raytheon Space and Airborne Systems, as Senior Director of Engineering.
Previously he worked for Lockheed Martin and DRS Leonardo in various senior technical and executive management roles and he is holding
experience in the areas of avionics, naval combat and sonar systems, intelligence, weapon and radar systems, satellite and tactical communications,
software-defined radios and waveform integration, radio frequency, high-frequency direction finding systems, and electronic warfare/electronic
attack systems. Prior to working in the defense industry, Mr. Wood served in the U.S. Navy Submarine Force. He earned a bachelor’s
degree in Mathematics and Computer Sciences from the State University of New York and a master’s degree in Business Administration
and Finance from Syracuse University.
B. Compensation
The following table includes information for the year ended
December 31, 2021 concerning the five (5) most
highly compensated executive officers of
our company, (the figures below reflect the applicable cost of employment on an annual basis):
|
|
|
|
|
Bill Watson |
|
|
Max Cohen |
|
|
Avi Israel |
|
|
Oleg Kiperman |
|
Annual salary cost and other benefits ($)2
|
|
|
842,164 |
|
|
|
522,410 |
|
|
|
428,315 |
|
|
|
365,625 |
|
|
|
396,817 |
|
Non-cash employees’ options compensation cost for 2021 ($)3
|
|
|
873,076
|
|
|
|
183,256
|
|
|
|
191,878
|
|
|
|
156,605
|
|
|
|
123,835
|
|
Total ($) |
|
|
1,715,240 |
|
|
|
705,666 |
|
|
|
620,193 |
|
|
|
522,230 |
|
|
|
520,652 |
|
(1) Mr. Sella’s terms of employment were approved
by our shareholders on
January 15, 2017,
January 16, 2019 and
June 4, 2020. As part of his compensation package Mr. Sella is entitled
to receive an annual performance bonus of up to 6 monthly salaries in total, which is calculated according to quantitative and qualitative
parameters that are determined by our Board of Directors that allocates also a respective weight per each parameter. Effective as of the
annual bonus for 2021 and for the duration of Mr. Sella’s employment, the formula for payment of the performance bonus is as follows:
the respective part of the bonus (in accordance with the proportional weight allocated to such component) will be paid (in full) only
if
the company, or the CEO, (as applicable) meets at least 85% of the target for the applicable component, provided, however that if the
company, or the CEO, as applicable, meets 120% or more of the target for the applicable component, the respective part of the Bonus shall
be increased to 120%, and provided further that the maximum annual Bonus payable to the CEO shall not exceed six (6) base salaries. In
addition, Mr. Sella received a special bonus equal to three base salaries for 2020. In 2021, Mr. Sella was also granted options to purchase
550,000 additional Ordinary Shares at an exercise price of US$12.783 per Ordinary Share, which reflects the average closing price of our
Ordinary Shares on NASDAQ during the 30 day period before the date of grant. The options are subject to our 102 Option Plan as amended
pursuant to the capital gain route provided by Section 102 of the Israeli Income Tax Ordinance.
(2) Includes the gross salary of the five (5) most highly compensated executive officers plus payments
of (i) salary bonus; (ii) social benefits such as payments for savings funds, education funds, pension, severance, insurances, social
security; (iii) general benefits such as company car (including maintenance and gas) and cell phone; and (iv) option compensation and
other benefits pursuant to
our company’s policy.
(3) Option compensation pursuant to
our company’s policy. Our 2015 Share Option Plan (as amended
from time to time) provides the framework to issue certain awards, e.g., Non Trustee 102 Share Options, 102 Ordinary Income Share Options
and 3(9) Share Options, all as defined in our 2015 Share Option Plan. Apart from issuance under the applicable Israeli laws and regulations,
the 2015 Share Option Plan enables issuances to grantees in other jurisdictions with respect to which the plan’s administrator is
empowered to make the requisite adjustments in the plan. In November 2021,
the Company's Board of Directors adopted the
"2021 Equity Incentive
Plan" (the
"2021 Plan"), as amended on
December 30, 2021. The 2021 Plan authorized the grant of options to purchase Ordinary Shares to
officers, directors, consultants and key employees of
the Company and its
subsidiaries. Awards granted under the plan may be options,
restricted shares and restricted share units. As of
December 31, 2021 no allocations were made pursuant to 2021 Plan.
Generally, and except as detailed below, all of our directors are entitled to receive directors’
fees in the same amount of those payable to our External Director. In addition, On
June 23, 2021 our shareholders approved in addition
to the directors fees, currently paid to all of our directors (as long as they serve in such position), the additional payments made to
Mr. Guy Zur and Mr. Joseph Weiss and the management fees payable to Mr. Ben Shalom, as further described below, Mr. Yossi Ben Shalom will
be granted options to purchase 125,000 Ordinary Shares and each of Messrs. Joseph Weiss, Guy Zur, and Alon Dumanis will be granted options
to purchase 25,000 Ordinary Shares. All such options are granted pursuant to our 2015 Share Option Plan. These options shall vest over
a period of four (4) years as follows: 25% shall vest at the first anniversary of the date of grant thereof and the balance shall vest
in 12 equal consecutive quarterly installments of 6.25%. The exercise price of such options is $12.675, which is equal to the average
closing price of our Ordinary Shares in NASDAQ during the 30 days prior to the date of the grant thereof. Based on the Black &
Scholes formula, the benefit component per each option is $5.121, which shall be written off as provision over a period of four (4) years,
in accordance with the US GAAP.
Mr. Yossi Ben Shalom has served as the Executive Chairman of our Board of Directors since
May 18, 2016.
In June 2020 our shareholders approved that effective as of
January 1, 2020 we would pay him a monthly payment of NIS 35,000 (approximately
$11,254) in consideration for the time devoted by Mr. Ben Shalom to such position. In 2021, Mr. Ben Shalom was granted options to purchase
125,000 Ordinary Shares at an exercise price of $12.675 per Ordinary Share, which reflects the average closing price of our Ordinary Shares
on NASDAQ during the 30-day period before the date of grant. The options are subject to our 102 Option Plan as amended pursuant to the
capital gain route provided by Section 102 of the Israeli Income Tax Ordinance.
Mr. Guy Zur has served as a member of our Board of Directors since
March 27, 2017. Mr. Zur is entitled
to receive, in addition to his directors' fees, a monthly retainer of NIS 10,000 for business development consulting services. Pursuant
to the consultancy agreement with Mr. Zur, both Mr. Zur and
our company may terminate the engagement with or without reason by giving
30 days’ prior notice. In 2021 Mr. Zur received $37,135 from us for his consulting services. In 2021, Mr. Zur was granted options
to purchase 25,000 Ordinary Shares at an exercise price of $12.675 per Ordinary Share, which reflects the average closing price of our
Ordinary Shares on NASDAQ during the 30-day period before the date of grant. The options are subject to our 102 Option Plan as amended
pursuant to the capital gain route provided by Section 102 of the Israeli Income Tax Ordinance.
Mr. Weiss is entitled to receive, in addition to his directors' fees, a monthly retainer for business development
and consulting services of NIS 15,000. In addition, Mr. Weiss is also entitled to receive a commission of 2.5% of our net revenues with
respect to specific transactions introduced to us by Mr. Weiss and pre-approved by our Audit Committee. Both Mr. Weiss and
our company
may terminate the services agreement with or without reason by giving a 30 days’ prior written notice. The agreement is subject
to the approval of our shareholders. In 2021, Mr. Weiss received $55,745 from us for these services. In 2021, Mr. Weiss was granted options
to purchase 25,000 Ordinary Shares at an exercise price of $12.675 per Ordinary Share, which reflects the average closing price of our
Ordinary Shares on NASDAQ during the 30-day period before the date of grant. The options are subject to our 102 Option Plan as amended
pursuant to the capital gain rout provided by Section 102 of the Israeli Income Tax Ordinance.
In 2021, Mr. Dumanis was granted options to purchase 25,000 Ordinary Shares at an exercise price of US$12.675
per Ordinary Share, which reflects the average closing price of our Ordinary Shares on NASDAQ during the 30-day period before the date
of grant. The options are subject to our 102 Option Plan as amended pursuant to the capital gain route provided by Section 102 of the
Israeli Income Tax Ordinance.
During the year ended
December 31, 2021, the aggregate compensation paid to our above-mentioned executive
officers and directors as a group was approximately $4,305,091. As of
December 31, 2021, the aggregate amount set aside or accrued for
pension, retirement, recreation payments and vacation or similar benefits for our directors and executive officers was approximately $568,930.
During the year ended
December 31, 2021, we paid (i) to Mr. Elan Sigal our external director
a per-meeting attendance fee of NIS 1,131 (approximately $364) and an annual fee of NIS 44,276 (approximately $14,237), (ii) to Ms. Misch
(whose term of office as external director has expired on
October 21, 2021) a per-meeting attendance fee of NIS 1,131 (approximately $364)
and an annual fee of NIS 44,276 (approximately $14,237) and (iii) to Ms. Ofra Brown (who was appointed as director on
October 25, 2022)
a per-meeting attendance fee of NIS 1,131 (approximately $364) and an annual fee of NIS 44,276 (approximately $14,237).
Pursuant to the Israeli Companies Law, we have adopted a compensation policy and are required to follow
certain approval requirements with respect to the compensation of our directors and executive officers. See below “Board of Directors
– Compensation Committee”.
We follow Israeli law and practice instead of the requirements of the NASDAQ Stock Market Rules regarding
the compensation of our Chief Executive Officer and other executive officers. See Item 16G. “Corporate Governance.”
C. Board Practices
Introduction
According to the Israeli Companies Law and our
articles of association, the management of our business
is vested in our board of directors. The board of directors may exercise all powers and may take all actions that are not specifically
granted to our shareholders. Our executive officers are responsible for our day-to-day management. The executive officers have individual
responsibilities established by our Chief Executive Officer and board of directors. Executive officers are appointed by and serve at the
discretion of the board of directors, subject to any applicable agreements.
Board of Directors
Our
Articles of Association provide for a board of directors consisting no less than four (4) and no more
than twelve (12) members, or such other number as may be determined from time to time at a general meeting of shareholders. All the directors
in
the company must be qualified to serve as a director and the time required for such position, taking into consideration the type and
size of
the company and the scope and complexity of its operation. The directors must provide the electing general meeting with a detailed
declaration as to the compliance with the above-listed requirements. Our board of directors is currently composed of nine (9) directors.
Pursuant to our
Articles of Association, our directors, except for External Directors, are elected at the
Annual General Meeting by the vote of the holders of a majority of the voting power represented at such meeting in person or by proxy
and voting on the election of directors, and each director generally serves until the Annual General Meeting next following the Annual
General Meeting at which such director was appointed, or his earlier vacation of office or removal. Except with respect to the removal
of External Directors, the shareholders are entitled to remove any director(s) from office, by a simple majority of the voting power of
the company represented at the meeting in person or by proxy and voting thereon. All the members of our board of directors (except the
external director as detailed below) may be reelected upon completion of their term of office. The majority of directors may appoint additional
directors to fill any vacancies in the board of directors until the next annual general meeting; provided, however that the total number
of directors will not exceed the maximum number, if any, fixed by or in accordance with our
Articles of Association. Our Chairman of the
Board has a casting vote. We do not follow the requirements of the NASDAQ Marketplace Rules with regard to the nomination process of directors
and instead follow Israeli law and practice. See Item 16G.
“Corporate Governance.”
External and Independent Directors
External Directors. The Israeli Companies Law requires publicly
held Israeli companies to appoint at least two external directors. However, pursuant to the Companies Regulations (Relief for Companies
whose Securities are listed for trading in Stock Exchange outside of Israel), 5760-2000, or the Relief Regulations, if a company whose
securities are listed in certain foreign exchanges, such as the NASDAQ Capital Market, does not have a controlling shareholder it may
elect to not be required to appoint External Directors provided that (i) its Board of Directors’ composition includes the requisite
number of independent directors that satisfy the independence requirement of the foreign law that applies to its listing, (ii) that the
composition of its audit and compensation committee comply with the requirements of such foreign law and (iii) if at the time of appointment
of any director all the directors are of the same gender, at least one of the directors must be of the other gender. As of October 2021,
we have utilized this opt-out from the External Directors requirement.
Independent Directors. In general, NASDAQ Stock Market Rules require
that the board of directors of a NASDAQ-listed company have a majority of independent directors and its audit committee must have at least
three members and be comprised only of independent directors, each of whom satisfies the respective
“independence” requirements
of NASDAQ and the SEC. However, foreign private issuers, such as
our company, may follow certain home country corporate governance practices
instead of certain requirements of the NASDAQ Stock Market Rules. We do not follow the requirement of the NASDAQ Stock Market Rules to
maintain a majority of independent directors on our board and instead follow Israeli law and practice (see Item 16G.
“Corporate
Governance”). However, we have the mandated three independent directors on our audit committee, in accordance with the rules of
the SEC and NASDAQ.
Pursuant to the Israeli Companies Law, a director may be qualified as an independent director if such director
is either (i) an external director; or (ii) a director that serves as a board member for less than nine years and the audit committee
has approved that he or she meets the independence requirements of an external director. A majority of the members serving on the audit
committee and the compensation committee must be independent under the Israeli Companies Law.
Our board of directors has determined that Ms. Brown, Mr. Sigal and Prof. Dumanis qualify as independent
directors under the SEC and NASDAQ requirements, as well as qualifying as independent directors under the Israeli Companies Law requirements
(taking into consideration the provisions of the Relief Regulations).
We do not follow the requirements of the NASDAQ Stock Market Rules with regard to regularly scheduled meetings
of independent directors. Under Israeli law, independent directors are not required to hold executive sessions. See Item 16G. “Corporate
Governance.”
Committees of the Board of Directors
Audit Committee. Under the Israeli Companies Law, the board of
directors of any public company must establish an audit committee. The audit committee must be comprised of at least three directors,
the majority of which must be independent directors. Such independent directors must meet all of the standards required of an external
director and may not serve as a director for more than consecutive nine years (a cessation of service as a director for up to two years
during any nine years period will not be deemed to interrupt the nine years period). However, pursuant to the Relief Regulations, if a
company whose securities are listed in certain foreign exchanges, such as the NASDAQ Capital Market, does not have a controlling shareholder
it may elect not to appoint external directors provided that (i) its Board of Directors’ composition includes the requisite number
of independent directors that satisfy the independence requirement of the foreign law that applies to its listing, (ii) that the composition
of its audit and compensation committee comply with the requirements of such foreign law and (iii) if at the time of appointment of any
director all the directors are of the same gender, at least one of the directors must be of the other gender. As of October 2021, we have
utilized this opt-out from the external directors’ requirement.
The audit committee may not include the chairman of the board of directors; any director employed by the
company or providing services to
the company on an ongoing basis; a controlling shareholder or any of the controlling shareholder’s
relatives; and any director who rendered services to the controlling shareholder or an entity controlled by the controlling shareholder.
Any person who is not permitted to be a member of the audit committee may not be present in the meetings of the audit committee unless
the chairman of the audit committee determines that such person’s presence is necessary in order to present a specific matter. However,
an employee who is not a controlling shareholder or relative of a controlling shareholder may participate in the audit committee’s
discussions but not in any vote, and at the request of the audit committee, the secretary of
the company and its legal counsel may be
present during the meeting. The chairman of the audit committee must be an external director.
The role of the audit committee, pursuant to the Israeli Companies Law, includes:
|
● |
monitoring deficiencies in the management of the company, including in consultation with the independent auditors or the internal
auditor, and to advise the board of directors on how to correct such deficiencies. If the audit committee finds a material deficiency,
it will hold at least one meeting regarding such material deficiency, with the presence of the internal auditor or the independent auditors
but without the presence of the senior management of the company. However, a member of the company’s senior management can participate
in the meeting in order to present an issue which is under his or her responsibility; |
|
● |
determining, on the basis of detailed arguments, whether to classify certain engagements or transactions as material or extraordinary,
as applicable, and therefore as requiring special approval under the Israeli Companies Law. The audit committee may make such determination
according to principles and guidelines predetermined on an annual basis; |
|
● |
determining if transactions (excluding extraordinary transactions, that is, a transaction other than in the ordinary course of business,
other than market terms, or likely to have a material impact on our company’s profitability, assets or liabilities) with a controlling
shareholder, or in which a controlling shareholder has a personal interest, are required to be rendered pursuant to a competitive procedure;
|
|
● |
deciding whether to approve engagements or transactions that require the audit committee approval under the Israeli Companies Law;
|
|
● |
determining the approval procedure of non-extraordinary transactions, following classification as such by the audit committee, including
whether such specific non-extraordinary transactions require the approval of the audit committee; |
|
● |
examining and approving the annual and periodical working plan of the internal auditor; |
|
● |
overseeing the company’s internal auditing and the performance of the internal auditor; confirm that the internal auditor has
sufficient tools and resources at his disposal, taking into account, among other, the special requirements of the company and its size;
|
|
● |
examining the scope of work of the independent auditor and its pay, and bringing such recommendations on these issue before the Board;
determining the procedure of addressing complaints of employees regarding shortcomings in the management of the company and ensure the
protection of employees who have filed such complaints; |
|
● |
determining with respect to transactions with the controlling shareholder or in which such controlling shareholder has personal interest,
whether such transactions are extraordinary or not, an obligation to conduct competitive process under supervisions of the audit committee
or determination that prior to entering into such transactions the company shall conduct other process as the audit committee may deem
fit, all taking into account the type of the company. The audit committee my set such qualifications for one year in advance; and
|
|
● |
determining the manner of approval of transactions with the controlling shareholder or in which it has personal interest which (i)
are not negligible transactions (pursuant to the committee’s determination) and (ii) are not qualified by the committee as extraordinary
transactions. |
In addition, the NASDAQ Stock Market Rules require us to establish an audit committee comprised of at least
three members, all of whom must be financially literate, satisfy the respective “independence” requirements of the SEC and
NASDAQ and one of whom must have an accounting or related financial management expertise at senior levels within a company.
Pursuant to the Israeli Companies Law, an audit committee that complies with the requirements of the Israeli
Companies Law may act also as a compensation committee. Our board of directors has determined that our audit committee complies with such
requirements and therefore, it also serves as our compensation committee.
The current members of our audit and compensation committees are Ms. Ofra Brown, Mr. Elan Sigal and Prof.
Alon Dumanis, each of whom satisfies the “independence” requirements of both the SEC and NASDAQ. We also comply with Israeli
law requirements for audit committee members. The audit committee meets at least once each quarter.
Compensation Committee. Our Board of Directors is required to appoint
a compensation committee, whose role is to: (i) recommend to the board on a compensation policy for office holders and to recommend to
the board, once every three years, on the approval of the continued validity of the compensation policy that was determined for a period
exceeding three years; (ii) recommend an update the compensation policy from time to time and to examine its implementation; (iii) determine
whether to approve the Terms of Service and Employment of Office Holders that require the committee’s approval; and (iv) exempt
a transaction from the requirement for shareholders’ approval. The compensation committee also has oversight authority over the
actual terms of employment of directors and officers and may make recommendations to the board of directors and the shareholders (where
applicable) with respect to deviation from the compensation policy that was adopted by
the company. Under Israeli law, our compensation
committee must consist of no less than three members, including at least two independent directors (who must constitute a majority of
its members of the committee), and the remainder of the members of the compensation committee must be directors whose terms of service
and employment were determined pursuant to the applicable regulations. The same restrictions on the actions and membership in the audit
committee apply to the compensation committee with respect to, among other things, the requirement that an independent director serve
as the chairman of the committee and the list of persons who may not serve on the committee. As noted above, our board of directors established
a compensation committee composed of Ms. Ofra Brown, Mr. Elan Sigal and Prof. Alon Dumanis. In August 2019, our shareholders approved
an updated compensation policy for an additional period of three years. In June 2020, our shareholders approved an amendment to the compensation
policy (related to the maximum premium payable in connection with our D&O insurance) and in June 2021 our shareholders approved additional
amendments to the compensation policy, mainly adopting changes to the performance bonus of the CEO, the maximum per claim and per annum
coverage permitted under our D&O insurance and allowing the grant of options to our directors.
Board Diversity
While we do not have a formal policy on diversity, our Board considers diversity to include the skill set,
background, reputation, type and length of business experience of our board members, as well as a particular nominee’s contribution
to that mix. Although there are many other factors, the Board seeks individuals with experience in the defense industry, sales and marketing,
legal and accounting skills and board experience.
Nasdaq’s Board Diversity Rule requires companies listed on Nasdaq to (i) publicly disclose board-level
diversity statistics using a standardized template; and (ii) have, or explain why they do not have, at least two diverse directors. Under
the new rule the required disclosure must generally be provided by Nasdaq-listed companies by
August 8, 2022. The rule also provides additional
flexibility for smaller reporting companies, which can meet the diversity objective by including two female directors, and for all companies
with five or fewer directors, which can meet the diversity objective by including one diverse director. Foreign issuers, including foreign
private issuers and foreign issuers with principal executive offices located outside the U.S., like
our company, must have, or explain
why they do not have, at least two board members who are female or have (i) one female director and (ii) one director is LGBTQ+ or an
“underrepresented individual” in their home country jurisdiction (i.e., Israel).
The Board Diversity Rule is currently being challenged under constitutional grounds in the U.S. and may
be subject to changes.
Internal Audit
The Israeli Companies Law also requires the board of directors of a publicly held company to appoint an
internal auditor nominated by the audit committee. An internal audit must satisfy the Israeli Companies Law’s independence requirements.
The role of the internal auditor is to examine, among other things, the compliance of
the company’s conduct with applicable law
and orderly business practice. Under the Companies Law, the internal auditor may not be an interested party or an office holder, or a
relative of any of the foregoing, nor may the internal auditor be
the company’s independent accountant or its representative. Our
internal auditor complies with the requirements of the Israeli Companies Law.
Approval of Related Party Transactions under Israeli Law
Fiduciary Duties of Office Holders
The Israeli Companies Law codifies the fiduciary duties that
“office holders,” including directors
and executive officers, owe to a company. An
“office holder” is defined in the Israeli Companies Law as a director, general
manager, chief business manager, deputy general manager, vice general manager, other manager directly subordinated to the general manager
or any other person assuming the responsibilities of any of the foregoing positions without regard to such person’s title. An office
holder’s fiduciary duties consist of a duty of care and a duty of loyalty. The duty of care requires an office holder to act at
a level of care that a reasonable office holder in the same position would employ under the same circumstances. This includes the duty
to utilize reasonable means to obtain (i) information regarding the appropriateness of a given action brought for his approval or performed
by him by virtue of his position and (ii) all other information of importance pertaining to the foregoing actions. The duty of loyalty
includes (i) avoiding any conflict of interest between the office holder’s position in
the company and any other position he holds
or his personal affairs, (ii) avoiding any competition with
the company’s business, (iii) avoiding exploiting any business opportunity
of
the company in order to receive personal gain for the office holder or others, and (iv) disclosing to
the company any information or
documents relating to
the company’s affairs that the office holder has received due to his position as an office holder.
Disclosure of Personal Interests of an Office Holder; Approval of Transactions with
Office Holders
The Israeli Companies Law requires that an office holder promptly and no later than the first board meeting
at which such transaction is considered, disclose any personal interest that he or she may have, including any personal interest held
by the office holder’s spouse, siblings, parents, grandparents, descendants, spouse’s descendants and the spouses of any of
the forgoing, or by any corporation in which the office holder or a relative is a 5% or greater shareholder, director or general manager,
or in which he or she has the right to appoint at least one director or the general manager, and all related material information known
to him or her and any documents in their position, in connection with any existing or proposed transaction by us.
Some transactions, actions and arrangements involving an office holder (or a third party in which an office
holder has an interest) must be approved by the board of directors or as otherwise provided for in a company’s
articles of association,
however, a transaction that is adverse to
the company’s interest may not be approved. In some cases, such a transaction must be
approved by the audit committee and by the board of directors itself, and under certain circumstances shareholder approval may also be
required. A director who has a personal interest in a transaction that is considered at a meeting of the board of directors or the audit
committee may not be present during the board of directors or audit committee discussions and may not vote on the transaction, unless
the transaction is not an extraordinary transaction or the majority of the members of the board or the audit committee have a personal
interest, as the case may be. In the event the majority of the members of the board of directors or the audit committee have a personal
interest, then the approval of the general meeting of shareholders is also required.
Approval of a Compensation Policy for Office Holders
The Israeli Companies Law and the regulations adopted thereunder require the compensation committee to
adopt a policy for director and office holders.
The compensation policy needs to be re-approved every three years by the board of directors, following
the recommendation of the compensation committee, and by
the company’s shareholders, by a Special Majority (as defined below). In
the event that the compensation policy is not so approved by the shareholders, the board of directors may nonetheless approve it, provided
that the compensation committee and the board of directors, following further discussion of the matter and for specified reasons, determine
that the approval of the compensation policy is in the best interests of
the company.
Special Majority means: (a) a majority of the shareholders who are not controlling shareholders of the
Company and do not have a
“Personal Interest” in the approval of the respective resolution who participate in the vote, in
person, by proxy or by a voting instrument vote to approve it (abstentions will not be taken into account) or (b) the total number of
votes of the shareholders referred to in (a) above that are voted against the proposed resolution does not exceed two percent (2%) of
the company’s total voting rights.
The compensation policy serves as the basis for decisions concerning the financial terms of employment
or engagement of officer holders, including exculpation, insurance, indemnification or any monetary payment or obligation of payment in
respect of employment or engagement.
In addition, compensation of the directors and the Chief Executive Officer is also subject to the approval
of the compensation /audit committee, the board of directors and the shareholders at a general meeting. The approval of the compensation
of the Chief Executive Officer is subject to the Special Majority requirements
Any deviations from the compensation policy in respect of the compensation of the office holders require
the approval of the compensation/audit committee, the board of directors and the shareholders by Special Majority.
Under the Israeli Companies Law, all arrangements as to compensation of office holders who are not directors
require the approval of the compensation/audit committee prior and in addition to the approval of the board of directors. However, if
the company duly adopts a compensation plan for its office holders, the approval of the board of directors is not required if the new
arrangement only modifies an existing arrangement and the compensation committee determines that such modification is not material.
Disclosure of Personal Interests of a Controlling Shareholder; Approval of Transactions
with Controlling Shareholders
Pursuant to the Israeli Companies Law, the disclosure requirements regarding personal interests that apply
to directors and executive officers also apply to a controlling shareholder of a public company. A controlling shareholder is a shareholder
who has the ability to direct the activities of a company, but excludes a shareholder whose power derives solely from its position on
the board of directors or any other position at
the company. A person is presumed to be a
“controlling shareholder” if it
holds or controls, by itself or together with others, one half or more of any one of the
“Means of Control” of
the company.
“Means of Control” is defined as any one of the following: (i) the right to vote at a General Meeting of
the company, or (ii)
the right to appoint directors of
the company or its Chief Executive Officer. For the purpose of related party translations, under the
Israeli Companies Law, a controlling shareholder is also a shareholder who holds 25% or more of the voting rights if no other shareholder
who holds more than 50% of the voting rights. For this purpose, the holdings of all shareholders who have a personal interest in the same
transaction will be aggregated. As of Admission,
the company does not have a controlling shareholder.
An extraordinary transaction between a public company and a controlling shareholder, or in which a controlling
shareholder has a personal interest, including a private placement in which the controlling shareholder has a personal interest, and the
terms of engagement of
the company, directly or indirectly, with a controlling shareholder or a controlling shareholder’s relative
(including through a corporation controlled by a controlling shareholder), regarding
the company’s receipt of services from the
controlling shareholder, and if such controlling shareholder is also an office holder of
the company, regarding his or her terms of employment,
require the approval of a company’s audit committee (or compensation committee with respect to compensation arrangements), board
of directors and shareholders, in that order. Such transaction must be elected by a majority vote of the Ordinary Shares present and voting
at a shareholders’ meeting, provided that either: (i) such majority includes at least a majority of votes held by all shareholders
who do not have a personal interest in such transaction, present and voting at such meeting (excluding abstentions); or (ii) the total
number of votes of shareholders who do not have a personal interest in such transaction voting against the approval of the transaction,
does not exceed 2% of the aggregate voting rights in
the company.
Pursuant to the Israeli Companies Law, the audit committee of
the company should determine in connection
with such transaction if it requires rendering pursuant to a competitive procedure or pursuant to other proceedings.
See
“Audit Committee” above.
To the extent that any such transaction with a controlling shareholder or his relative is for a period
extending beyond three years, shareholder approval is required once every three years, unless, in respect to certain transactions, the
audit committee determines that the longer duration of the transaction is reasonable under the circumstances.
Pursuant to regulations promulgated pursuant to the Israeli Companies Law, a transaction with a controlling
shareholder that would otherwise require approval of the shareholders is exempt from shareholders’ approval if each of the audit
committee and the board of directors determine that the transaction meets certain criteria that are set out in specific regulations promulgated
under the Israeli Companies Law. Under these regulations, a shareholder holding at least 1% of the issued share capital of
the company
may require, within 14 days of the publication of such determination, that despite such determination by the audit committee and the board
of directors, such transaction will require shareholder approval under the same majority requirements that otherwise apply to such transactions.
The Israeli Companies Law provides that an acquisition of shares in a public company must be made by means
of a tender offer if as a result of the acquisition the purchaser would become a 25% or greater shareholder of
the company. This rule
does not apply if there is already another 25% or greater shareholder of
the company. Similarly, the Israeli Companies Law provides that
an acquisition of shares in a public company must be made by means of a tender offer if as a result of the acquisition the purchaser would
hold greater than a 45% interest in
the company, unless there is another shareholder holding more than a 45% interest in
the company.
These requirements do not apply if, in general, (i) the acquisition was made in a private placement that received shareholder approval,
(ii) was from a 25% or greater shareholder of
the company which resulted in the acquirer becoming a 25% or greater shareholder of the
company, if there is not already a 25% or greater shareholder of
the company, or (iii) was from a shareholder holding a 45% interest in
the company which resulted in the acquirer becoming a holder of a 45% interest in
the company if there is not already a 45% or greater
shareholder of
the company.
If, as a result of an acquisition of shares, the acquirer will hold more than 90% of a public company’s
outstanding shares or a class of shares, the acquisition must be made by means of a tender offer for all of the outstanding shares or
a class of shares. If less than 5% of the outstanding shares are not tendered in the tender offer, all the shares that the acquirer offered
to purchase will be transferred to the acquirer. If more than 5% of the outstanding shares are not tendered in the tender offer, then
the acquirer may not acquire shares in the tender offer that will cause his shareholding to exceed 90% of the outstanding shares. The
Israeli Companies Law provides for appraisal rights if any shareholder files a request in court within six months following the consummation
of a full tender offer. However, in the event of a full tender offer, the offeror may determine that any shareholder who accepts the offer
will not be entitled to appraisal rights. Such determination will be effective only if the offeror or
the company has timely published
all the information that is required to be published in connection with such full tender offer pursuant to all applicable laws.
Shareholder Duties
Pursuant to the Israeli Companies Law, a shareholder has a duty to act in good faith and in a customary
manner toward
the company and other shareholders and to refrain from abusing his or her power with respect to
the company, including,
among other things, in voting at a general meeting and at shareholder class meetings with respect to the following matters:
|
● |
interested party transactions that require shareholder approval. |
In addition, a shareholder has a general duty to refrain from discriminating against other shareholders.
Certain shareholders also have a duty of fairness toward
the company. These shareholders include any controlling
shareholder, together with any shareholder who knows that it has the power to determine the outcome of a shareholder vote and any shareholder
who has the power to appoint or to prevent the appointment of an office holder of
the company or exercise any other rights available to
it under
the company’s
articles of association with respect to
the company. The Israeli Companies Law does not define the substance
of this duty of fairness, except to state that the remedies generally available upon a breach of
contract will also apply in the event
of a breach of the duty of fairness.
Exculpation, Indemnification and Insurance of Directors and Officers
Exculpation of Office Holders
The Israeli Companies Law provides that an Israeli company cannot exculpate an office holder from liability
with respect to a breach of his or her duty of loyalty. If permitted by its
articles of association, a company may exculpate in advance
an office holder from his or her liability to
the company, in whole or in part, with respect to a breach of his or her duty of care. However,
a company may not exculpate in advance a director from his or her liability to
the company with respect to a breach of his duty of care
in the event of distributions.
Insurance of Office Holders
The Israeli Companies Law provides that a company may, if permitted by its
articles of association, enter
into a
contract to insure office holders in respect of liabilities incurred by the office holder with a respect to an act performed in
his or her capacity as an office holder, as a result of:
|
● |
a breach of the office holder’s duty of care to the company or to another person; |
|
● |
a breach of the office holder’s duty of loyalty to the company, provided that the office holder acted in good faith and had
reasonable cause to assume that his or her act would not prejudice the company’s interests; or |
|
● |
a financial liability imposed upon the office holder in favor of another person. |
Indemnification of Office Holders
The Israeli Companies Law provides that a company may, if permitted by its
articles of association, indemnify
an office holder for acts or omissions performed by the office holder in such capacity for:
|
● |
a monetary liability imposed on the office holder in favor of another person by any judgment, including a settlement or an arbitrator’s
award approved by a court; |
|
● |
reasonable litigation expenses, including attorney’s fees, actually incurred by the office holder as a result of an investigation
or proceeding instituted against him or her by a competent authority, provided that such investigation or proceeding concluded without
the filing of an indictment against the office holder or the imposition of any monetary liability in lieu of criminal proceedings, or
concluded without the filing of an indictment against the office holder and a monetary liability was imposed on the officer holder in
lieu of criminal proceedings with respect to a criminal offense that does not require proof of criminal intent; and |
|
● |
reasonable litigation expenses, including attorneys’ fees, incurred by the office holder or which were imposed on him or her
by a court, in an action instituted by the company or on the company’s behalf or by another person, against the office holder, or
in a criminal charge from which he was acquitted, or in a criminal proceeding in which the office holder was convicted of a criminal offense
which does not require proof of criminal intent. |
|
● |
prospectively undertake to indemnify an office holder, except that with respect to a monetary liability imposed on the office holder
by any judgment, settlement or court-approved arbitration award, the undertaking must be limited to types of events which the company’s
board of directors deems foreseeable considering the company’s actual operations at the time of the undertaking, and to an amount
or standard that the board of directors has determined as reasonable under the circumstances. |
|
● |
retroactively indemnify an office holder of the company. |
Limitations on Exculpation, Insurance and Indemnification
The Israeli Companies Law provides that neither a provision of the
articles of association permitting the
company to enter into a
contract to insure the liability of an office holder, nor a provision in the
articles of association or a resolution
of the board of directors permitting the indemnification of an office holder, nor a provision in the
articles of association exculpating
an office holder from duty to
the company shall be valid, where such insurance, indemnification or exculpation relates to any of the following:
|
● |
a breach by the office holder of his duty of loyalty unless, with respect to insurance coverage or indemnification, the office holder
acted in good faith and had a reasonable basis to believe that the act would not prejudice the company; |
|
● |
a breach by the office holder of his duty of care if such breach was committed intentionally or recklessly, unless the breach was
committed only negligently; |
|
● |
any act or omission done with the intent to unlawfully yield a personal benefit; or |
|
● |
any fine or forfeiture imposed on the office holder. |
Under the Israeli Companies Law, exculpation, indemnification and insurance of office holders must be approved
by the compensation committee and the board of directors (and, with respect to directors and the chief executive officer, by the shareholders).
However, under regulations promulgated under the Israeli Companies Law, the insurance of office holders does not require shareholder approval
and may be approved by only the compensation committee, if the engagement terms are determined in accordance with
the company’s
compensation policy, which was approved by the shareholders by the same special majority required to approve a compensation policy, provided
that the insurance policy is on market terms and the insurance policy is not likely to materially impact
the company’s profitability,
assets or liabilities.
Our
Articles of Association allow us to insure, indemnify and exempt our office holders to the fullest
extent permitted by law, subject to the provisions of the Israeli Companies Law. Up until August 2017 we maintained directors and officers
liability insurance policy with per claim and aggregate coverage limit of $7.5 million. On August 2017, our Compensation Committee and
Board of Directors approved an increase in the per claim coverage and aggregate coverage of up to $10 million under its directors and
officers liability insurance policy Pursuant to additional amendment of our compensation policy adopted by our shareholders on
June 23,
2021 the per claim coverage and aggregate coverage have been increased to $15 million. Pursuant to resolutions adopted by our shareholders
on
May 15, 2016, we have also entered into agreements with our directors and officeholders providing for their indemnification and exemption
from the duty of care.
D. Employees
We consider our employees the most valuable asset of
our company. We offer competitive compensation and
comprehensive benefits to attract and retain our employees. The remuneration and rewards include retention through share-based compensation
and performance-based bonuses.
We believe that an engaged workforce is key to maintaining our ability to innovate. We have steadily increased
our workforce and have been successful in integrating our new employees and keeping our employees engaged. Investing in our employees’
career growth and development is an important focus for us. We offer learning opportunities and training programs including workshops,
guest speakers and various conferences to enable our employees to advance in their chosen professional paths.
We are committed to providing a safe work environment for our employees. We have taken necessary precautions
in response to the recent COVID-19 outbreak, including offering employees flexibility to work from home, mandatory social distancing
requirements in the workplace (such as adding more space between work spaces) and health monitoring for our employees, daily office disinfection
and sanitization, provision of hand sanitizer and face masks to all employees, and improvement and optimization of our telecommuting system
to support remote work arrangements.
As of
December 31, 2021, we employed 242 persons in Israel, of whom 90 persons were employed in research,
development and engineering, 92 persons in manufacturing and logistics, 6 persons in sales and marketing, 9 in quality management, 22
in customers support and 23 persons in administration, management and finance. In addition, RTL, RIL and RSI employed 66 persons in the
U.S., of whom 27 persons were employed in manufacturing and logistics, 6 persons in sales and marketing, 17 in customers support &
engineering and 16 persons in quality management, administration, management and finance.
As of
December 31, 2020, we employed 198 persons in Israel, of whom 86 persons were employed in research,
development and engineering, 87 persons in manufacturing and logistics, 11 persons in sales and marketing, and 14 persons in administration,
management and finance. In addition, RTL and RSI employed 46 persons in the U.S., of whom 29 persons were employed in manufacturing and
logistics, 6 persons in sales and marketing, and 10 persons in administration, management and finance.
As of
December 31, 2019, we employed 167 persons in Israel, of whom 44 persons were employed in research,
development and engineering, 101 persons in manufacturing and logistics, 11 persons in sales and marketing, and 11 persons in administration,
management and finance. In addition, RTL employed 25 persons in the U.S., of whom 8 persons were employed in research and development,
1 person in logistics and engineering, 5 persons in sales and marketing, and 11 persons in administration, management and finance.
Our technical employees have signed nondisclosure agreements covering all proprietary information that
they might possess or to which they might have access. Employees are not organized in any union, although they are employed according
to provisions established by the Israeli Ministry of Economy and Industry. Certain provisions of the collective bargaining agreements
between the General Federation of Labor in Israel (Histadrut) and the Coordination Bureau of Economic Organizations (including the Industrialists
Association) are applicable to our Israeli employees by order of the Israeli Ministry of Economy and Industry. These provisions primarily
concern the length of the workday, minimum daily wages for professional workers, contributions to a pension fund, insurance for work-related
accidents, procedures for dismissing employees, determination of severance pay and other conditions of employment. We generally provide
our employees with benefits and working conditions beyond the required minimums.
Israeli law generally requires severance pay upon the retirement or death of an employee or termination
of employment without due cause. Further, Israeli employees and employers are required to pay predetermined sums to the National Insurance
Institute; such amounts also include payments for national health insurance. Most of our ongoing severance obligations for our Israeli
employees are provided for by monthly payments made by us for insurance policies to cover these obligations.
E. Beneficial Ownership of Executive Officers and Directors |
The following table sets forth certain information
as of
March 24, 2022 regarding the beneficial ownership by each of our directors and executive officers:
Name |
|
Number of Ordinary Shares or Options
Beneficially
Owned (1)
|
|
|
Percentage of
Ownership (2)
|
|
Yossi Ben Shalom (3)
|
|
|
2,012,629
|
|
|
|
3.96 |
% |
Alon Dumanis |
|
|
6,250 |
|
|
|
* |
|
Joseph Weiss |
|
|
6,250 |
|
|
|
* |
|
Ofra Brown |
|
|
- |
|
|
|
* |
|
Elan Sigal |
|
|
- |
|
|
|
* |
|
Guy Zur |
|
|
6,250 |
|
|
|
* |
|
|
|
|
450,000 |
|
|
|
* |
|
Avi Israel |
|
|
177,500 |
|
|
|
* |
|
Oleg Kiperman |
|
|
111,875 |
|
|
|
* |
|
Yaniv Dorani |
|
|
112,500 |
|
|
|
* |
|
Max Cohen |
|
|
73,750 |
|
|
|
* |
|
Bill Watson |
|
|
259,375 |
|
|
|
* |
|
Scott Wood |
|
|
15,625 |
|
|
|
* |
|
All directors and executive officers as a group (13 persons) |
|
|
3,232,004 |
|
|
|
6.36 |
% |
* Less than 1%
Except as otherwise indicated, the business address of all directors and executive officers is c/o RADA
Electronic Industries Ltd., 7 Giborei Israel Street, Netanya, 4250407, Israel.
(1) |
Beneficial ownership is determined in accordance with the rules of the SEC and generally includes voting or investment power with
respect to securities. Ordinary shares relating to options and warrants currently exercisable or exercisable within 60 days of the date
of this table are deemed outstanding for computing the percentage of the person holding such securities but are not deemed outstanding
for computing the percentage of any other person. Except as indicated by footnote, and subject to community property laws where applicable,
the persons named in the table above have sole voting and investment power with respect to all shares shown as beneficially owned by them.
|
(2) |
The percentages shown are based on 49,609,992 Ordinary Shares issued
and outstanding as of March 24, 2022. |
(3) |
Mr. Yossi Ben Shalom and Mr. Barak Dotan, by virtue of their relationship with and indirect interests in DBSI may be deemed to control
DBSI and consequently share the beneficial ownership of the 1,981,379 Ordinary Shares of the company beneficially owned by DBSI (Based
on a Schedule 13D/A filed on May 26, 2021 with the SEC by DBSI), including the right to jointly direct the voting of, and disposition
of, such shares. Mr. Barak Dotan holds his shares of DBSI through his ownership of B.R.Y.N. Investments Ltd. Mr. Yossi Ben Shalom holds
his shares of DBSI through his control of White Condor Holdings Ltd. and Pulpit Rock Investments Ltd. The address of DBSI is 85 Medinat
Hayehudim Street, Herzliya 4676670, Israel. |
|
MAJOR SHAREHOLDERS AND RELATED PARTY TRANSACTIONS |
A. Major Shareholders
The following table sets forth certain information
as of
March 24, 2022, regarding the beneficial ownership by all shareholders known to us to own beneficially 5% or more of our Ordinary
Shares:
Name |
|
Number of Ordinary
Shares Beneficially Owned (1) |
|
|
Percentage
of
Ownership
(2) |
|
|
|
|
|
|
|
|
The Phoenix Holding Ltd. (3)
|
|
|
4,242,814 |
|
|
|
8.55 |
% |
Wellington Group Holdings LLP (4)
|
|
|
3,319,054 |
|
|
|
6.69 |
% |
Franklin Resources Inc. (5)
|
|
|
2,961,648 |
|
|
|
5.97 |
% |
(1) |
Beneficial ownership is determined in accordance with the rules of the SEC and generally includes voting or investment power with
respect to securities. Ordinary Shares relating to options and notes currently exercisable or convertible or exercisable or convertible
within 60 days of the date of this table are deemed outstanding for computing the percentage of the person holding such securities but
are not deemed outstanding for computing the percentage of any other person. Except as indicated by footnote, and subject to community
property laws where applicable, the persons named in the table above have sole voting and investment power with respect to all shares
shown as beneficially owned by them. |
(2) |
The percentages shown are based on 49,609,992 Ordinary Shares issued
and outstanding as of March 24, 2022. |
(3) |
Based on a Schedule 13G/A filed with the SEC on February 7, 2022 by The Phoenix Holdings Ltd. The address of its principal office
is Derech Hashalom 53, Givataim, 53454, Israel. |
(4) |
Based on an initial Schedule 13G filed with the SEC on February 4, 2022 by Wellington Group Holdings LLP. The address of its principal
office is 280 Congress Street, Boston MA 02210. |
(5) |
Based on an initial Schedule 13G filed with the SEC on February 7, 2022 by Franklin Resources Inc. (together with Templeton Investment
Counsel, LLC). The address of the principal office of Franklin Resources is One Franklin Parkway, San Mateo CA 94403.
|
Significant Changes in the Ownership of Major Shareholders
On
January 29, 2019 DBSI reported on Schedule 13D/A that it held 9,547,088 Ordinary Shares, constituting
25.1% of our issued and outstanding Ordinary Shares. On
September 16, 2019 DBSI reported on Schedule 13D/A that it held 6,821,309 Ordinary
Shares, constituting 15.7% of our issued and outstanding Ordinary Shares. On
January 11, 2021 DBSI reported on Schedule 13D/A that it
held 2,818,182 Ordinary Shares constituting 6.45% of our issued and outstanding Ordinary Shares. On
March 15, 2021, DBSI reported on Schedule
13D/A that it held 2,673,205 Ordinary Shares constituting 5.45% of our issued and outstanding Ordinary Shares. On
May 26, 2021, DBSI reported
on Schedule 13D/A that it held 1,981,379 Ordinary Shares constituting 4.04% of our issued and outstanding Ordinary Shares at the time
of this report.
On
February 11, 2019, Yelin Lapidot filed a Schedule 13G/A with the SEC reflecting ownership of 3,113,873
Ordinary Shares, or 8.30%, of our Ordinary Shares as of
December 31, 2018. On
February 10, 2020, Yelin Lapidot filed a Schedule 13G/A
with the SEC reflecting ownership of 2,235,362 Ordinary Shares, or 5.82%, of our Ordinary Shares as of
December 31, 2019. On
February
2, 2021, Yelin Lapidot filed a Schedule 13G/A with the SEC reflecting ownership of 1,305,201 Ordinary Shares, or 2.99%, of our Ordinary
Shares as of
December 31, 2020.
On
August 27, 2019, the Phoenix Holding Ltd., Delek Group Ltd. and Itshak Sharon (Tshuva) (together
the
“Phoenix Group”) reported holdings of 2,144,282 Ordinary Shares or 5.63% of our Ordinary Shares. On
February 18, 2020,
the Phoenix Group filed a Schedule 13G/A, reflecting holdings of 3,005,340 Ordinary Shares, or 7.89%, of our Ordinary Shares as of
December
31, 2019. On
December 28, 2020, Phoenix Holding Ltd.filed a Schedule 13G/A, reflecting holdings of 2,177,407 Ordinary Shares or 4.99%
of our ordinary shares. On
January 19, 2021, Phoenix Holding Ltd. filed a Schedule 13G/A, reflecting holdings of 2,278,224 Ordinary
Shares, or 5.22%, of our Ordinary Shares. On
February 1, 2021, Phoenix Holding Ltd.filed a Schedule 13G/A, reflecting holdings of 2,178,788
Ordinary Shares, or 4.99%, of our Ordinary Shares as of
December 31, 2020. On
April 5, 2021, Phoenix Holding Ltd. filed a Schedule 13G/A,
reflecting holdings of 2,637,923 Ordinary Shares, or 5.38% of our Ordinary Shares. On
February 7, 2022, Phoenix Holding Ltd. filed
a Schedule 13G/A, reflecting holdings of 4,242,814 Ordinary Shares, or 8.61% of our Ordinary Shares at the time of this report.
On
January 7, 2019, Psagot Investment House Ltd. jointly with Psagot Securities Ltd and Psagot Provident
Funds and Pension Ltd. and Psagot Index Funds Ltd. (all are wholly owned
subsidiaries of Psagot Investment House Ltd.) filed a Schedule
13G with the SEC reflecting ownership of 2,423,326, or 6.46%, of our Ordinary Shares. On
February 19, 2019, Psagot filed a Schedule 13G/A,
reflecting ownership of 2,424,883 Ordinary Shares, or 6.46%, of our Ordinary Shares as of
December 31, 2018. On
February 18, 2020,
Psagot filed a Schedule 13G/A, reflecting ownership of 2,179,255 Ordinary Shares, or 5.67%, of our Ordinary Shares as of
December 31,
2019. On
February 16, 2021, Psagot filed a Schedule 13G/A, reflecting ownership of 1,379,539, or 3.71%, of our Ordinary Shares as of
December
31, 2020.
On February 4, 2022, Wellington Group
Holdings LLP. filed a Schedule 13G, reflecting holdings of 3,319,054 Ordinary Shares, or
6.72% of our Ordinary Shares at the time of this report.
On February 7, 2022, Franklin Resources
Inc. (together with Templeton Investment Counsel, LLC) filed a Schedule 13G, reflecting holdings
of 2,961,648 Ordinary Shares, or 6.0% of our Ordinary Shares at the time of this report.
Shareholders Voting Rights
Our major shareholders do not have different voting rights.
Record Holders
Based on a review of the information provided to us
by American Stock Transfer & Trust Company, our transfer agent, as of
March 21, 2022, there were 46 holders of record of our Ordinary
Shares, of which 37 record holders holding approximately 47,336,482 of our Ordinary Shares had registered addresses in the U.S., including
banks, brokers and nominees. These numbers are not representative of the number of beneficial holders of our shares nor are they representative
of where such beneficial holders reside, since many of these Ordinary Shares were held of record by banks, brokers or other nominees.
B. Related Party Transactions
On
January 16, 2019 we sold 545,454 Ordinary Shares to DBSI in a shareholder approved private placement
for approximately $1.5 million, reflecting a price per share of $2.75.
C. Interests of Experts and Counsel
Not applicable.
A. Consolidated Statements and Other Financial Information
Export Sales
Export sales (whether direct sales or revenues of RTL, our U.S. subsidiary) constitute a significant portion
of our sales. In 2021, we had approximately $99.4 million of export sales, constituting approximately 85% of our total sales. For further
information regarding the allocation of our revenues by geographic region see Item 4 – “
Information
on the Company - Geographical Markets.”
Legal Proceedings
Currently, we are not a party to any material legal proceedings; however, from time to time we are involved
in legal proceedings arising from the operation of our business. Based on the advice of our legal counsel, management believes such current
proceedings, if any, will not have a material adverse effect on our financial position or results of operations.
Dividend Distribution Policy
We have never paid cash dividends to our shareholders. We intend to retain future earnings for use in our
business and do not anticipate paying cash dividends on our Ordinary Shares in the foreseeable future. Any future dividend policy will
be determined by the board of directors and will be based upon conditions then existing, including our results of operations, financial
condition, current and anticipated cash needs, contractual restrictions and other conditions as the board of directors may deem relevant.
According to the Israeli Companies Law, a company may distribute dividends out of its profits, so long
as
the company reasonably believes that such dividend distribution will not prevent
the company from paying all its current and future
debts. Profits, for purposes of the Israeli Companies Law, means the greater of retained earnings or earnings accumulated during the preceding
two years. In the event cash dividends are declared, such dividends will be paid in NIS.
B. Significant Changes
Except as otherwise disclosed in this annual report, no significant change has occurred since
December
31, 2021.
A. Offer and Listing Details
Our capital consists of Ordinary Shares, which are traded on the NASDAQ Capital Market and the Tel Aviv
Stock Exchange under the symbol “RADA.”
B. Plan of Distribution
Not applicable.
C. Markets
Our Ordinary Shares are traded on the NASDAQ Capital Market and the TASE under the symbol “RADA.”
D. Selling Shareholders
Not applicable.
E. Dilution
Not applicable.
F. Expense of the Issue
Not applicable.
A. Share Capital
Not applicable.
We are registered with the Israeli Companies Registry and have been assigned company number 52-003532-0.
Section 2 of our memorandum of association provides that we were established for the purpose of engaging in the business of providing
services of planning, development, consultation and instruction in the electronics field. In addition, the purpose of
our company is to
perform various corporate activities permissible under Israeli law.
The Powers of the Directors
Under the provisions of the Israeli Companies Law, and our
articles of association, a director cannot participate
in a meeting nor vote on a proposal, arrangement or
contract in which he or she is materially interested. In addition, our directors cannot
vote compensation to themselves or any members of their body without the approval of our audit committee and our shareholders at a general
meeting. The authority of our directors to enter into borrowing arrangements on our behalf is not limited, except in the same manner as
any other transaction by us.
Under our
articles of association, retirement of directors from office is not subject to any age limitation
and our directors are not required to own shares in
our company in order to qualify to serve as directors.
Rights Attached to Shares
Annual and Extraordinary General Meetings
The board of directors must convene an annual meeting of shareholders at least once every calendar year,
within 15 months of the last annual meeting. Depending on the matter to be voted upon, notice of at least 21 days or 35 days prior to
the date of the meeting is required. Our board of directors may, in its discretion, convene additional meetings as
“Extraordinary
General Meetings.” In addition, the board of directors must convene an Extraordinary General Meeting upon the demand of two of the
directors, 25% of the nominated directors, one or more shareholders having at least 5% of the outstanding share capital and at least 1%
of the voting power in
the company, or one or more shareholders having at least 5% of the voting power in
the company.
The quorum required for a General Meeting of shareholders consists of at least two shareholders present
in person or represented by proxy who hold or represent, in the aggregate, at least 25% of the voting rights of the issued share capital.
A meeting adjourned for lack of a quorum is adjourned to the same day in the following week at the same time and place or any time and
place as the directors designate in a notice to the shareholders or to such day and at such time and place as the Chairman of the General
Meeting shall determine. At the reconvened meeting, if the original meeting was convened upon the demand of one or more shareholders having
at least 5% of the outstanding share capital and at least 1% of the voting power in
the company, or one or more shareholders having at
least 5% of the voting power in
the company, the quorum will be one or more Shareholders, present in person or by proxy, and holding the
number of shares required for making such requisition. In any other case the required quorum consists of any two members present in person
or by proxy.
Please refer to Exhibit 2.2 for Items 10.B.3, B.4, B.6, B.7, B.8, B.9 and B.10.
We do not deem any individual
contract to be a
material contract which is not already discussed and filed
as an exhibit or in the ordinary course of our business.
D. Exchange Controls
Israeli law and regulations do not impose any material foreign exchange restrictions on non-Israeli holders
of our Ordinary Shares.
Non-residents of Israel who purchase our Ordinary Shares will be able to convert dividends, if any, thereon,
and any amounts payable upon our dissolution, liquidation or winding up, as well as the proceeds of any sale in Israel of our Ordinary
Shares to an Israeli resident, into freely repairable dollars, at the exchange rate prevailing at the time of conversion, provided that
the Israeli income tax has been withheld (or paid) with respect to such amounts or an exemption certificate has been obtained from the
Israel Tax Authority, or the ITA, prior to the payment.
E. Taxation
The following is a discussion of Israeli and U.S. tax consequences material to us and our shareholders.
To the extent that the discussion is based on tax legislation which has not been subject to judicial or administrative interpretation,
the views expressed in the discussion might not be accepted by the tax authorities in question. The discussion is not intended, and should
not be construed, as legal or professional tax advice and does not exhaust all possible tax considerations.
You are urged to consult your own tax advisors as to the U.S., Israeli or other tax consequences of the
purchase, ownership and disposition of Ordinary Shares, including, in particular, the effect of any foreign, state or local taxes.
Israeli Tax Considerations
The following is a summary of the current tax structure applicable to companies in Israel, with special
reference to its effect on us. The following also contains a discussion of the material Israeli tax consequences to purchasers of our
Ordinary Shares and Israeli government programs benefiting us. This summary does not discuss all the aspects of Israeli tax law that may
be relevant to a particular investor in light of his or her personal investment circumstances or to some types of investors subject to
special treatment under Israeli law. Examples of this kind of investor include residents of Israel or traders in securities who are subject
to special tax regimes not covered in this discussion. Since some parts of this discussion are based on new tax legislation that has not
yet been subject to judicial or administrative interpretation, we cannot assure you that the appropriate tax authorities or the courts
will accept the views expressed in this discussion.
General Corporate Tax Rate
Generally, Israeli companies are subject to corporate tax on taxable income and capital gains at the rate
of 23% as of the 2018 tax year onwards. However, the effective tax rate payable by a company that derives income from a Beneficiary Enterprise,
a Preferred Enterprise, or a Preferred Technological Enterprise (as discussed below) may be considerably less.
Law for the Encouragement of Industry (Taxes), 1969
The Law for the Encouragement of Industry (Taxes), 5729-1969, generally referred to as the Industry Encouragement
Law, provides several tax benefits for “Industrial Companies”. The Industry Encouragement Law defines an “Industrial
Company” as a company resident in Israel and which was incorporated in Israel, of which 90% or more of its income in any tax year,
other than income from defense loans, capital gains, interest and dividends, is derived from an “Industrial Enterprise” owned
by it and located in Israel or in the “Area,” as such terms are defined in the Israeli Income Tax Ordinance [New Version]
5721-1961, or the Ordinance. An “Industrial Enterprise” is defined as an enterprise which is held by an Industrial Company
whose principal activity in a given tax year is industrial production.
The following corporate tax benefits, among others, are available to Industrial Companies:
|
• |
Amortization over an eight-year period of the cost of purchased know-how and patents and rights (other than goodwill) to use a patent
and know-how which are used for the development or advancement of the Industrial Enterprise, commencing from the tax year where the Industrial
Enterprise began to use them; |
|
• |
Accelerated depreciation rates on equipment and buildings; |
|
• |
Under limited conditions, an election to file consolidated tax returns with related Israeli Industrial Companies; and |
|
• |
Expenses related to a public offering are deductible in equal amounts from income attributed to the Industrial Enterprise over three
years commencing in the year of the offering. |
Eligibility for the benefits under the Industry Encouragement Law is not subject to receipt of prior approval
from any governmental authority. As of the date of this annual report, we have industrial production activities. Therefore, we qualify
as an Industrial Company and may be eligible for the benefits described above. However, we cannot assure that we will qualify as an Industrial
Company in the future or that the benefits described above will be available to us.
Tax Benefits and Grants for Research and Development
Israeli tax law allows, under certain conditions, a tax deduction for expenditures related to scientific
research and development projects, including capital expenditures, for the year in which they are incurred. Expenditures are deemed related
to scientific research and development projects, if:
|
• |
The expenditures are approved by the relevant Israeli government ministry, determined by the field of research; or |
|
• |
The research and development are for the promotion of the company and is carried out by or on behalf of the company seeking such
tax deduction. |
The amount of such deductible expenses is reduced by the sum of any funds received through government grants
for the financing of such scientific research and development projects. No deduction under these research and development deduction rules
is allowed if such deduction is related to an expense invested in an asset depreciable under the general depreciation rules of the Ordinance.
Expenditures not so approved are deductible in equal amounts over three years.
From time to time, we may apply to the Israeli Innovation Authority, or the IIA, for approval to allow
a tax deduction for research and development expenses during the year incurred. There can be no assurance that such applications will
be accepted. For more information about these programs, see “Item 5.C.
Operating and Financial
Review and Prospects – Research and Development, Patents and Licenses” of our annual report on Form 20-F for the year
ended
December 31, 2021.
Law for the Encouragement of Capital Investments, 5719-1959
The Law for the Encouragement of Capital Investments, 5719-1959, or the Investment Law, provides certain
incentives for capital investments in production facilities (or other eligible assets) by “Industrial Enterprises” (as defined
under the Investment Law). The benefits available under the Investment Law are subject to the fulfillment of conditions stipulated therein.
If a company does not meet these conditions, it may be required to refund the amount of tax benefits, as adjusted by the Israeli consumer
price index, and interest, or other monetary penalties.
Tax Benefits Prior and Subsequent to the 2005 Amendment
Prior to
April 1, 2005, the Investment Law provided that capital investments in an Industrial Enterprises
(or other eligible assets) may, upon approval by the Investment Center of the Israel Ministry of Economy and Industry, or the Investment
Center, be designated as an
“Approved Enterprise.” Each certificate of approval for an Approved Enterprise relates to a specific
investment program, delineated both by the financial scope of the investment and by the physical characteristics of the facility or the
asset. The tax benefits from any certificate of approval relate only to taxable profits attributable to the specific Approved Enterprise.
On
April 1, 2005, a comprehensive amendment to the Investment Law came into effect, which we refer to as
the 2005 Amendment. The 2005 Amendment included revisions to the criteria for investments qualified to receive tax benefits. The 2005
Amendment does not retroactively apply to investment programs having an Approved Enterprise approval certificate issued by the Investment
Center prior to
December 31, 2004, unless chosen otherwise. Approved Enterprises are subject to the provisions of the Investment Law prior
to its revision, while new investments and tax benefits, if any, will be subject to the provisions of the 2005 Amendment.
Pursuant to the 2005 Amendment, only Approved Enterprises receiving cash grants required the approval of
the Investment Center. Approved Enterprises which do not receive benefits in the form of governmental cash grants, such as benefits in
the form of tax benefits, are no longer required to obtain this approval. An eligible investment program under the 2005 Amendment qualifies
for benefits as a “Beneficial Enterprise.” However, a “Beneficial Enterprise” is required to comply with certain
requirements and make certain investments as specified in the 2005 Amendment.
In addition, the benefits available to an Approved Enterprise are conditioned upon terms stipulated in
the Investment Law and the regulations thereunder and the criteria set forth in the applicable certificate of approval. In March 2019,
our investment program was approved as an Approved Enterprise under the Investment Law, which entitles us to an approximately NIS 1,095,000
cash grant. If we do not fulfill the conditions set forth in the certificate of approval, in whole or in part, the benefits may be cancelled
and we could be required to refund the amounts of the benefits, with the addition of the Israeli consumer price index linkage differences
and interest. We have not yet activated such investment plan and as a result we have not yet received the cash grant. There can be no
assurance that we will activate the investment plan or that the cash grant will be available to us if we do.
The extent of the tax benefits available under the 2005 Amendment to qualifying income of a Beneficial
Enterprise depend on, among other things, the geographic location of the Beneficial Enterprise in Israel. The location will also determine
the period for which tax benefits are available. Such tax benefits include an exemption from corporate tax on undistributed income for
a period of between two to 10 years, depending on the geographic location of the Beneficial Enterprise in Israel, and a reduced corporate
tax rate of between 10% and the applicable corporate tax rate for the remainder of the benefits period, depending on the level of foreign
investment in
the company in each year during the benefits period.
A Beneficial Enterprise may, at its discretion, in order to obtain greater certainty, elect to apply for
a pre-ruling from the Israeli tax authorities confirming that it is in compliance with the provisions of the amendments in the Investment
Law and is therefore entitled to receive such benefits provided under the amendments to Investment Law as set below.
Tax Benefits Under the 2011 Amendment
The Investment Law was significantly amended as of
January 1, 2011, or the 2011 Amendment. The 2011 Amendment
introduced new benefits to replace those granted in accordance with the provisions of the Investment Law in effect prior to the 2011 Amendment.
The 2011 Amendment introduced new tax benefits for income generated by a “Preferred Company”
through its “Preferred Enterprise,” in accordance with the definition of such terms in the Investment Law. The definition
of a Preferred Company, includes, inter alia, a company incorporated in Israel that (1) is not wholly owned by a government entity, (2)
owns a Preferred Enterprise and (3) is controlled and managed from Israel and is subject to further conditions set forth in the Investment
Law. Moreover, a Preferred Company needs to meet certain conditions stipulated in the Investment Law such as being an industrial company
(including a minimum threshold of 25% export).
A Preferred Company is entitled to a reduced corporate tax rate of 16% with respect to the income attributed
to its Preferred Enterprise, unless the Preferred Enterprise is located in development area “A,” in which case the rate will
be 7.5%.
Dividends distributed from income which is attributed to a “Preferred Enterprise” will be subject
to withholding tax at the following rates: (i) Israeli resident individuals — 20% (iii) non-Israeli residents — 20%, subject
to a reduced tax rate under the provisions of an applicable double tax treaty and subject to the receipt in advance of valid certificate
from the ITA. If such dividends are paid to an Israeli company, no tax is generally required to be withheld. However, if such dividends
are subsequently distributed by such Israeli company to individuals or a non-Israeli company, withholding tax at a rate of 20% or such
lower rate as may be provided in an applicable tax treaty will apply.
The provisions of the 2011 Amendment do not apply to existing
“Beneficial Enterprises” or
“Approved
Enterprises,” which will continue to be entitled to the tax benefits under the Investment Law, as in effect prior to the 2011 Amendment,
unless
the company owning such enterprises had made an election to apply the provisions of the 2011 Amendment (such election cannot be
later rescinded), which is to be filed with the ITA, not later than the date prescribed for the filing of
the company’s annual Israeli
tax return for the respective year.
Tax Benefits Under the 2017 Amendment
Additional amendments to the Investment Law became effective in January 2017, or the 2017 Amendment. The
2017 Amendment provides new tax benefits for two types of “Technological Enterprises,” as described below, and is in addition
to the other existing tax benefit programs under the Investment Law.
The 2017 Amendment provides that a technological company satisfying certain conditions may qualify as a
“Preferred Technological Enterprise” and thereby enjoy a reduced corporate tax rate of 12% on income that qualifies as
“Preferred
Technological Income,” as defined in the Investment Law. The tax rate is further reduced to 7.5% for a Preferred Technological Enterprise
located in development area
“A.” In addition, a Preferred Technological Company will enjoy a reduced corporate tax rate of
12% on capital gain derived from the sale of certain
“Benefited Intangible Assets” (as defined in the Investment Law) to a
related foreign company if the Benefited Intangible Assets were acquired from a foreign company on or after
January 1, 2017 for at least
NIS 200 million, and the sale receives prior approval from the IIA.
The 2017 Amendment further provides that a technological company satisfying certain conditions may qualify
as a
“Special Preferred Technological Enterprise” and thereby enjoy a reduced corporate tax rate of 6% on
“Preferred
Technological Income” regardless of
the company’s geographic location within Israel. In addition, a Special Preferred Technological
Enterprise will enjoy a reduced corporate tax rate of 6% on capital gain derived from the sale of certain
“Benefited Intangible
Assets” to a related foreign company if the Benefited Intangible Assets were either developed by an Israeli company or acquired
from a foreign company on or after
January 1, 2017, and the sale received prior approval from the IIA. A Special Preferred Technological
Enterprise that acquires Benefited Intangible Assets from a foreign company for more than NIS 500 million may be eligible for these benefits
for a period of at least 10 years, subject to certain approvals as specified in the Investment Law.
Dividends distributed by a Preferred Technological Enterprise or a Special Preferred Technological Enterprise,
paid out of Preferred Technological Income or income attributed to production are generally subject to withholding tax at the rate of
20% or such lower rate, as may be provided in an applicable tax treaty (subject to the receipt in advance of a valid certificate from
the ITA allowing for a reduced tax rate). However, if such dividends are paid to an Israeli company, no tax is required to be withheld.
However, if such dividends are subsequently distributed by such Israeli company to individuals or a non-Israeli company, withholding tax
at a rate of 20% or such lower rate as may be provided in an applicable tax treaty will apply, subject to the receipt in advance of a
valid certificate from the ITA allowing for a reduced tax rate. If dividends paid out of Preferred Technological Income are distributed
to a foreign company and other conditions are met, the withholding tax rate will be 4% (or a lower rate under a tax treaty, if applicable,
subject to the receipt in advance of a valid certificate from the ITA allowing for a reduced tax rate).
Taxation of Our Shareholders
Capital Gains
Capital gain tax is imposed on the disposition of capital assets by an Israeli resident for tax purposes,
and on the disposition of such assets by a non-Israeli resident for tax purposes if those assets are (i) located in Israel; (ii) are shares
or a right to a share in an Israeli resident corporation, or (iii) represent, directly or indirectly, rights to assets located in Israel,
unless a specific exemption is available or unless a tax treaty between Israel and the shareholder’s country of residence provides
otherwise. The Ordinance distinguishes between “Real Capital Gain” and the “Inflationary Surplus.” Real Capital
Gain is the excess of the total capital gain over Inflationary Surplus. Inflationary Surplus is a portion of the total capital gain
which is equivalent to the increase in the relevant asset’s cost basis that is attributable to the increase in the Israeli consumer
price index or, in certain circumstances, a foreign currency exchange rate, between the date of purchase and the date of disposition.
Inflationary Surplus is not currently subject to tax in Israel.
Real Capital Gain accrued by individuals on the sale of our Ordinary Shares will be taxed at the rate of
25%. However, if the individual shareholder is a
“Controlling Shareholder” (i.e., a person who holds, directly or indirectly,
alone or together with another, 10% or more of one of the Israeli resident company’s
“means of control,” which includes,
among other things, the right to receive profits of
the company, voting rights, the rights to receive proceeds upon
the company’s
liquidation and the right to appoint a director) at the time of sale or at any time during the preceding 12-month period, such capital
gain will be taxed at the rate of 30%. Furthermore, where an individual claimed real interest expenses and linkage differentials on securities,
the capital gain on the sale of the securities will taxed at a rate of 30%. Real Capital Gain derived by corporations will be generally
subject to the corporate tax rate (23% in 2018 and thereafter).
Individual and corporate shareholder dealing in securities in Israel are taxed at the tax rates applicable
to business income - 23% for corporations in 2018 and thereafter and a marginal tax rate of up to 47% in 2020 and 2021 for individuals,
not including excess tax (described below). Notwithstanding the foregoing, Real Capital Gain derived from the sale of our Ordinary Shares
by a non-Israeli shareholder may be exempt under the Ordinance from Israeli taxation provided that the following cumulative conditions
are met: (i) the shares were purchased upon or after the registration of the shares on the stock exchange, (ii) the seller does not have
a permanent establishment in Israel to which the derived capital gain is attributable, and (iii) if the seller is an entity (including
a corporation), no more than 25% of its means of control are held, directly and indirectly, by Israeli residents, and there is no
Israeli resident that is entitled to 25% or more of the revenues or profits of the entity, directly or indirectly. In addition, such exemption
would not be available to a person whose capital gains from selling or otherwise disposing of the securities are deemed to be business
income.
In addition, the sale of Ordinary Shares may be exempt from Israeli capital gain tax under the provisions
of an applicable tax treaty. For example, the Convention Between the Government of the United States and the Government of Israel with
respect to Taxes of Income, as amended, or the U.S.-Israel Double Tax Treaty, exempts U.S. residents for the purposes of the treaty from
Israeli capital gain tax in connection with such sale, provided (i) the U.S. resident owned, directly or indirectly, less than 10% of
the Israeli resident company’s voting power at any time within the 12-month period preceding such sale; (ii) the seller, being an
individual, is present in Israel for a period or periods of less than 183 days during the taxable year; and (iii) the capital gain from
the sale was not derived through a permanent establishment of the U.S. resident in Israel; (iv) the capital gain arising from such sale,
exchange or disposition is not attributed to real estate located in Israel; and (v) the capital gain arising from such sale, exchange
or disposition is not attributed to royalties. Eligibility to benefit from tax treaties is conditioned upon the shareholder presenting
a withholding certificate issued by the ITA prior to the applicable payment.
Shareholders may be liable for Israeli tax on the sale of their Ordinary Shares and the payment of the
consideration may be subject to withholding of Israeli tax. Shareholders may be required to demonstrate that they are exempt from Israeli
tax on their capital gains in order to avoid withholding at the time of sale. For example, in transactions involving a sale of all of
the shares of an Israeli resident company, in the form of a merger or otherwise, the ITA may require from shareholders who are not liable
for Israeli tax to sign declarations in forms specified by this authority or obtain a specific exemption from the ITA to confirm their
status as a non-Israeli resident for tax purposes, and, in the absence of such declarations or exemptions, may require the purchaser of
the shares to withhold taxes.
Either the purchaser, the Israeli stockbrokers or financial institutions through which the shares are held
is obligated to withhold tax on the amount of consideration paid upon the sale of the shares (or on the Real Capital Gain on the sale,
if known) at the rate of 25% in respect of an individual and 23% in respect of a corporation, unless a valid exemption certificate is
issued by the ITA prior to the applicable payment.
Upon the sale of securities traded on a stock exchange, a detailed return, including a computation of the
tax due, must be filed and an advanced payment must be paid on January 31 and July 31 of every calendar year in respect of sales of securities
made within the previous six months. However, if all tax due was withheld according to applicable provisions of the Ordinance and regulations
promulgated thereunder the aforementioned return need not be filed and no advance payment must be paid. Capital gain is also reportable
on the annual income tax return.
Dividends
We have never paid cash dividends to our shareholders. A distribution of dividend by
our company from income
attributed to a Preferred Enterprise to Israeli residents should generally be subject to withholding tax in Israel at the following tax
rates: Israeli resident individuals — 20%; Israeli resident companies — 0% (although, if such dividends are subsequently distributed
to individuals or a non-Israeli company, withholding tax at a rate of 20% or such lower rate as may be provided if an applicable tax treaty
will apply (subject to the receipt in advance of a valid tax certificate from the ITA allowing for a reduced tax rate)). A distribution
of dividends from income, which is not attributed to a Preferred Enterprise to an Israeli resident individual, should generally be subject
to tax at a rate of 25% or 30% if the dividend recipient is a
“Controlling Shareholder” (as defined above) at the time of
distribution or at any time during the preceding 12-month period. If the recipient of the dividend is an Israeli resident corporation,
such dividend should be exempt from income tax provided the income from which such dividend is distributed was derived or accrued within
Israel (although, if such dividends are subsequently distributed to individuals or a non-Israeli company, withholding tax at a rate of
25% or such lower rate as may be provided if an applicable tax treaty will apply (subject to the receipt in advance of a valid tax certificate
from the ITA allowing for a reduced tax rate)).
A non-Israeli resident (either individual or corporation) is generally subject to Israeli tax on the receipt
of dividends at the rate of 25% (30% if the dividends recipient is a “Controlling Shareholder” (as defined above), at the
time of distribution or at any time during the preceding 12-month period); those rates are subject to a reduced tax rate under the provisions
of an applicable double tax treaty (subject to the receipt in advance of a valid certificate from the ITA allowing for a reduced tax rate).
Under the U.S.-Israel Double Tax Treaty, and subject to the eligibility to the benefits under such treaty, the following withholding rates
will apply in respect of dividends distributed by an Israeli resident company to a U.S. resident: (i) if the U.S. resident is a corporation
which holds during that portion of the taxable year which precedes the date of payment of the dividend and during the whole of its prior
taxable year (if any), at least 10% of the outstanding voting shares of the Israeli resident paying corporation and not more than 25%
of the gross income of the Israeli resident paying corporation for such prior taxable year (if any) consists of certain type of interest
or dividends — the withholding tax rate is 12.5%, (ii) if both the conditions mentioned in (i) above are met and the dividend is
paid from an Israeli resident company’s income which was entitled to a reduced tax rate applicable to an Approved Enterprise, Beneficial
Enterprise or Preferred Enterprise — the withholding tax rate is 15% if a certificate for a reduced withholding tax rate would be
provided in advance from the ITA and (iii) in all other cases, the withholding tax rate is 25%. The aforementioned rates under the U.S.-Israel
Double Tax Treaty will not apply if the dividend income was derived through a permanent establishment of the U.S. resident in Israel
A non-Israeli resident who receives dividends from which full tax was withheld is generally exempt from
the obligation to file tax returns in Israel with respect to such income, provided that (i) such income was not generated from business
conducted in Israel by the taxpayer, (ii) the taxpayer has no other taxable sources of income in Israel with respect to which a tax return
is required to be filed, and (iii) the taxpayer is not subject to excess tax (described below).
We cannot assure you that we will designate the profits that we may distribute in a way that will reduce
shareholders’ tax liability.
Excess Tax
Individuals who are subject to tax in Israel (whether such individual is an Israeli resident or non-Israeli
resident) are also subject to an additional tax on annual income exceeding a certain threshold (NIS 647,640 for 2021 and NIS 663,240 for
2022), which amount is linked to the Israeli consumer price index, at a rate of 3%, including, but not limited to, income derived from
dividends, interest and capital gains.
Foreign Exchange Regulations
Non-residents for Israeli tax purposes who hold our Ordinary Shares are able to receive any dividends,
and any amounts payable upon the dissolution, liquidation and winding up of our affairs, repayable in non-Israeli currency at the rate
of exchange prevailing at the time of conversion. However, Israeli income tax is generally required to have been paid or withheld on these
amounts. In addition, the statutory framework for the potential imposition of currency exchange control has not been eliminated, and may
be restored at any time by administrative action.
Estate and Gift Tax
Israeli law presently does not impose estate or gift taxes.
United States Federal Income Taxation
The following is a general discussion of the material U.S. federal income tax consequences of the acquisition,
ownership and disposition of our Ordinary Shares. This description addresses only the U.S. federal income tax considerations that may
be relevant to U.S. Holders (as defined below) who hold our Ordinary Shares as capital assets. This summary is based on the U.S. Internal
Revenue Code of 1986, as amended, (the “Code”) Treasury regulations promulgated thereunder, judicial and administrative interpretations
thereof and the U.S.-Israel Tax Treaty (the “Treaty”), all as in effect on the date hereof and all of which are subject to
change either prospectively or retroactively or to differing interpretations. There can be no assurance that the U.S. Internal Revenue
Service (“IRS”) will not take a different position concerning the tax consequences of the acquisition, ownership or disposition
of our Ordinary Shares or that such a position would not be sustained. This discussion does not address all tax considerations that may
be relevant to a U.S. Holder of Ordinary Shares. In addition, this description does not account for the specific circumstances of any
particular investor, such as:
|
● |
financial institutions or financial services entities; |
|
● |
certain insurance companies; |
|
● |
investors liable for alternative minimum tax; |
|
● |
regulated investment companies, real estate investment trusts, or grantor trusts; |
|
● |
dealers or traders in securities, commodities or currencies; |
|
● |
tax-exempt organizations; |
|
● |
certain former citizens or long-term residents of the United States; |
|
● |
non-resident aliens of the United States or taxpayers whose functional currency is not the U.S. dollar; |
|
● |
persons who hold Ordinary Shares through partnerships or other pass-through entities; |
|
● |
persons who acquire their Ordinary Shares through the exercise or cancellation of employee stock options or otherwise as compensation
for services; |
|
● |
direct, indirect or constructive owners of investors that actually or constructively own at least 10% of the total combined voting
power of our shares or at least 10% of our shares by value; or |
|
● |
investors holding Ordinary Shares as part of a straddle, appreciated financial position, a hedging transaction or conversion transaction.
|
If a partnership or an entity treated as a partnership for U.S. federal income tax purposes owns our Ordinary
Shares, the U.S. federal income tax treatment of a partner in such a partnership will generally depend upon the status of the partner
and the activities of the partnership. A partnership that owns our Ordinary Shares and the partners in such partnership should consult
their tax advisors about the U.S. federal income tax consequences of holding and disposing of Ordinary Shares.
This summary does not address the effect of any U.S. federal taxation (such as estate and gift tax) other
than U.S. federal income taxation. In addition, this summary does not include any discussion of state, local or non-U.S. taxation.
For purposes of this summary the term “U.S. Holder” means a person that is eligible for the
benefits of the Treaty and is a beneficial owner of Ordinary Shares who is, for U.S. federal income tax purposes:
|
● |
an individual who is a citizen or a resident of the United States; |
|
● |
a corporation or other entity taxable as a corporation for United States federal income tax purposes, created or organized in or
under the laws of the United States or any political subdivision thereof; |
|
● |
an estate the income of which is subject to U.S. federal income taxation regardless of its source; or |
|
● |
a trust if the trust has validly elected to be treated as a U.S. person for U.S. federal income tax purposes or if (1) a court within
the United States is able to exercise primary supervision over the trust’s administration and (2) one or more U.S. persons have
the authority to control all of the substantial decisions of the trust. |
Unless otherwise indicated, it is assumed for the purposes of this discussion that
the Company is not,
and will not become, a
“passive foreign investment company” (
“PFIC”) for U.S. federal income tax purposes. See
“—Passive Foreign Investment Companies” below.
Taxation of Distributions
Subject to the discussion below under the heading “—Passive
Foreign Investment Companies,” the gross amount of any distributions received with respect to our Ordinary Shares, including
the amount of any Israeli taxes withheld therefrom, will constitute dividends for U.S. federal income tax purposes when such distribution
is actually or constructively received, to the extent such distribution is paid out of our current and accumulated earnings and profits,
as determined for U.S. federal income tax purposes. Because we do not expect to maintain calculations of our earnings and profits under
U.S. federal income tax principles, you should expect that the entire amount of any distribution will be taxable to you as dividend income.
Dividends are included in gross income at ordinary income rates, unless such dividends constitute “qualified dividend income,”
as set forth in more detail below. Distributions in excess of our current and accumulated earnings and profits would be treated as a non-taxable
return of capital to the extent of your adjusted tax basis in our Ordinary Shares and any amount in excess of your tax basis would be
treated as gain from the sale of Ordinary Shares. See “—Sale, Exchange or Other Disposition
of Ordinary Shares” below for a discussion of the taxation of capital gains. Our dividends would not qualify for the dividends-received
deduction generally available to corporations under section 243 of the Code.
Dividends that we pay in NIS, including the amount of any Israeli taxes withheld therefrom, will be included
in your income in a U.S. dollar amount calculated by reference to the exchange rate in effect on the day such dividends are received,
regardless of whether the payment is in fact converted into U.S. dollars. A U.S. Holder who receives payment in NIS and converts NIS into
U.S. dollars at an exchange rate other than the rate in effect on such day may have a foreign currency exchange gain or loss that would
generally be treated as U.S.-source ordinary income or loss. U.S. Holders should consult their own tax advisors concerning the U.S. tax
consequences of acquiring, holding and disposing of NIS.
Subject to complex limitations, some of which vary depending upon the U.S. Holder’s circumstances,
any Israeli withholding tax imposed on dividends paid with respect to our Ordinary Shares, may be a foreign income tax eligible for credit
against a U.S. Holder’s U.S. federal income tax liability (or, alternatively, for deduction against income in determining such tax
liability). Israeli taxes withheld in excess of the applicable rate allowed by the Treaty (if any) will not be eligible for credit against
a U.S. Holder’s federal income tax liability. The limitation on foreign income taxes eligible for credit is calculated separately
with respect to specific classes of income. Dividends paid with respect to our common stock generally will be treated as foreign-source
passive category income or, in the case of certain U.S. Holders, general category income for U.S. foreign tax credit purposes. Further,
there are special rules for computing the foreign tax credit limitation of a taxpayer who receives dividends subject to a reduced tax
rate. A U.S. Holder may be denied a foreign tax credit with respect to Israeli income tax withheld from dividends received on our Ordinary
Shares if such U.S. Holder fails to satisfy certain minimum holding period requirements or to the extent such U.S. Holder’s position
in Ordinary Shares is hedged. An election to deduct foreign taxes instead of claiming a foreign tax credit applies to all foreign taxes
paid or accrued in the taxable year. The rules relating to the determination of the foreign tax credit are complex. You should consult
with your own tax advisors to determine whether and to what extent you would be entitled to this credit.
Subject to certain limitations (including the PFIC rules discussed below), “qualified dividend income”
received by a non-corporate U.S. Holder may be subject to tax at the lower long-term capital gain rates (currently, a maximum rate of
20%). Distributions taxable as dividends paid on our Ordinary Shares should qualify for a reduced rate if we are a “qualified foreign
corporation,” as defined in Code section 1(h)(11)(C). We will be a qualified foreign corporation if either: (i) we are entitled
to benefits under the Treaty or (ii) our Ordinary Shares are readily tradable on an established securities market in the United States
and certain other requirements are met. We believe that we are entitled to benefits under the Treaty and that our Ordinary Shares currently
are readily tradable on an established securities market in the United States. However, no assurance can be given that our Ordinary Shares
will remain readily tradable. The rate reduction does not apply unless certain holding period requirements are satisfied, nor does it
apply to dividends received from a PFIC (see discussion below), in respect of certain risk-reduction transactions, or in certain other
situations. U.S. Holders of our Ordinary Shares should consult their own tax advisors regarding the effect of these rules in their particular
circumstances.
Sale, Exchange or Other Disposition of Ordinary Shares
Subject to the discussion of the PFIC rules below, if you sell or otherwise dispose of our Ordinary Shares
(other than with respect to certain non-recognition transactions), you will generally recognize gain or loss for U.S. federal income tax
purposes in an amount equal to the difference between the amount realized on the sale or other disposition and your adjusted tax basis
in our Ordinary Shares, in each case determined in U.S. dollars. Such gain or loss will generally be capital gain or loss and will be
long-term capital gain or loss if you have held the Ordinary Shares for more than one year at the time of the sale or other disposition.
Long-term capital gain realized by a non-corporate U.S. Holder is generally eligible for a preferential tax rate (currently at a maximum
of 20%). In general, any gain that you recognize on the sale or other disposition of Ordinary Shares will be U.S.-source for purposes
of the foreign tax credit limitation; losses will generally be allocated against U.S. source income. Deduction of capital losses is subject
to certain limitations under the Code.
In the case of a cash basis U.S. Holder who receives NIS in connection with the sale or disposition of
our Ordinary Shares, the amount realized will be based on the U.S. dollar value of the NIS received with respect to the Ordinary Shares
as determined on the settlement date of such exchange. A cash basis U.S. Holder who receives payment in NIS and converts NIS into U.S.
dollars at a conversion rate other than the rate in effect on the settlement date may have a foreign currency exchange gain or loss, based
on any appreciation or depreciation in the value of NIS against the U.S. dollar, which would be treated as ordinary income or loss.
An accrual basis U.S. Holder may elect the same treatment of currency exchange gain or loss required of
cash basis taxpayers with respect to a sale or disposition of our Ordinary Shares that are traded on an established securities market,
provided that the election is applied consistently from year to year. Such election may not be changed without the consent of the IRS.
In the event that an accrual basis U.S. Holder does not elect to be treated as a cash basis taxpayer (pursuant to the Treasury regulations
applicable to foreign currency transactions), such U.S. Holder is required to calculate the value of the proceeds as of the “trade
date” and may have a foreign currency gain or loss for U.S. federal income tax purposes in the event of any difference between the
U.S. dollar value of NIS prevailing on the trade date and on the settlement date. Any such currency gain or loss generally would be treated
as U.S.- source ordinary income or loss and would be subject to tax in addition to the gain or loss, if any, recognized by such U.S. Holder
on the sale or disposition of such Ordinary Shares.
Passive Foreign Investment Company Considerations
Based on the composition of our income, assets (including the value of our goodwill, going-concern value
or any other unbooked intangibles, which may be determined based on the price of the ordinary shares), and operations, we believe we will
not be classified as a “passive foreign investment company”, or PFIC, for the 2021 taxable year. However, because PFIC status
is based on our income, assets and activities for the entire taxable year, it is not possible to determine whether we will be characterized
as a PFIC for our current taxable year or future taxable years until after the close of the applicable taxable year. Moreover, we must
determine our PFIC status annually based on tests that are factual in nature, and our status in the current year and future years will
depend on our income, assets and activities in each of those years and, as a result, cannot be predicted with certainty as of the date
hereof. If we were a PFIC for any taxable year during which a U.S. Holder owned Ordinary Shares, certain adverse consequences could apply
to the U.S. Holder. Specifically, unless a U.S. Holder makes one of the elections mentioned below, gain recognized by the U.S. Holder
on a sale or other disposition of Ordinary Shares would be allocated ratably over the U.S. Holder’s holding period for the Ordinary
Shares. The amounts allocated to the taxable year of the sale or other disposition and to any year before we became a PFIC would be taxed
as ordinary income. The amount allocated to each other taxable year would be subject to tax at the highest rate in effect for individuals
or corporations, as appropriate, for that taxable year, and an interest charge would be imposed on the resulting tax liability. Further,
any distribution in excess of 125% of the average of the annual distributions received by the U.S. Holder on our Ordinary Shares during
the preceding three years or the U.S. Holder’s holding period, whichever is shorter, would be subject to taxation as described immediately
above. In addition, if we were a PFIC for a taxable year in which we pay a dividend or the immediately preceding taxable year, the preferential
dividend rates discussed above with respect to dividends paid to certain non-corporate U.S. Holders would not apply. If we were a PFIC
for any taxable year in which a U.S. Holder owned our shares, the U.S. Holder would generally be required to file annual returns with
the IRS, on IRS Form 8621.
If we are treated as a PFIC with respect to you for any taxable year, you will be deemed to own shares
in any entities in which we own equity that are also PFICs (“lower tier PFICs”), and you may be subject to the tax consequences
described above with respect to the shares of such lower tier PFIC you would be deemed to own.
i. Mark-to-market elections
If we are a PFIC for any taxable year during which you hold ordinary shares, then instead of being subject
to the tax and interest charge rules discussed above, you may make an election to include gain on the ordinary shares as ordinary income
under a mark-to-market method, provided that such ordinary shares are “marketable.” The ordinary shares will be marketable
if they are “regularly traded” on a qualified exchange or other market, as defined in applicable U.S. Treasury regulations,
such as the New York Stock Exchange (or on a foreign stock exchange that meets certain conditions). For these purposes, the ordinary shares
will be considered regularly traded during any calendar year during which they are traded, other than in de minimis quantities, on at
least 15 days during each calendar quarter. Any trades that have as their principal purpose meeting this requirement will be disregarded.
However, because a mark-to-market election cannot be made for any lower tier PFICs that we may own, you will generally continue to be
subject to the PFIC rules discussed above with respect to your indirect interest in any investments we own that are treated as an equity
interest in a PFIC for U.S. federal income tax purposes. As a result, it is possible that any mark-to-market election with respect to
the ordinary shares will be of limited benefit.
If you make an effective mark-to-market election, in each year that we are a PFIC, you will include in
ordinary income the excess of the fair market value of your ordinary shares at the end of the year over your adjusted tax basis in the
ordinary shares. You will be entitled to deduct as an ordinary loss in each such year the excess of your adjusted tax basis in the ordinary
shares over their fair market value at the end of the year, but only to the extent of the net amount previously included in income as
a result of the mark-to-market election. If you make an effective mark-to-market election, in each year that we are a PFIC, any gain that
you recognize upon the sale or other disposition of your ordinary shares will be treated as ordinary income and any loss will be treated
as ordinary loss, but only to the extent of the net amount of previously included income as a result of the mark-to-market election.
Your adjusted tax basis in the ordinary shares will be increased by the amount of any income inclusion
and decreased by the amount of any deductions under the mark-to-market rules discussed above. If you make an effective mark-to-market
election, it will be effective for the taxable year for which the election is made and all subsequent taxable years unless the ordinary
shares are no longer regularly traded on a qualified exchange or the IRS consents to the revocation of the election. You should consult
your tax advisor about the availability of the mark-to-market election, and whether making the election would be advisable in your particular
circumstances.
ii. Qualified electing fund elections
In certain circumstances, a U.S. equity holder in a PFIC may avoid the adverse tax and interest charge
regime described above by making a “qualified electing fund” election to include in income its share of the corporation’s
income on a current basis. However, you may make a qualified electing fund election with respect to the ordinary shares only if we agree
to furnish you annually with a PFIC annual information statement as specified in the applicable U.S. Treasury regulations. We do not intend
to provide the information necessary for you to make a qualified electing fund election if we are classified as a PFIC. Therefore, you
should assume that you will not receive such information from us and would therefore be unable to make a qualified electing fund election
with respect to any of our ordinary shares were we to be or become a PFIC.
Additional Tax on Investment Income
In addition to the income taxes described above, U.S. Holders that are individuals, estates or trusts and
whose income exceeds certain thresholds may be subject to a 3.8% Medicare contribution tax on net investment income, which includes dividends
and capital gains from the sale or exchange of our Ordinary Shares.
Backup Withholding and Information Reporting
Payments in respect of our Ordinary Shares may be subject to information reporting to the IRS and to U.S.
backup withholding tax at the rate (currently) of 24%. Backup withholding will not apply, however, if you (i) fall within certain exempt
categories and demonstrate the fact when required or (ii) furnish a correct taxpayer identification number and make any other required
certification.
Backup withholding is not an additional tax. Amounts withheld under the backup withholding rules may be
credited against a U.S. Holder’s U.S. tax liability. A U.S. Holder may obtain a refund of any excess amounts withheld under the
backup withholding rules by filing the appropriate claim for refund with the IRS.
U.S. citizens and individuals taxable as resident aliens of the United States that (i) own “specified
foreign financial assets” (as defined in Section 6038D of the Code and the regulations thereunder) with an aggregate value in a
taxable year in excess of certain thresholds (as determined under rules in Treasury regulations) and (ii) are required to file U.S. federal
income tax returns generally will be required to file an information report with respect to those assets with their tax returns. IRS Form
8938 has been issued for that purpose. “Specified foreign financial assets” include any financial accounts maintained by foreign
financial institutions, foreign stocks held directly, and interests in foreign estates, foreign pension plans or foreign deferred compensation
plans. Under those rules, our Ordinary Shares, whether owned directly or through a financial institution, estate or pension or deferred
compensation plan, would be “specified foreign financial assets.” Under Treasury regulations, the reporting obligation applies
to certain U.S. entities that hold, directly or indirectly, specified foreign financial assets. Penalties can apply if there is a failure
to satisfy this reporting obligation. In addition, in the event a U.S. Holder that is required to file IRS Form 8938 does not file such
form, the statute of limitations on the assessment and collection of U.S. federal income taxes of such U.S. Holder for the related tax
year may not close until three years after the date that the required information is filed. A U.S. Holder is urged to consult the U.S.
Holder’s tax advisor regarding the reporting obligation.
Any U.S. Holder who acquires more than $100,000 of our Ordinary Shares or holds 10% or more of our Ordinary
Shares by vote or value may be subject to certain additional U.S. information reporting requirements.
The above description is not intended to constitute a complete analysis of all tax consequences
relating to acquisition, ownership and disposition of our Ordinary Shares. You should consult your tax advisor concerning the tax consequences
of your particular situation.
F. Dividend and Paying Agents
Not applicable.
G. Statement by Experts
Not applicable.
H. Documents on Display
We are subject to certain of the reporting requirements of the Exchange Act, as applicable to
“foreign
private issuers” as defined in Rule 3b-4 under the Exchange Act. As a foreign private issuer, we are exempt from certain provisions
of the Exchange Act. Accordingly, our proxy solicitations are not subject to the disclosure and procedural requirements of Regulation
14A under the Exchange Act, and transactions in our equity securities by our officers and directors are exempt from reporting and the
“short-swing” profit recovery provisions contained in Section 16 of the Exchange Act. In addition, we are not required under
the Exchange Act to file periodic reports and financial statements as frequently or as promptly as U.S. companies whose securities are
registered under the Exchange Act. However, we file with the SEC an annual report on Form 20-F containing financial statements audited
by an independent accounting firm. We also submit to the SEC reports on Form 6-K containing (among other things)
press releases and unaudited
financial information. We post our annual report on Form 20-F on our
website (
www.rada.com )
promptly following the filing of our annual report with the SEC. The information on our
website is not
incorporated by reference into
this annual report.
The SEC maintains a
website at
www.sec.gov that contains
reports, proxy and information statements, and other information regarding registrants that make electronic filings with the SEC using
its EDGAR (Electronic Data Gathering, Analysis, and Retrieval) system.
The documents concerning
our company that are referred to in this annual report may also be inspected at
our offices located at: 7 Giborei Israel Street, Netanya 4250407, P.O. Box 8606, Israel.
I. Subsidiary Information
Not applicable.
|
QUANTITATIVE AND QUALITATIVE DISCLOSURE ABOUT MARKET RISKS
|
Interest Rate Risk
We currently do not invest in or otherwise hold, for trading or other purposes, any financial instruments
subject to market risks. Generally, we pay interest on our credit facilities and short-term loans based on Libor, for dollar-denominated
loans. As a result, changes in the general level of interest rates may affect the amount of interest payable by us under these facilities.
Foreign Currency Exchange Risk
The depreciation of the NIS against the dollar has the effect of reducing the dollar amount of any of our
expenses or liabilities which are payable in NIS (unless such expenses or payables are linked to the dollar). As of
December 31, 2021,
we had liabilities payable in NIS which are not linked to the dollar in the amount of $17.9 million and cash and receivables in the amount
of $10.1 million denominated in NIS. Accordingly, 1% appreciation of the NIS against the dollar would increase our financing expenses
by approximately $77,801. A 1% depreciation of the NIS against the dollar would decrease our financing expenses by the same amount. However,
the amount of liabilities payable and/or cash and receivables in NIS is likely to change from time to time.
Because exchange rates between the NIS and the dollar fluctuate continuously, exchange rate fluctuations
and especially larger periodic devaluations will have an impact on our profitability and period-to-period comparisons of our results.
The effects of foreign currency re-measurements are reported in our consolidated financial statements in continuing operations.
|
DESCRIPTION OF SECURITIES OTHER THAN EQUITY SECURITIES
|
Not applicable.
|
DEFAULTS, DIVIDEND ARREARAGES AND DELINQUENCIES |
None.
|
MATERIAL MODIFICATIONS TO THE RIGHTS OF SECURITY HOLDERS AND
USE OF PROCEEDS |
None.
Disclosure Controls and Procedures
Our management, including our Chief Executive Officer, and Chief Financial Officer, has evaluated the effectiveness
of our disclosure controls and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) of the Exchange Act) as of
December
31, 2021. Based on such evaluation, our Chief Executive Officer and our Chief Financial Officer, have concluded that, as of
December 31,
2021,
our company’s disclosure controls and procedures are effective.
Management's Annual Report on Internal Control over Financial Reporting
Our management is responsible for establishing and maintaining adequate internal control over financial
reporting, as such term is defined in Rules 13a-15(f) and 15d-15(f) of the Exchange Act. Our management, including our Chief Executive
Officer and our Chief Financial Officer, conducted an evaluation of the effectiveness of our internal control over financial reporting
based on the framework and criteria established in Internal Control—Integrated Framework (2013) issued by the Committee of Sponsoring
Organizations of the Treadway Commission (COSO) as of the end of the period covered by this report.
Based on that evaluation, our management has concluded that our internal control over financial reporting
was effective as of
December 31, 2021. Notwithstanding the foregoing, there can be no assurance that our internal control over financial
reporting will detect or uncover all failures of persons within
the Company to comply with our internal procedures, as all internal control
systems, no matter how well designed, have inherent limitations. Therefore, even those systems determined to be effective may not prevent
or detect misstatements.
Attestation Report of the Registered Public Accounting Firm
The attestation report of
Kost Forer Gabbay & Kasierer, a member of EY Global, an independent registered
public accounting firm in Israel, on our management’s assessment of our internal control over financial reporting as of
December
31, 2021 is provided on page F-4, as included under Item 18 of this annual report.
Changes in Internal Control over Financial Reporting
Based on the evaluation conducted by our Chief Executive Officer and our Chief Financial Officer pursuant
to Rules 13a-15(d) and 15d-15(d) under the Exchange Act, our management has concluded that there was no change in our internal control
over financial reporting that occurred during the year ended
December 31, 2021 that materially affected, or is reasonably likely to materially
affect, our internal control over financial reporting.
|
AUDIT COMMITTEE FINANCIAL EXPERT |
Our board of directors has determined that Ms. Ofra Brown, Mr. Elan Sigal and Prof. Alon Dumanis, our external/independent
directors, within the meaning of the Israeli Companies Law, and independent directors, as defined by the SEC and NASDAQ, meet the definition
of an audit committee financial experts, as defined by rules of the SEC. For a brief listing of their relevant experience, see Item 6.A.
“Directors, Senior Management and Employees — Directors and Senior Management.”
We have adopted a code of ethics that applies to our Chief Executive Officer and all senior financial officers
of
our company, including the Chief Financial Officer, Chief Accounting Officer or controller, or persons performing similar functions.
Written copies of our code of ethics are available upon request. If we make any substantive amendment to the code of ethics or grant any
waivers, including any implicit waiver, from a provision of the codes of ethics, we will disclose the nature of such amendment or waiver
on our
website.
|
PRINCIPAL ACCOUNTANT FEES AND SERVICES |
Independent Registered Public Accounting Firm Fees
The following table sets forth, for each of the years indicated, the fees billed by our principal independent
registered public accounting firm,
Kost Forer Gabbay & Kasierer, a Member of Ernst & Young Global (
“EY Israel”). All
of such fees were pre-approved by our Audit Committee.
|
|
Year Ended December 31 |
|
Services Rendered: |
|
2020 |
|
|
2021 |
|
Audit (1) |
|
$ |
145,214 |
|
|
$ |
171,272 |
|
Audit-related (2)
|
|
$ |
57,861 |
|
|
$ |
173,280 |
|
Tax (3) |
|
$ |
86,983 |
|
|
$ |
30,831 |
|
Total |
|
$ |
290,058 |
|
|
$ |
375,383 |
|
(1) |
Audit fees are fees for audit services for each of the years shown in this table, including fees associated with the annual audit,
services provided in connection with audit of our internal control over financial reporting and audit services provided in connection
with other statutory or regulatory filings. |
(2) |
Audit-related fees relate to assurance and associated services that traditionally are performed by the independence auditor including
SEC filings, comfort letters, consents and comment letters in connection with regulatory filings. |
(3) |
Tax fees are the aggregate fees billed for professional services rendered for tax compliance and tax advice, other than in connection
with the audit. Tax compliance involves preparation of original and amended tax returns, tax planning and tax advice. |
EY Israel and other EY affiliates did not bill
our company for services other than the fees described above
for fiscal year 2021 or fiscal year 2020.
Pre-Approval Policies and Procedures
Our Audit Committee has adopted a policy and procedures for the pre-approval of audit and non-audit services
rendered by our independent registered public accounting firm,
Kost Forer Gabbay & Kasierer, a Member of Ernst & Young Global
(
“EY Israel”). Pre-approval of an audit or non-audit service may be given as a general pre-approval, as part of the audit
committee’s approval of the scope of the engagement of our independent auditor, or on an individual basis. The policy prohibits
retention of the independent public accountants to perform the prohibited non-audit functions defined in Section 201 of the Sarbanes-Oxley
Act or the rules of the Securities and Exchange Committee, and also requires the Audit Committee to consider whether proposed services
are compatible with the independence of the public accountants.
|
EXEMPTIONS FROM THE LISTING STANDARDS FOR AUDIT COMMITTEES |
Not applicable.
|
PURCHASE OF EQUITY SECURITIES BY THE ISSUER AND AFFILIATED
PURCHASERS |
Issuer Purchase of Equity Securities
Neither we, nor any
“affiliated purchaser” of
our company, has repurchased any of our securities
during 2021.
|
CHANGES IN REGISTRANT’S CERTIFYING ACCOUNTANT
|
None.
Under NASDAQ Stock Market Rule 5615(a) (3), foreign private issuers, such as
our company, are permitted
to follow certain home country corporate governance practices instead of certain provisions of the NASDAQ Stock Market Rules. A foreign
private issuer that elects to follow a home country practice instead of any of such NASDAQ rules must submit to NASDAQ, in advance, a
written statement from an independent counsel in such issuer’s home country certifying that the issuer’s practices are not
prohibited by the home country’s laws.
We have notified NASDAQ pursuant to Rule 5615(a) (3), that we do not comply with the following Rules and
instead follow Israeli law and practice in respect of such Rules:
|
● |
The Rule requiring maintaining a majority of independent directors, as defined under the NASDAQ Marketplace
Rules. Instead, we will follow Israeli law and practice See above in Item 6C. “Directors, Senior Management and Employees - External
and Independent Directors.” |
|
● |
The Rule requiring that our independent directors have regularly scheduled meetings at which only independent directors are present:
instead, we follow Israeli law according to which independent directors are not required to hold executive sessions. |
|
● |
The Rule regarding independent director oversight of director nominations process for directors. Instead,
we follow Israeli law and practice according to which our board of directors recommends directors for election by our shareholders. See
above Item 6C. “Directors, Senior Management and Employees - Board Practices - Board of Directors.” |
|
● |
The requirement to obtain shareholder approval for the establishment or amendment of certain equity-based compensation plans, an
issuance that will result in a change of control of the company, certain transactions other than a public offering involving issuances
of a 20% or more interest in the company and certain acquisitions of the stock or assets of another company. Under Israeli law and practice,
the approval of the board of directors is required for the establishment or amendment of equity-based compensation plans and private placements.
For the approvals and procedures required under Israeli law and practice for an issuance that will result in a change of control of the
company and acquisitions of the stock or assets of another company, see Item 6C “Directors, Senior Management and Employee - Board
Practices - Approval of Related Party Transactions Under Israeli Law - Disclosure of Personal Interests of a Controlling Shareholder;
Approval of Transactions with Controlling Shareholders”. |
Not applicable
ITEM 16I. |
DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS
|
Not applicable.
Not applicable.
Consolidated Financial Statements
Index to Financial Statements |
F-1 |
Reports of Independent Registered Public Accounting Firm (PCAOB ID
No. 1281) |
F-2 - F-5 |
Consolidated Balance Sheets |
F-6 – F-7 |
Consolidated Statements of Operations |
F-8 |
Consolidated Statements of Changes in Shareholders’ Equity |
F-9 |
Consolidated Statements of Cash Flows |
F-10 – F-11 |
Notes to Consolidated Financial Statements |
F-12 – F-40 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
101.INS |
|
Inline XBRL Instance Document (The instance document does not appear in the interactive data file because
its XBRL tags are embedded within the Inline XBRL document) |
|
|
|
101.SCH |
|
Inline XBRL Taxonomy Extension Schema Document. |
|
|
|
101.CAL |
|
Inline XBRL Taxonomy Calculation Linkbase Document. |
|
|
|
101.LAB |
|
Inline XBRL Taxonomy Label Linkbase Document. |
|
|
|
101.PRE |
|
Inline XBRL Taxonomy Presentation Linkbase Document. |
|
|
|
101.DEF |
|
Inline XBRL Taxonomy Extension Definition Linkbase Document. |
|
|
|
104 |
|
Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit
101) |